Risk factors and predictors of dementia and cognitive impairment by Neergaard, Jesper
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
General rights 
Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners 
and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights. 
 
• Users may download and print one copy of any publication from the public portal for the purpose of private study or research. 
• You may not further distribute the material or use it for any profit-making activity or commercial gain 
• You may freely distribute the URL identifying the publication in the public portal  
 
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately 
and investigate your claim. 
   
 
Downloaded from orbit.dtu.dk on: Apr 10, 2018
Risk factors and predictors of dementia and cognitive impairment
Neergaard, Jesper; Pedersen, Susanne Brix; Workman, Christopher; Henriksen, Kim; Karsdal, Morten
Asser
Publication date:
2017
Document Version
Publisher's PDF, also known as Version of record
Link back to DTU Orbit
Citation (APA):
Neergaard, J., Pedersen, S. B., Workman, C., Henriksen, K., & Karsdal, M. A. (2017). Risk factors and
predictors of dementia and cognitive impairment. Technical University of Denmark (DTU).
Risk factors and predictors of dementia and cognitive dysfunction 
An Epidemiological Approach 
PhD Thesis 
2017 
Supervisors 
Associate Professor Susanne Brix Pedersen, PhD 
DTU Bioengineering 
Technical University of Denmark  
Associate Professor Christopher Workman, PhD 
DTU Bioengineering 
Technical University of Denmark 
Head of Neurodegenerative Diseases Kim Henriksen, PhD 
Biomarkers & Research 
Nordic Bioscience A/S 
Chief Executive Officer Morten Asser Karsdal, PhD 
Biomarkers & Research 
Nordic Bioscience A/S 
Funding 
The PhD project was supported financially by the Danish Research Foundation and the Technical 
University of Denmark. 
Jesper Skov Neergaard, ID: 136536 
Copyright: Reproduction of this publication in whole or in part must include the 
customary bibliographic citation, including author attribution, report title, 
etc. 
Published by: Department of Biotechnology and Biomedicine, Søltofts Plads, Building 
221, DK-2800 Kgs. Lyngby, Denmark 
Request report from: www.bio.dtu.dk 
   
  
 
To Louise, Erika and Kamille 
“Prediction is very difficult,  
especially when it is about the future” 
Niels Bohr, Danish physicist 
  
  
 i 
Preface 
This thesis is based on work carried out at Nordic Bioscience A/S and the Department of 
Biotechnology and Biomedicine at the Technical University of Denmark from November 2013 to 
February 2017 (excluding August 2015 to November 2015). All research has been anchored in 
the Prospective Epidemiological Risk Factor Study (PERF), a Danish population-based cohort of 
postmenopausal women. The project was divided in two parts. First, recruitment, data collection 
and data management for the follow-up study (PERFII). This part required 14 months of full-time 
involvement and ended up with enrolling a total of 2,103 elderly Danish women, of whom I 
personally met 800 – an exciting, challenging and truly educational experience. Alongside the 
data collection the application for register-linkage was submitted and approved. The second part 
included the data analysis and manuscript preparation. 
  
The Technical University of Denmark has funded the PhD in collaboration with the Danish 
Research Foundation.  
 
Copenhagen, February 2017 
 
 
 
Jesper Skov Neergaard 
Risk factors and predictors of dementia and cognitive dysfunction 
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Summary 1 
Summary 
The greying of the world population has led to what was previously referred to as the “silent” 
epidemic of our century, namely dementia. The epidemic is primarily driven by an epidemiological 
transition, where prolonged longevity and declining fertility rates have led to increasing 
proportions of older people in the total population. Dementia and cognitive impairment are by far 
the leading causes of disability and in particularly the need for care among older people. 
Surprisingly there has been much less investment in dementia research, given its burden. 
Consequently, Alzheimer’s disease, being the most prevalent dementia type, is the only cause of 
death among the top 10 killers in the United States that cannot be prevented, cured, or even 
delayed. The knowledge of risk and protective factors is therefore especially important for the 
development of prevention strategies, as prevention by risk factor intervention, is considered the 
key to a better control of the epidemic. Women outlive men on average, however they have poorer 
health status. Moreover, women have an elevated risk of dementia. This clearly justifies an 
increased focus on dementia specifically for women. In the development of new disease modifying 
interventions there has been a devastating low rate of success in the area of dementia. Resources 
have therefore been directed at identifying preclinical stages of dementia-related diseases as this 
is considered the optimal “window” for intervention. Identification of subjects with preclinical 
disease and subsequent high likelihood of progression are therefore an indisputable prerequisite 
for the success of future drugs. Here, biomarkers play a crucial role, as the pre-symptomatic 
diagnosis will rely on these. Hence, advances in biomarkers, especially non-invasive blood-based 
biomarkers, are required to ensure that the new drugs are tested on the right patients at the right 
time.  
The aims of this thesis were: i) to identify risk factors for all cause and differential dementia 
diagnoses, ii) to identify risk factors associated with progression from normal cognition to 
dementia within the follow-up period and iii) to evaluate the possible utility of two novel serological 
biomarkers of truncated tau as predictors of incident dementia. This was investigated using data 
from the Prospective Epidemiological Risk Factor (PERF) study, a population-based prospective 
cohort study on 5,855 elderly Danish women initially enrolled between year 1999 and 2001 with 
a follow-up examination of 2,103 of the women in year 2013-2014.  
We aimed at identifying risk factors for incident dementia and its subtypes in chapter 4. With 
special focus on a range of metabolic risk factors we investigated how these factors were related 
to cognitive dysfunction at the follow-up visit (chapter 5). These studies found that Body Mass 
Index (BMI) in the overweight range and physical activity were associated with lower risk of 
dementia (Chapter 4), while increasing age, history of depression, insulin resistance (using the 
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homeostasis model assessment index) and elevated fasting plasma glucose increased the risk of 
dementia or cognitive dysfunction (chapter 4 or Chapter 5, respectively). 
 
In chapter 6 we specifically aimed at assessing the risk of progression to dementia in 
subpopulation(s) of women with signs of mild cognitive deficits and further to investigate the 
cognitive courses from baseline to follow-up (reverse trajectory, stable, and progressive) including 
a risk-profile specifically associated with progression. We found that the degree of cognitive 
impairment at baseline (single versus multiple domains) was an important predictor of dementia 
and in subjects with subtle objective cognitive impairment physical inactivity, elevated total 
cholesterol and a history of depression were associated with progression to dementia or severe 
cognitive impairment. 
 
In chapter 7, we evaluated the possible utility of two novel serological biomarkers of truncated tau 
as predictors of incident dementia in women. We found that high levels of Tau-A and Tau-C were 
associated with lower risk of dementia and Alzheimer’s disease. Tau-C gave a very modest 
increase in the area under the curve (AUC) in a 5-year prediction horizon as compared to a 
reference model with age and education. 
 
Finally, we summarised our results in a nomogram, a simple tool for prediction of dementia 
tailored for individual risk prediction. This illustrates the applicability of such findings for dementia 
risk screening (chapter 8). Overall, many of the identified risk factors are considered modifiable 
and therefore provide further evidence that prevention strategies could be a way to counteract 
the otherwise poor future prospects for dementias in the ageing population. Also, we show that 
the risk factors and blood-based tau biomarkers may be useful in screening and thereby early 
identification of individuals at-risk for dementia, one of the most persisting needs in dementia drug 
development. 
  
 Summary 3 
Resume 
Verdens befolkning ældes, hvilket har medført dét, der tidligere blev omtalt som vores 
århundredes "tavse" epidemi; nemlig demens. Epidemien er primært drevet af en demografisk 
forskydning, hvor en højere middellevealder og faldende fødselsrater har medført en stadigt 
stigende andel af ældre i den samlede befolkning. Demens og kognitiv svækkelse er de primære 
årsager til invaliditet og især behov for pleje blandt ældre mennesker, men overraskende nok har 
der, på trods af dets byrde, været signifikant færre investeringer i demens forskning. Alzheimers 
sygdom som er den hyppigste form for demens er som en konsekvens heraf, den eneste 
dødsårsag blandt de 10 hyppigste dødsårsager i USA, som ikke kan forebygges, helbredes, eller 
blot forsinkes. Viden om risikofaktorer er derfor specielt vigtigt for udviklingen af 
forebyggelsesstrategier, da disse anses for at være nøglen til en bedre kontrol af epidemien. 
Kvinder lever i gennemsnit længere end mænd, de har dog en dårligere helbredstilstand. 
Desuden har kvinder en forøget risiko for demens. Dette berettiger et øget fokus på demens 
specielt hos kvinder. Der har været en meget lav succesrate i udviklingen af nye 
sygdomsmodificerende behandlinger på demens området. Ressourcerne er derfor nu blevet 
rettet mod identifikation af præklinisk demens. Dette sygdomsstadie betragtes af mange, som det 
optimale tidspunkt for opstart af sygdomsmodificerende behandlinger. Identifikation af personer 
med præklinisk sygdom og en efterfølgende stor sandsynlighed for progression er derfor en 
forudsætning for fremtidige lægemidlers succes. Biomarkører har her en afgørende rolle, da den 
præ-symptomatiske diagnose vil afhænge af disse. Udvikling af især non-invasive blod-baserede 
biomarkører skal derfor sikre, at de nye lægemidler testes i de rette patienter på det rette 
tidspunkt. 
 
Formålene med dette projekt var: i) at identificere risikofaktorer for demens og undertyper heraf, 
ii) at identificere risikofaktorer forbundet med progression i opfølgningsperioden og iii) at vurdere 
potentialet af to nye serologiske biomarkører som prædiktorer for udvikling af demens. Dette blev 
undersøgt ved hjælp af data fra det Prospektive Epidemiologiske Risikofaktor (PERF) studie, en 
prospektiv kohorteundersøgelse af 5855 ældre danske kvinder oprindeligt inkluderet mellem 
årene 1999 og 2001, med en opfølgende undersøgelse på 2103 af kvinderne i årene 2013-2014. 
 
Vi undersøgte hvilke risikofaktorer, der var associeret med generel demens og undertyper af 
demens in kapitel 4. Med særligt fokus på en række af metaboliske risikofaktorer, undersøgte vi 
hvordan disse faktorer var relateret til kognitiv dysfunktion ved den opfølgende undersøgelse 
(kapitel 5). Disse studier viste, at Body Mass Index (BMI) i det overvægtige interval samt fysisk 
aktivitet var associeret med en lavere risiko for demens (kapitel 4), samtidig var stigende alder, 
en nuværende eller tidligere depression, insulinresistens (målt ved hjælp af HOMA-IR indekset) 
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og et forhøjet faste glukose i blodet associeret med en øget risiko for udvikling af demens eller 
kognitiv dysfunktion (kapitel 4 eller kapitel 5). 
 
Vi havde i kapitel 6 til formål at undersøge risikoen for progression til demens hos en 
subpopulation af kvinder, der ved inklusionen viste tegn på mild kognitiv svækkelse samt 
yderligere at undersøge hvorledes deres kognitive funktion havde udviklet sig fra baseline til 
follow-up. Herunder identificerede vi en risikoprofil specifikt forbundet med progression. Vi fandt, 
at graden af kognitiv svækkelse ved inklusionen (et enkelt versus flere kognitive domæner) var 
en vigtig prædikator for fremtidig demens og hos personer med mild kognitiv svækkelse var fysisk 
aktivitet, forhøjet total kolesterol og en tidligere eller nuværende depression forbundet med 
progression til demens eller svær kognitiv svækkelse. 
 
I kapitel 7 vurderede vi to nye serologiske biomarkørers potentiale til identifikation af fremtidig 
demens hos kvinder. Vi fandt, at høje niveauer af Tau-A og Tau-C var forbundet med lavere risiko 
for demens og Alzheimers sygdom. Sammenlignet med en referencemodel indeholdende alder 
og uddannelsesniveau gav Tau-C en beskeden stigning i arealet under kurven (AUC) i en 5-års 
forudsigelseshorisont. 
 
Til sidst opsummerede vi vores resultater i et nomogram, som er et simpelt værktøj, som baseret 
på den enkelte patients risikoprofil, anvendes til at forudsige demens. Nomogrammet illustrerer 
anvendeligheden af vores resultater i relation til demens screening (kapitel 8). Samlet set 
konkluderer vi, at mange af de identificerede risikofaktorer kan betragtes som modificer bare, 
hvilket giver yderligere bevis for, at forebyggelsesstrategier kan være en måde at påvirke de ellers 
dystre fremtidsudsigter for demenssygdomme i den aldrende befolkning. Desuden viser vi, at 
risikofaktorer og blod-baserede biomarkører kan være nyttige i screening og dermed tidlig 
identifikation af demens, hvilket er et af de mest presserende behov i udviklingen af ny demens 
medicin. 
1 
Introduction 
1. Introduction
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1. Introduction 
Dementia is a syndrome that describes a wide range of symptoms that occur when the brain is 
affected by certain conditions. Dementia can be grouped in reversible and irreversible dementia 
disorders. The reversible dementia disorders are most often drug induced, caused by hormonal 
imbalance or vitamin deficiencies and are out of scope in this thesis. The irreversible dementia 
disorders are progressive, degenerative disorders that are affecting memory and other cognitive 
functions to the extent that they interfere with a person’s daily life and activities. The most common 
types of irreversible dementia include Alzheimer’s disease (AD), vascular dementia (VaD) and 
mixed dementia, particularly the combination of AD and VaD. 
 
Cognitive impairment is used as a broad term describing impairment in any one (or all) of the 
cognitive domains assessed by objective cognitive performance irrespective of the underlying 
cause. This thesis deals with cognitive impairment and all-cause dementia in general and the 
major types of dementia including AD, VaD and other/unspecified dementias (OD). The following 
sections will describe the causes, symptoms and underlying mechanisms of the dementia 
disorders, with emphasis on AD. 
 
1.1 Dementia, a threat to Global Health and Aging 
Advances in medicine and socioeconomic development have made one of humanity’s greatest 
achievements, namely: prolonged longevity [1]. The rise in life expectancy accompanied by 
declining fertility rates is now driving an epidemiological transition increasing the proportion of 
older people in the total population. In Europe alone, the elderly population (>65 years) is 
estimated to double from 88 to 153 million by 2060 and the fastest growing segment of the 
population will be those aged 80 and older tripling in number from 24 to 60 million [2]. This 
demographic shift is associated with increased prevalence of chronic diseases and as it is also 
accompanied by prolonged survival, it will put a large pressure on healthcare systems [3]. 
Maintaining a healthy life is therefore of outmost importance. While women outlive men on 
average, they have poorer health status [4,5] and this clearly justifies an increased focus on 
ageing, specifically of women. 
 
One of the most daunting and costly consequences of ever-longer life expectancies is dementia. 
Dementia and cognitive impairment are by far the leading causes of disability and in particularly 
need for care among older people worldwide, thus it has been estimated that the health and social 
care costs for dementia exceed costs of other chronic diseases like cancer, cardiovascular 
disease and stroke [6]. Unfortunately, there has been much less investment in dementia research, 
given its burden, compared with research in cancer and cardiovascular disease. In Denmark, 
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women account for more than 2/3 of the total number of people living with dementia [7], and 
dementia is the second leading cause of death in women [8]. 
 
In 2015, Alzheimer’s Disease International estimated that 46.8 million people were living with 
dementia worldwide. They projected the number to nearly triple by 2050 reaching 131.5 million 
people worldwide [6]. In Denmark, approximately 84,000 people were living with dementia in 
2015. The number was estimated to increase with 80% reaching more than 150,000 by 2040 [7]. 
The 2015 World Alzheimer’s Report states that the incidence of dementia doubles with every 6.3-
year increase in age, from 3.9 per 1000 person-years at age 60-64 to 104.8 per 1000 person-
years at age 90+ [6]. 
 
1.2 Nosology of Dementia Disorders 
1.2.1 Diagnosis and Classification 
The concept of dementia and its classification has developed on the basis of accumulating 
evidence of clinicopathological entities and presumed etiological factors. Two major diagnostic 
classification systems exist and are used for diagnosis of dementia. The WHO's International 
Classification of Diseases and Related Health Problems 10th Revision (ICD-10) and the American 
Psychiatric Association's Diagnostic and Statistical Manual of Mental Disorders (DSM 5). Further, 
the National Institute on Aging and the Alzheimer's Association (NIA-AA) proposed new 
diagnostic criteria for dementia, AD and mild cognitive impairment (MCI) in 2011 [9,10], and a 
working group also proposed diagnostic criteria for preclinical AD. Preclinical AD refers to an early 
disease stage where pathological changes in the brain can be detected using biomarkers [11]. 
Alongside the NIA-AA also an International Working Group proposed similar research diagnostic 
criteria for AD. Like the NIA-AA criteria it defines three stages of AD: preclinical AD, prodromal 
AD (MCI due to AD in the NIA-AA criteria) and AD dementia [12]. There are differences on how 
the stages are conceptualized however this will not be elaborated any further in this thesis. The 
diagnostic guidelines outline several cognitive stages ranging from normal cognition to dementia, 
as illustrated in figure 1. 
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Figure 1: Overview of the cognitive stages from normal cognition to dementia. The overview is based on the 
diagnostic criteria for preclinical dementia suggested by Sperling et al. [11] and the core clinical criteria for 
mild cognitive impairment suggested by Petersen et al.[13] together with the revised MCI classification by 
Albert et al.[10]. The figure was made with modification from [14]. The concept of SNAP was introduced by 
Jack et al.[15]. *In this figure, SNAP includes common amyloid-negative neurodegenerative conditions like 
cerebrovascular disease, hippocampal sclerosis and the preclinical brain lesions of FTD and LBD. MCI: Mild 
Cognitive Impairment, CSF: Cerebrospinal fluid, PET: positron emission tomography, MRI: magnetic 
resonance imaging, FDG: Fluorodeoxyglucose. 
 
The clinical diagnosis of dementia is based on the medical history, a neuropsychological test 
battery and a thorough clinical examination of symptoms. In addition, there are certain imaging 
biomarkers such as computed tomography (CT), magnetic resonance imaging (MRI), single 
photon emission computed tomography (SPECT), positron emission tomography (PET) and 
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cerebral spinal fluid (CSF) biomarkers that may be used to support the clinical diagnosis [9]. 
These techniques are however mainly used in specialized clinics and for research purposes rather 
than in general practice. Detection of neuropathological lesions in the brain by autopsy is the gold 
standard for the diagnosis of dementia-related diseases [16]. 
 
1.2.2 Subtypes of Dementia 
Traditionally there is a distinction between early and late onset dementia. AD is the most prevalent 
cause of dementia irrespective of the time of onset. Among younger people (<65 years of age) 
approximately one third of all dementia cases is caused by AD. Frontotemporal dementia (FTD), 
Dementia with Lewy bodies (DLB) and other types of dementia are relatively more prevalent 
among the younger as compared with the elder population [17]. It is estimated that AD accounts 
for up to 67% of all late onset dementia cases in women. The second most prevalent dementia 
type in women is VaD accounting for 15% followed by mixed dementia with 10% of the total 
number of dementia cases. The remaining 8% can be attributed to other types of dementia 
including: DLB (3%), FTD (1%) and Parkinson disease dementia (1%) [18]. The clinical and 
pathological features of the main subtypes of dementia are outlined in table 1. 
 
Table 1: Overview of main dementia subtypes. The table was made with inspiration from [19] 
 Subtypes of dementia 
 
Alzheimer’s 
Disease 
Vascular 
Dementia 
Lewy Body 
Dementia 
Frontotemporal 
Dementia 
Onset Gradual 
Acute or  
gradual 
Insidious 
Early 
Insidious 
Progression Gradual Stepwise or gradual Fluctuating Rapid 
Signs and  
Symptoms 
Memory loss, 
language deficits, 
mood and 
personality changes 
Memory loss, 
language deficits, 
dysarthria, 
emotional lability, 
decreased 
concentration 
Depression, 
hallucinations, 
variability in terms of 
day to day 
symptoms 
Poor judgement, 
social withdrawal,  
inappropriate 
behaviour 
Regions  
of atrophy 
General atrophy 
noted in the medial 
temporal lobe 
Strokes, lacunar 
infarcts, white 
matter lesions 
Generalized atrophy 
throughout 
Frontal and 
temporal lobes 
Pathologic  
features 
Amyloid plaques 
Neurofibrillary 
tangles 
Cerebrovascular 
disease 
Lewy bodies Pick bodies 
 
Mixed dementia is used when more than one type of dementia occurs simultaneously in the brain. 
The most common mixed pathology is AD with VaD followed by AD with DLB [20]. The distinction 
between the subtypes of dementia may seem straightforward, however evidence from autopsy 
studies shows that differential diagnosis is very challenging. As outlined in figure 2, a previous 
study found that 77% of subjects with VaD and 66% of subjects with DLB also had AD pathology, 
while up to 50% of subjects with AD also had another pathology e.g. VaD or OD [21]. These 
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findings prove that different pathologies are often coexisting highlighting that mixed dementia 
might be more common than previously anticipated. This has been confirmed in another study 
where about half of the people with dementia had evidence of more than one co-existing 
pathology [20]. 
 
Figure 2: Venn diagram showing the diagnostic overlap of differential dementia diagnoses confirmed by 
autopsy. Diagram created based on findings by Barker et al.[21]. AD: Alzheimer’s disease, VaD: Vascular 
dementia, OD: Other types of dementia (Frontotemporal dementia, Dementia with Lewy bodies, 
hippocampal sclerosis) 
 
1.2.3 The disease continuum  
The continuum of dementia-related diseases can cover a wide spectrum ranging from apparently 
normal cognition to advanced dementia. It progresses through several preclinical and clinical 
stages as illustrated in figure 3. 
 
Figure 3: The disease continuum from normal cognition to severe dementia. Figure modified from [22]. 
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1.2.3.1 Normal and Pathological Brain Aging 
It is well-known that the brain shrinks in volume as we age [23]. The shrinkage is especially seen 
in areas related to learning, memory, planning, and other complex mental activities. Brain regions 
most commonly affected include the prefrontal cortex and the hippocampus. Brain regions that 
are also affected when a person develops a dementia disorder [24,25]. Alterations in 
neurotransmission by reduction of neurotransmitter levels and reduced blood flow are also found 
in the brain as a result of normal aging, but to a much lesser degree as compared to pathological 
brain aging [26]. Accumulation of pathological hallmarks of AD has been observed in about a third 
of very old people without dementia or cognitive impairment [27]. This evidence indicates that 
there is a certain degree of overlap between normal and pathological changes in the aging brain, 
making it difficult to determine when normal aging stops and pathological neurodegeneration 
begins.  
 
1.2.3.2 The Preclinical stage 
Dementia-related diseases, and AD in particular, are characterized by a long preclinical phase, 
where the pathological alterations in the brain are believed to begin decades before the clinical 
onset [28]. The general consensus is, that the preclinical stage provides the best opportunity for 
potential disease modifying interventions [11]. The recent research recommendations from the 
NIA-AA [11] approach a diagnostic guideline for preclinical AD, however, it is still lengths from 
clinical implementation. The recommendations contain a temporal framework with three stages 
defined from; biomarker evidence of amyloid-beta (Aβ) accumulation (stage 1), presence of one 
or more markers of neuronal injury (stage 2) and finally positivity on amyloid and neuronal injury 
markers combined with a subtle cognitive decline (stage 3) (figure 1). A concept named 
Suspected non-AD pathophysiology (SNAP) was later introduced by Jack et al. [15]. SNAP was 
defined by biomarker evidence of non-AD neurodegenerative processes (normal Aβ biomarkers, 
abnormal markers of neuronal injury. 
 
1.2.3.3 Mild Cognitive Impairment 
MCI has become the most widely used concept in research on early cognitive deficits. In MCI, the 
cognitive deficits are worse than would normally be expected for a healthy person of equivalent 
age, however not severe enough to interfere with activities in daily life [13]. It is well-known that 
MCI increases the risk of later developing dementia, and the condition is therefore often 
considered an intermediate stage between normal aging and the earliest features of dementia. 
Importantly, not all people with MCI progress; some people remain stable over time while others 
even return to normal levels [29] (figure 3). Due to this heterogeneity researchers are focusing on 
identifying people with MCI who are most likely to progress to dementia. 
 12 1. Introduction 
 
To qualify for an MCI diagnosis subjects should present with: i) a subjective cognitive complaint 
ii) objective cognitive impairment, iii) preserved activities of daily living, and iv) not demented [13]. 
According to the Petersen criteria [13], subjects that fulfil this core clinical criteria are then 
subdivided in four subgroups of MCI. If memory is impaired, subjects are characterised with 
amnestic MCI. Alternatively, if memory is not impaired, subjects are designated as having non-
amnestic MCI. The presence or absence of impairment in multiple other cognitive domains further 
divide these subjects into amnestic or non-amnestic MCI with either single or multiple domain 
involvements [13]. The amnestic subtypes of MCI are believed to progress to AD if there is an 
underlying degenerative etiology. In contrast, non-amnestic MCI may progress to other types of 
dementia such as FTD if a single domain is affected or DLB if multiple domains are affected [29]. 
Both amnestic and non-amnestic MCI may precede VaD as illustrated in figure 1. 
 
The revised MCI classification by Albert et al. in 2011 was outlined with the purpose of developing 
diagnostic criteria for the symptomatic predementia phase of AD. Subjects fulfilling the core 
clinical criteria for MCI are divided into two subgroups: MCI due to AD and MCI with other etiology. 
Additional information from imaging and CSF biomarkers determines whether a person with MCI 
has underlying AD pathology and thus is characterized with MCI due to AD [10].  
  
1.2.3.4 The clinical stages of dementia 
The initial clinical stage of dementia designated mild dementia is characterised by memory lapses 
that will affect daily life, such as forgetting words, misplacing things and problem-solving 
difficulties. As mild dementia progresses subjects will need more assistance in their daily life. The 
moderate stage of dementia implies personality and behavioural changes. There is increasing 
confusion and memory loss. The end stage of severe dementia is often manifested by loss of the 
ability to communicate, loss of physical capabilities and eventually death [30]. 
 
1.3 Risk Factors for Dementia 
Dementia disorders are multifactorial disorders and the development is regulated by several 
environmental and genetic risk factors. The degree of inheritance and inheritance patterns varies 
considerably between different dementia disorders. It is well-known that genes play a role in the 
development of AD and FTD, while the impact of genes seems to be much smaller in the 
development of VaD and DLB. AD can be divided into a dominantly inherited familial form also 
referred to as early onset AD (EOAD) and a non-familial or “sporadic” form known as late onset 
AD (LOAD). The genetic predispositions are considered non-modifiable risk factors while the 
modifiable risk factors can be of demographic, behavioural, biomedical, environmental or social 
origin. Non-modifiable and modifiable risk factors can act independently but most often in 
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combination [31]. A huge body of research has been conducted in relation to risk factors for 
dementia and AD in particular. 
1.3.1 Risk Factors across the lifespan - The importance of time 
An important aspect in the study of risk factors is that risk factors may change over time [32], 
wherefore it is important to consider when the risk factor is assessed relative to the outcome. The 
relation between time and some of the most well studied risk factors is illustrated in figure 4. 
Figure 4: Risk factors for dementia across the lifespan. Strength of evidence is indicated on grey-scale 
with strongest evidence in black, moderate evidence in grey and limited evidence in light grey. Timeline 
was created based on information from [33,34] 
It is obvious that genetic risks develop prenatally, while factors in early life such as certain life 
events and length of education have been linked to later risk of dementia [33]. Lifestyle and 
vascular risk factors have been found to impact the risk of dementia in mid- to late-life. Risk factors 
like hypertension and dyslipidaemia are most important in midlife while diabetes, depression and 
physical and mental activity affect the risk of dementia in both mid- and late-life [33]. 
1.3.2 Non-Modifiable Risk Factors 
1.3.2.1 Age, gender and family history 
The primary risk factor for dementia is advancing age. After the age of 65 the risk of dementia 
increases exponentially as it approximately doubles with every five years of ageing. 
Disproportionality has been observed in relation to gender and risk of dementia and most 
evidence suggests that women have an increased risk of AD, while men may be slightly more 
prone to develop VaD [34]. Subjects with a family history of dementia are also suspected to 
have a higher risk of dementia and AD although the evidence is limited [36,37]. 
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1.3.2.2 Genetic factors 
The dominantly inherited EOAD, accounting for up to five percent of all AD cases, is caused by 
mutations in one of three deterministic genes encoding for the amyloid precursor protein (APP), 
presenilin-1 and presenilin-2 on chromosome 21, chromosome 14 and chromosome 1, 
respectively [38–40]. Evidence also indicates the presence of other unidentified causative genes 
that remain to be identified, since EOAD cases without these known mutations have been 
observed [41]. FTD is also inherited in an autosomal dominant manner and one of the most 
common mutations in FTD is found in the MAPT gene on chromosome 17, encoding for tau.  
 
Beside the deterministic genes, a range of risk genes have been linked to risk of AD. The 
apolipoprotein E gene (APOE) is the risk gene with the highest impact, and has been associated 
with both EOAD and LOAD. Specific variants of the APOE, namely the epsilon 4 alleles increase 
the risk of AD. Subjects that are heterozygous for epsilon 4 have a 3 times higher risk of AD while 
homozygosity increases the risk up to 15 times as compared to subjects with two copies of the 
epsilon 3 allele [42]. The epsilon 4 allele also affects the time of disease onset. The age of onset 
is lowered by approximately a decade from when a similar person, without this genotype, would 
have otherwise developed AD [43].  
 
Several other genes have been linked to a greater risk of AD. The CLU, CR1 and TREM2 genes 
involved in the clearance of Aβ and inflammation appear to be associated with AD however the 
impact and exact role have not been fully elucidated [44,45]. It has also recently been suggested 
that the MAPT gene may also play a role in relation to AD [46]. 
  
1.3.3 Modifiable Risk Factors 
1.3.3.1 Vascular factors 
Many cases of dementia and AD can be attributed to vascular risk factors such as hypertension 
and diabetes. It appears that a dose-response like relationship exists between the number of risk 
factors and subsequent risk of dementia and AD, where subjects with several concurrently 
occurring risk factors are at a particular high risk [47,48]. Diabetes and its associated conditions; 
insulin resistance and metabolic syndrome are associated with an increased risk of dementia 
[49,50]. Diabetes has been intensively studied and consistent evidence shows that the risk of 
dementia is increased on average between 50–100% for subjects with diabetes as compared to 
subjects without diabetes. The association is strongest for VaD compared to LOAD [51]. 
 
Hypertension in midlife, not late-life, increases the risk of dementia, and is generally stronger for 
VaD than with AD [52,53]. Overweight and obesity have previously been linked to dementia and 
AD in both midlife and late-life. A BMI in midlife indicating overweight or obesity has often been 
proposed to increase risk of developing dementia in later life [54,55]. In late-life several large 
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prospective cohort studies have shown a negative relationship between higher BMI and risk of 
dementia [56,57]. The most recent evidence strengthened this inverse association in late-life and 
suggests that a negative association does apply also in midlife [58]. Most studies on midlife total 
cholesterol show a positive association with risk of dementia, while the evidence on late-life total 
cholesterol most often reports negative or no association however there is a high degree of 
inconsistency in general [59].  
 
1.3.3.2 Lifestyle factors 
Smoking is associated with an elevated risk of dementia and cessation decreases the risk to that 
of never smokers [60]. There is a degree of dose-response relationship, suggesting that the higher 
amount of smoking, the greater the risk of developing dementia [61]. The evidence between 
alcohol consumption and risk of dementia is sparser. A J-shape relationship has been 
suggested, with moderate drinkers having a lower risk than abstainers and heavy drinkers, which 
was confirmed by a meta-analysis in the 2014 World Alzheimer’s Report [33].  
 
Leisure activities comprising physical activity, mental activities and social engagement have 
all been found to have protective effects in relation to development of dementia [62]. Physical 
activity may be associated with up to 40% lower risk of dementia, which is believed to be 
modulated partly through improved cardiovascular health [33]. Cognitive leisure activities during 
mid‐ or late-life have also been associated with lower risk of dementia in late-life [63]. Adherence 
to a Mediterranean style diet is associated with lower risk of developing dementia, AD in 
particular [64]. 
 
1.3.3.3 Other factors 
A high level of education has consistently been associated with reduced risk of dementia. 
Recently, a critical threshold of completing more than 10 years of education was identified as an 
important mediator of the educational effect [65]. High level of education is known to be 
associated with a healthier lifestyle and this is assumed to explain part of the inverse relation 
between educational level and dementia. Another accepted explanation is the idea of the 
‘cognitive reserve’, i.e. the ability to maintain a good cognitive performance despite brain 
pathology [66].  
 
Late-life depression increases the risk of dementia and has been associated with both VaD and 
AD, with the strongest association with the former condition [67]. However, the causality has been 
questioned [68]. 
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1.3.4 The need for further studies on risk factors for dementia 
In dementia research, there are certain issues that may challenge the ability to establish true 
cause-effect relationships, where the non-arguable criterion in epidemiology is that the exposure 
has to precede the outcome in time. First, due to the insidious onset of dementia-related disorders 
it is challenging to establish causal relations between risk factors and outcomes. At present 
identification of a specific time for dementia onset is challenging, and while it may partly be 
possible with the available biomarkers, these biomarkers are expensive, time-consuming and 
invasive, limiting the use in the general population. Secondly, most epidemiological studies are 
conducted in older populations with shorter follow-up times, and there are few large prospective 
long-term studies starting in midlife or at younger ages where the preclinical neuropathological 
changes are less likely to have started [69]. Lastly, although we now know much about individual 
risk factors for dementia, we do not know how they interact or which risk factors account for what 
proportion of dementia cases. These issues inherent to dementia justify the need for further 
studies on potential risk factors, their potential interactions and their temporal relationship to 
dementia and cognitive impairment, especially in larger prospective studies with longer follow-up. 
 
1.4 Prevention and treatment 
1.4.1 Primary, Secondary and Tertiary Prevention 
Prevention is divided in three levels: primary, secondary and tertiary prevention. The ultimate goal 
with primary prevention is to prevent the onset of specific diseases. The main focus is risk 
reduction by preventing exposures to certain hazards. This is done e.g. through education and 
health promotion initiatives. Secondary prevention involves initiatives to detect and treat 
preclinical pathological changes. The goal is to control disease progression, postpone onset of 
clinical symptoms resulting in reduced incidence of manifest impairment, and a compression of 
morbidity. Finally, tertiary prevention seeks to minimize the damage caused by the disease, its 
recurrence and related disabilities. The main interventions are treatment and rehabilitation aiming 
to enhance the ability to function, increase quality of life and/or prolong life expectancy [70]. 
Dementia and AD treatment has traditionally aimed at tertiary prevention, however during the past 
decade(s) the focus has moved to secondary and even primary prevention [71]. The perceived 
reason is the fact that several clinical trials of potential disease modifying interventions have failed 
to meet their primary outcomes in study populations already diagnosed with AD dementia. The 
purpose of interventions across the levels of prevention in relation to stage of dementia is outlined 
in figure 5.  
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Figure 5: Overview of primary, secondary and tertiary prevention as a function of dementia disease stage. 
Figure made with inspiration from [72]. 
 
Several prevention trials are on-going including both pharmacological and non-pharmacological 
interventions. The pharmacological approaches include early intervention studies for both EOAD 
and LOAD. The Dominantly Inherited Alzheimer Network Trial (NCT01760005) will assess the 
potential disease modifying effect of gantenerumab and solanezumab, two monoclonal antibodies 
targeting Aβ, in individuals with genetic mutations leading to EOAD. LOAD studies include the 
Anti-Amyloid Treatment in Asymptomatic Alzheimer’s study (A4 study, NCT02008357). This study 
will assess the effect of solanezumab in asymptomatic or very mildly symptomatic individuals who 
have biomarker evidence of Aβ deposition. The A4 study will be followed by other public-private 
partnership trials; the A5 and the A3 studies. The A5 trial (NCT02569398) will test a β-secretase 
cleaving enzyme (BACE) inhibitor in a similar preclinical population as the A4 study, while the so-
called Ante-Amyloid Prevention of Alzheimer's disease study (A3) is planned to identify individuals 
with a subthreshold level of Aβ who are at high risk for further accumulation [73]. The 
TOMMORROW trial (NCT01931566) will assess the utility of a genetic-based biomarker risk 
assignment algorithm and the effect of the insulin sensitizer pioglitazone, in an asymptomatic high 
risk population carrying the APOE and TOMM40 risk genes [74]. 
 
Recent population-based randomized controlled trials (RCTs) assessing the impact of multi-
domain lifestyle interventions on cognitive decline or incident dementia include the FINGER, 
MAPT and PreDIVA studies [75–77].  
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1.4.1.1 Potential challenges 
Some challenges are still in the way of successful prevention. First, as AD and other dementia 
disorders are multifactorial conditions with several different pathways driving the pathogenesis, 
each of these pathways might need different interventions, or likely a combination of different 
interventions. Therefore, it is of utmost importance to identify who to treat with a certain treatment 
and also a matter of when we should intervene. Since the “window of opportunity” is believed to 
be years before dementia onset where the cognitive decline is normally limited, we need to identify 
the subjects with highest likelihood of progression and develop sensitive outcome measures 
including cognitive tests and reliable biomarkers to measure efficacy. 
 
Finally, in the absence of disease modifying interventions, ethical concerns are raised regarding 
the disclosure of an elevated risk e.g. through genetic testing or biomarker positivity.  
 
1.4.2 Current and Future Treatment Options 
The current available treatments for dementia are limited to symptomatic relief. In Denmark, three 
cholinesterase inhibitors (donepezil, rivastigmine and galantamine) are approved for treatment of 
mild to moderate AD and memantine, a non-competitive N-methyl-d-aspartate acid (NMDA) 
receptor antagonist, for treatment of moderate to severe AD [78]. The cholinesterase inhibitors 
postpone the worsening of symptoms for an average of up to 12 months, but only for about half 
of the treated subjects [79]. Cholinesterase inhibitors have shown no clinical effect in subjects 
with MCI [80].  
 
The central role of Aβ in the pathogenesis of AD has made this the prevailing drug target in the 
development of disease modifying interventions. Other relevant treatment strategies target tau or 
alternative pathways that have emerged because of the multifactorial and heterogeneous nature 
of LOAD. The strategies are outlined in table 2. 
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Table 2: Drug targets in the development of disease modifying interventions for AD. Aβ: Amyloid-β. The 
table include information from [81–88]. 
Target Strategy Rational 
   
 Reduce  
Stimulation of α-secretase favours the non-amyloidogenic metabolism of APP 
reducing formation of Aβ1-42. 
Aβ 
production Inhibition of β- or γ-secretase reduces the level of toxic Aβ species. 
   
 Enhance  
Direct activation of the Aβ-degrading enzymes or blocking the inhibitor of a 
protease that is required to activate an Aβ-degrading enzyme. 
 
clearance Antibody-mediated amyloid clearance by stimulating an immune response 
against monomeric-, oligomeric- or fibrillar species of Aβ. 
    
 Prevent  Monomeric Aβ molecules can form oligomeric aggregates that are thought to 
initiate the pathogenic cascade.  aggregation 
   
 Stabilization of  Does not interfere directly with tau, the rational is rather to compensate for the 
loss function once tau dissociates from the microtubules.  microtubule 
    
 Modulation of  Hyperphosphorylation is critical for tau to detach from microtubules and is 
believed to be a prerequisite for it to aggregate. Tau phosphorylation 
    
 Prevent  The initial stages of the aggregation process are the best stage to inhibit 
aggregation as the oligomers are considered the toxic specie.   aggregation 
    
 Enhance Stimulate an immune response against pathologically modified forms of tau 
and thereby enhance the clearance of tau.   clearance 
   
 Insulin  Antagonism of the peroxisome-proliferator activated receptor γ (PPARγ) 
increases Aβ phagocytosis and thereby the clearance of Aβ. 
Other 
sensitizer 
   
 
Anti-
inflammatory  
Combination therapy consisting a mast cell stabilizer and a non-steroid anti-
inflammatory agent inducing an anti-inflammatory response. 
  
Inhibition of the receptor for advanced glycation end products as it induces 
inflammation and oxidative damage.    
      
 
1.4.3 Precision Medicine 
The introduction of the term “precision medicine” marked the end of the traditional “one size fits 
all” approach and kick-started the paradigm shift towards individualized medicine [89]. The 
National Institute of Health in the United States defines precision medicine as: "an emerging 
approach for disease treatment and prevention that takes into account individual variability in 
genes, environment, and lifestyle for each person" [90] and with the new initiative on precision 
medicine outlined by Barack Obama in early 2015, efforts are now focused to accelerate progress 
within this new era [91]. 
 
In the dementia field, the concept of precision medicine is also emerging and is considered the 
key to success in the development of disease modifying interventions. Researchers are now 
recognizing that the complex multifactorial nature of LOAD will require a comprehensive 
exploratory systemic approach to understand the complex mix of processes that underlie the 
pathogenesis [92,93]. Three key elements to precision medicine in AD have been outlined: i) 
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comprehensive risk assessment, ii) tools for early detection of pathophysiological processes and 
iii) “customizing” interventions based on an individual’s molecular drivers [92]. A more detailed 
understanding of the pathogenesis of dementia and AD is however still needed to pave the way 
for precision medicine. Unravelling the various pathological pathways and their interactions is key 
to determine the risk of developing AD on an individual level [94]. A comprehensive risk 
assessment is necessary for prognosis and early intervention and should facilitate the 
identification of individuals with high risk for incident dementia, but also identify individuals with 
preclinical pathological evidence with a high likelihood of progression. The individual’s molecular 
drivers should aid in identification of optimal treatment with an optimal risk-benefit profile [95].  
 
Biomarkers are an integrated part of precision medicine and are therefore considered key to 
unlocking precision medicine [96]. In AD, a range of well-established biomarkers exists, however 
their widespread use at the population level is limited, as outlined in section 1.7. 
 
1.5 Pathways to dementia: The multifactorial trigger and hit hypothesis 
The pathways leading to FTD and DLB are still largely unknown and therefore this section is 
limited to pathways leading to AD. Beside synaptic dysfunction, extracellular deposition of Aβ 
plaques and formation of intracellular neurofibrillary tangles (NFT), there are several other 
processes implicated in the pathology including structural and functional abnormalities of the 
mitochondria, chronic inflammation and oxidative damage [97]. The mitochondrial abnormalities 
occur early in AD pathology and can promote both synaptic damage and apoptosis [98]. Oxidative 
damage is speculated to have a causative role in the pathogenesis of AD since it has been shown 
to occur prior to Aβ plaque formation [99]. The high frequency of coexisting pathologies from 
autopsy confirmed human studies indicates that the various pathological pathways are 
interconnected. This is further supported by findings from animal studies where it has been shown 
that tau is required for Aβ to impair synaptic plasticity in mice hippocampus and that tau deletion 
in mice affects intracellular Aβ1-42 clearance resulting in extracellular plaques [100,101]. It is 
therefore reasonable to think that several pathways will lead to AD, and that each of these 
pathways are somewhat heterogeneous (as outlined in figure 6). Whether there is a common 
upstream driver for all pathways and how interactions between genetic and environmental factors 
are driving the disease progression is still not fully understood. The evidence, that Aβ plaques are 
required but insufficient to independently drive the pathological conversion of tau, suggests that 
other factors (hits) are necessary to drive the pathological progression. Thus, there is still a range 
of unanswered questions: what is the initial trigger(s)? and how many subsequent hits are needed 
for the disease to manifest clinically? The multifactorial model outlined in figure 6 could explain 
why many of the reported genetic and environmental risk factors are neither sufficient nor 
necessary for the disease to occur and could also suggest that different pathways may need 
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different interventions and if several pathways are interacting several co-administered 
pharmacological interventions are probably needed. 
 
 
Figure 6: Hypothetical pathways to Alzheimer’s disease including genetic and environmental triggers. NFT: 
Neurofibrillary tangles, Aβ: Amyloid-β. Red color represent a vascular pathway, magenta is a metabolic 
pathway, green represent an inflammatory pathway, and the endocytic pathway is cyan while the familial 
and dominantly inherited pathway is blue. 
 
1.6 Neuropathology  
The common denominator of all neurodegenerative dementias is that cognitive function is 
impaired due to synapse degeneration and neuronal death. Several hypotheses have been 
suggested for the etiology of the main dementia subtypes. However, what triggers the 
characteristic hallmarks like the Aβ plaques, NFT and Lewy Bodies, and the sequence of events 
driving the disease progression is still not fully elucidated.  
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The molecular defects observed in EOAD gave rise to the “amyloid hypothesis” which still is the 
dominant hypothesis for AD, and since EOAD and LOAD share many clinical and 
histopathological features this hypothesis was also adopted to LOAD [102]. It was originally 
proposed as one pathway with a specific temporal relation where failure in clearance and 
overproduction of the Aβ peptide drives the downstream events including hyperphosphorylation 
of tau. During the past 25 years, the hypothesis has been challenged on several occasions, 
especially in light of the recent anti-amyloid trials that did not provide any clinical improvement in 
relation to AD [103,104]. Inflammatory involvement through microglial activation triggered by 
certain damage signals, e.g. Aβ, was later proposed in the “revitalized tau hypothesis” [105]. The 
pathways linking Aβ and tau to synapse degeneration and neuronal death are however still largely 
unknown, and whether the hallmarks share the same pathway, belong to independent pathways 
or are dual pathways that interact to exacerbate one another are still debated [106–108]. In a 
broad sense VaD is caused by problems in the supply of blood to the brain. It affects the neural 
networks and arises from systemic, cardiac, and local large and small vessel disease. It may 
manifest as a result of a single infarct, multiple infarcts, or microvascular insults [109].   
 
A striking similarity between all neurodegenerative diseases is the accumulation of misfolded 
protein aggregates and deposition of aggregates in so called inclusion bodies in different areas 
of the brain. As a consequence of post-mortem findings, the fibrillated end-products have 
traditionally been considered the toxic species. However, certain more recent evidence suggests 
that it may be the soluble forms of the proteins that are responsible for the neurotoxicity [110–
112]. 
 
1.6.1 The proteopathy of neurodegenerative diseases 
As illustrated in table 3 there is a marked overlap between the proteins involved in the different 
dementia-related neurodegenerative diseases. Neither Aβ plaques nor NFTs are specific for AD, 
they also accumulate in other neurodegenerative diseases. Aβ accumulate in cerebral amyloid 
angiopathy while NFTs are formed in other tauopathies like FTD [113,114]. Furthermore, Aβ 
plaques, NFT and Lewy bodies are found in cognitively normal elderly people, suggesting that 
these characteristic hallmarks are not in themselves sufficient to cause dementia [115–117]. The 
Aβ plaques were shown to consist of the peptide Aβ that aggregate and accumulate in the 
extracellular space [118]. In 1986, the microtubule associated protein tau was identified as the 
main constituent of the NFTs [119]. Lewy bodies are spherical clusters within the cerebral cells 
consisting of proteins α-Synuclein and ubiquitin entangled with abnormally phosphorylated 
neurofilament protein [120]. Tau has also been found to co-localize with α-Synuclein in Lewy 
Bodies [121].  
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Table 3: Overview of major aggregating proteins in neurodegenerative diseases. Aβ: Amyloid-β; FUS: Fused 
in Sarcoma protein; TDP-43: TAR DNA-binding protein 43; AD: Alzheimer’s disease; VaD: Vascular 
dementia; FTD: Frontotemporal dementia; DLB: Dementia with Lewy Bodies. 
Aggregating protein Proteopathy 
Aβ [122] AD, cerebral amyloid angiopathy, DLB 
Tau [123–125] 
AD, VaD, FTD, corticobasal degeneration, progressive supranuclear 
palsy, chronic traumatic encephalopathy, Pick’s disease 
Prion protein [126] Creutzfeldt-Jakob Disease 
α-Synuclein [127,128] AD, Parkinson's disease, DLB, multiple system atrophy 
TDP-43 [129,130] 
AD, FTD, amyotrophic lateral sclerosis, chronic traumatic 
encephalopathy 
FUS [129,130] FTD, amyotrophic lateral sclerosis 
Huntingtin [131] Huntington's disease 
1.6.2 Post-translational modifications implicated in neurodegeneration 
Post-translational modifications (PTMs) of the different proteins are known to play a central 
regulatory role in both physiological and pathological processes in a range of age-related non-
communicable diseases, including neurodegeneration [132]. Since the PTMs arise from specific 
combinations of covalent modifications e.g. enzymatic processing and proteins they are 
considered the defining feature of the molecular pathology and therefore they have the advantage 
over intact proteins to create a specific profile of each of the neurodegenerative disorders [133]. 
Several PTMs are enriched within the various inclusion bodies and are found to exist at higher 
levels in the brains of subjects suffering from neurodegenerative diseases, suggesting that certain 
modified species of these proteins might be more relevant biomarkers than the full-length protein 
[134,135]. The tau protein is involved in a range of neurodegenerative disorders known as 
tauopathies. In the following section focus will be on the abnormal processing of tau involved in 
the pathological self-aggregating process. 
1.6.2.1 The processing of Tau 
PTMs initiate the pathological processing cascade of tau. One of the earliest modification of tau 
is phosphorylation. The hyperphosphorylation occurs at several sites and results in a dissociation 
of tau from the microtubules [136,137]. Another early PTM is caspase cleavage leading to a 
truncation of the protein [123,135]. The PTMs increase the susceptibility of tau to self-aggregate. 
In the process of aggregation, tau monomers polymerize to form toxic oligomers, which assemble 
into paired helical filaments that eventually form NFTs [138]. Evidence indicates that there is a 
complex interaction between phosphorylation and truncation of tau and a recent model proposes 
that early truncation at the C-terminal generates neurotoxic tau species while phosphorylation 
may have a neuroprotective role [139]. Several of the PTMs are largely preserved across the 
different tauopathies, including AD [140]. The tau protein is also known to undergo other PTMs 
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such as glycosylation, nitration, ubiquitination and oxidation, however the role of these 
modifications is less well understood [141]. 
 
1.6.2.2 Caspase cleavage of tau  
Truncation of tau is known to accelerate the aggregation of tau in vitro [123,135]. Several 
caspase-cleavage sites have been identified and both caspase-3 and caspase-6 were found to 
cleave tau in the AD brain [142]. Interestingly, the N- and C-terminal regions of tau inhibit the 
polymerization of tau in vitro, implying that caspase cleavage is indeed an important early 
promotor of the aggregation process [143,144]. Among the known cleavage sites, an initial 
cleavage has been found to occur specifically at Asp421, catalysed preferably by caspase-3. This 
cleavage site is well-validated both in vitro and in vivo. Importantly the cleavage fragment (named 
ΔTau or Tau-C) is associated with clinical severity of dementia and neuropathogical severity [145]. 
Caspase cleavage was also proposed as a mechanistic link between Aβ and NFTs since Aβ was 
found to induce apoptosis and thereby the activation of caspases in vitro [146]. A novel pathogenic 
process related to caspase-2 cleavage of tau at Asp314 was recently published. Unlike the other 
PTMs described above, this truncation is unique in the sense that it resists fibrillation. The 
fragment was shown to drive other tau species to the dendritic spines, leading to reduced 
excitatory synaptic transmission and induced memory deficits in mice [147].  
 
1.7 Biomarkers of Neurodegeneration 
A biomarker is defined as “a characteristic that is objectively measured and evaluated as an 
indicator of normal biological processes, pathogenic processes, or pharmacologic responses to 
a therapeutic intervention” [148]. Biomarkers have a broad range of use in research, clinical 
practice and drug development and are classified per their application. The “BIPED” (Burden of 
Disease, Investigative, Prognostic, Efficacy of Intervention and Diagnostic) classification system 
as outlined in table 4 was originally designed for osteoarthritis but has also been proposed to be 
used for classification of biomarkers in the AD field [132,149].  
 
Table 4: The “BIPED” (Burden of Disease, Investigative, Prognostic, Efficacy of Intervention and Diagnostic) 
biomarker classification system. Modified from [149,150] 
 Biomarker Categories (BIPED) 
 
Burden of 
disease 
Investigative* Prognosis Efficacy (Predictive) Diagnostic 
Predictor of 
Disease Activity, 
Stage / Severity 
Explorative 
use 
Predict onset, 
Progression of 
disease 
Monitor treatment 
Predict efficacy 
Classify individuals as 
either having or not 
having the disease 
Design Cross-sectional NA Longitudinal Longitudinal Cross-sectional 
Ideal  
Properties 
b > e > a > d NA d > a > b > e e > b > a > d  c > a > b > d > e 
* Remain to be included in one of the other BIPED categories due to insufficient clinical evaluation. a: high 
sensitivity, b: reliable specificity, c: detectable early in the disease course, d: inexpensive, easy accessible 
and non-invasive, e: repeated measurement feasible. NA: Not applicable  
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Diagnostic biomarkers should aid in the distinction between diagnostic groups e.g. diseased 
versus healthy controls at a single point in time. Longitudinal biomarkers include prognostic and 
predictive biomarkers. A prognostic biomarker is used to obtain information about a future 
outcome e.g. progression of a disease or death, while a predictive biomarker should identify those 
subjects that are likely to respond to a given therapy. It is possible that a single biomarker can 
have several applications [151,152].  
 
Established biomarkers of neurodegeneration belong to two categories; CSF biomarkers and 
neuroimaging biomarkers (see section 1.7.1). These biomarkers aid in the diagnosis of dementia-
related diseases, however their large-scale use in clinical practice is limited because they are 
measured using expensive, time-consuming and invasive procedures (the lumbar puncture). In 
2010, a hypothetical model of the major biomarkers describing the temporal evolution across the 
clinical disease stages of AD was put forward [153]. The model, which was updated in 2013 [154], 
include the most well-established biomarkers assessing Aβ deposition and neurodegeneration 
(figure 7). 
 
Figure 7: The updated hypothetical model of dynamic biomarkers of the Alzheimer’s disease pathological 
cascade. FDG: Fluorodeoxyglucose; MCI: Mild Cognitive Impairment; PET: Positron Emission Tomography; 
MRI: Magnetic Resonance Imaging; Figure adapted from [154] 
 
An important update in the revised model was that CSF tau may become abnormal before Aβ as 
illustrated in the lower left of figure 7. The abnormality can however not be detected with the 
current sensitivity of the analytical methods. This evidence was based on autopsy data published 
by Braak and Del Tredici [155], and later also confirmed by Young and colleagues in a 
subpopulation using a data-driven modelling approach of CSF biomarker data from the 
Alzheimer’s Disease Neuroimaging Initiative [156]. 
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1.7.1 Cerebrospinal Fluid and Imaging Biomarkers 
The three core CSF biomarkers: Aβ1-42, t-tau and p-tau are used as diagnostic biomarkers for AD. 
Aβ1-42 is found in lower concentration in subjects with AD while t-tau and p-tau are found to be 
elevated in diseased subjects [157]. The diagnostic accuracy of these biomarkers has been 
assessed in a range of subjects and in 2011 this resulted in an incorporation of these biomarkers 
into the diagnostic research criteria for preclinical AD [11]. Beside the well-established diagnostic 
utility at both the MCI and dementia stages there is also evidence supporting a prognostic 
potential, as it was shown that the markers can predict a poor long-term clinical prognosis from 
an early disease stage [158]. There are also other emerging CSF biomarkers that have shown 
promising results however these will not be discussed in this thesis. 
 
There are several well-established imaging techniques used in the diagnosis and prognosis of 
AD and other types of dementia. Brain atrophy measured with MRI can aid in the diagnosis of 
dementia but more promising hippocampal atrophy has been shown to predict the conversion 
from MCI to dementia making it useful for early identification [159]. Fluorodeoxyglucose (FDG) 
uptake is a marker of synaptic activity and neuronal density. FDG PET is used to assess neuronal 
injury and dysfunction and was found to predict longitudinal cognitive decline suggesting that this 
marker may be useful in the selection of patients for clinical trials [160]. PET tracers visualizing 
the key pathological hallmarks of AD, Aβ plaques and NFT, have also been developed. Amyloid 
PET is becoming widely adopted and has been incorporated as a selection criterion for several 
of the on-going and planned prevention trials [73]. Tau PET is emerging but due to problems with 
selectivity and off-target binding, it is still lagging behind Amyloid PET [161].  
 
1.7.2 Blood-based Biomarkers 
Blood as a source for biomarkers hold promise since it persists many of the characteristics that 
define an optimal marker. Unlike CSF, it can be obtained rapidly by a minimally invasive and 
inexpensive procedure, and it allows for repeated measures over time [152]. The success has 
however been highly limited due to a lack of understanding of how a peripheral biomarker signal 
relates to processes occurring centrally in the brain. Another challenge is that the blood-brain-
barrier (BBB) exerts a natural limit for the transfer of substances from the central nervous system 
(CNS) to the peripheral blood. The transport of substances from the CNS into the periphery may 
be strictly controlled under normal conditions, however pathological alterations can potentially 
trigger a release of brain specific proteins into the periphery [162] or on the other hand interfere 
with the clearance of potentially harmful substances from the brain [163]. The disruption of the 
BBB may be phenotypically determined to the extent that the degree of BBB involvement is very 
heterogeneous across the diverse etiologies of AD [163]. Beside the transport over the BBB two 
recently described clearance systems were identified in the brain; a glymphatic system [164] and 
 Biomarkers of Neurodegeneration 27 
a lymphatic system [165] proving that macromolecules or fragments of these can be released 
from the brain and transported to the peripheral system.   
 
Several different approaches have been used for the identification of blood-based biomarkers. 
The approaches generally fall into two categories; i) the omics approaches including genomics, 
proteomics, metabolomics and transcriptomics searching for patient-specific multi-biomarker 
profiles and ii) single protein candidates or fragments hereof [166]. The former will not be 
discussed further in this thesis. Among the most extensively studied single protein candidates are 
Aβ and tau.  
 
As outlined earlier, the processing of both Aβ and tau involve several PTMs and they appear to 
be key pathological events. Specifically focusing on protein fragments generated by disease-
specific combinations of proteins and proteases could theoretically result in an easier release 
from the brain, as the fragments due to their smaller size can pass through the BBB more easily, 
and at the same time be more specific for pathological changes than their intact counterparts 
[133,166]. The resulting protein fragments are referred to as neo-epitopes. The use of neo-epitope 
biomarkers in the AD field is not new, as both Aβ and p-tau are examples of neo-epitope CSF 
biomarkers generated by cleavage and phosphorylation, respectively.  
 
This thesis focus on the utility of two such neo-epitope fragments of tau, named Tau-A and Tau-
C. Emphasis will not be put on the technical aspects of the biomarker development and 
measurement, but solely explore the potential use of these markers in a population-based cohort. 
 
1.7.2.1 Tau Neo-Epitope Biomarkers in Serum 
Processing of tau in the context of biomarker development is of great interest as the initial 
proteolytic cleavage appears to catalyse the aggregation cascade. As previously mentioned, the 
Tau-C fragment is generated by the caspase-3-mediated cleavage at Asp421, and its association 
with the AD pathology is well-established. The second fragment, Tau-A, is an N-terminally 
truncated fragment of tau generated by ADAM-10-mediated cleavage at Ala152. The 
development of this fragment as a potential biomarker for AD is based on the hypothesis that tau 
is exposed to secretase-mediated cleavage either directly in the brain or as a subsequent 
processing in the periphery [167]. Both potential biomarkers have previously been tested in minor 
clinical settings. In the initial evaluation of Tau-A, the marker was found to have an inverse 
correlation with cognitive function in a cross-sectional study of subjects with a clinical diagnosis 
of probable AD [167]. In serum samples from a Phase III clinical trial of subjects with mild to 
moderate AD, Tau-A and Tau-C showed very limited diagnostic utility, but the ratio between Tau-
A and Tau-C was related to the rate of disease progression [168]. In relation to sports-related 
concussion the level of Tau-A was found to peak rapidly after an injury, and within a timeframe of 
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12 hours the marker could identify the subjects with complicated concussion, suggesting that Tau-
A is indeed related to the extent of injury in the brain [169]. The potential for differential diagnosis 
was assessed in an observational cross-sectional study of patients originally presenting with 
memory complaints. The fragments, Tau-A in particular, were found to be elevated in patients 
with MCI and mild-to-moderate AD when compared to patients with other dementias and patients 
with non-dementia-related memory complaints [170]. 
    
1.7.2.2 The Need for Non-Invasive Biomarkers in Dementia 
Despite the fact, that the existing CSF and imaging biomarker for AD and dementia are highly 
accurate, barriers to clinical implementation exist as the invasiveness and high expenses of these 
procedures, preclude large-scale use at the population level. The blood based biomarkers are 
therefore key for early identification and prognosis, as a well-validated blood-based biomarker 
may be used as a screening tools to identify the subjects with high disease risk, or subjects with 
a high likelihood of progression. Additionally, sampling at multiple time-points is another key 
feature of blood-based biomarkers useful not only as an indicator of disease onset or risk, but 
also to carefully monitor treatment efficacy.  
2 
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2. Aims and Study Design 
Given the increase in average life expectancy and the subsequent rise of dementia prevalence, 
the identification of subjects at high risk of developing dementia is key for prognosis and early 
intervention. In their present form, no single diagnostic instrument or combination of instruments 
is sufficiently developed to be used for dementia screening.  
 
2.1 Research Questions and Hypothesis 
1) What risk factors are associated with dementia and cognitive dysfunction in late-life? 
2) Are blood levels of tau neo-epitope biomarkers associated with dementia, and if so, can these 
be used as prognostic biomarkers?  
 
The research questions lead to the following hypothesis: 
Modifiable risk factors and blood-based biomarkers are relevant predictors of dementia and can 
be used as first step in a multi-stage screening process for the identification of subjects in most 
need on preventive interventions or to identify subjects suitable for enrollment in clinical trials.  
 
2.2 Aims 
The overall aim was to obtain a better understanding of the underlying comorbidities driving the 
pathogenesis for the clinical representation of dementia in elderly women. The overall aim led to 
the following specific aims:  
1. Identify risk factors for incident dementia and its subtypes (Paper II). 
2. Assess the association between precursors of type 2 diabetes and cognitive dysfunction. 
(Paper III). 
3. Assess the risk of progression to dementia in subpopulations of women with signs of 
cognitive deficits and investigate cognitive courses in late-life including an identification 
of risk factors specifically associated with the progression (Paper IV).  
4. Evaluate the possible utility of two novel serological biomarkers of truncated tau as 
predictors of incident dementia in women (Paper V). 
 
The Prospective Epidemiological Risk Factor Study (PERF), a population-based prospective 
cohort study of elderly women in Denmark founded the basis of the current work. A cohort profile 
with a detailed outline of the overall study design, aims, available data and key findings was 
published recently (Paper I). 
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2.3 Study Design 
The flow chart depicted in figure 8 outlines a short summary of the study designs including size 
of study populations, endpoints, primary exposures of interest, methods of follow-up and the 
statistical methods used in each of the included papers.  
 
Figure 8: Flow chart depicting the relation between the individual papers and the baseline and follow-up 
studies. Study population size, primary endpoint and exposure of interest, method(s) of follow-up and the 
statistical method used are listed for each paper. FU: Follow-up.  
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Why was the cohort set up?
The world’s population is ageing.1 In Europe alone, the
elderly population over age 65 will double from 88 to 153
million and the fastest growing segment of the population
will be those over 80, tripling in number from 24 to 60 mil-
lion in 2060.2 Low birth rates and increasing longevity are
the key factors in this shifting trend in ageing demograph-
ics.3 Maintaining a healthy life is important, as an ageing
population in good health will limit the pressure on health
care systems.3,4 However, it is likely that risk factors com-
promising healthy ageing, such as smoking, obesity, excess
alcohol consumption, unemployment, and lack of physical
activity, will negatively affect the years people spend in
good non-treatment requiring health.1,5 In 2006, it was
estimated that women in the Western European countries
are expected to live about 80% of their lives in good
health. In other words, this predicts a healthy life expect-
ancy up to 20% shorter than the total life expectancy.4
Focus on a healthy elderly population is therefore of
greater interest than ever.
Age-related diseases are usually expressed as chronic
conditions commonly occurring in combination with each
other, with cardiovascular disease and type 2 diabetes
being two of the most common age-related diseases in the
EU.1,4 The ability to understand the links and underlying
pathogenesis are therefore crucial in order to be able to
shift the treatment regimen from disease treatment to pre-
ventive measures, thereby prolonging the period that eld-
erly people spend in good health.
The Prospective Epidemiological Risk Factor (PERF)
Study, an observational, prospective cohort study of
Danish postmenopausal women, was designed with the
purpose of obtaining a better understanding of the devel-
opment of age-related diseases in postmenopausal women.
In 1999, the source population was identified from a data-
base of subjects who had previously been screened for par-
ticipation in one of 21 clinical randomized controlled trials
(source studies6–24). All living subjects with a unique per-
sonal subject identification number and a valid postal ad-
dress constituted the source population (a total of 8875
women). The source studies were all initiated with the pur-
pose of obtaining further knowledge about the aetiology
and pathogenesis of menopause-related diseases, and
included both intervention and non-intervention studies
(as illustrated in Figure 1). The source population therefore
consists of women who previously participated in a source
study or were screened, without being randomized. The
first source study was initiated in 1977. In 1999, the first
participants were enrolled in the epidemiological cohort of
the PERF study (henceforth termed PERF I), and from
September 2013 to December 2014 the participants com-
pleted the latest follow-up (termed PERF II). The total
number of participants attending the baseline examination
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(PERF I) was 5855, of whom 2103 attended the follow-up
visit (PERF II) approximately 15 years later. Including the
source studies, the study may be considered an ambidirec-
tional cohort study with a total observation period of more
than 35 years. The PERF I and PERF II studies were funded
by the Danish Research Foundation (Den Danske
Forskningsfond).
The current paper outlines the study design, the study
population and an overview of the collected data together
with a summary of the key findings until now.
Who is in the cohort?
Inclusion
In 1999, an invitation to attend the baseline examination
was sent to the entire source population (n ¼ 8875) except
for those who died since their last contact with the clinic
(n ¼ 732). In this subgroup, causes and times of death
were collected from the Danish National Death registry.
No active recruitment initiatives besides the invitation was
taken, leaving a total of 5855 (72%) women to consent
and attend the baseline examination of the epidemiological
PERF I study conducted at the Center for Clinical and
Basic Research (CCBR) in cities of either Aalborg or
Ballerup, Denmark, between 1999 and 2001. There were
no in-/exclusion criteria at the time of enrolment in the co-
hort study.
A subcohort (PERF II), initially being enrolled at the
CCBR clinic in Ballerup, was re-investigated in 2013-14,
when invitations were sent to 2813 women from the ori-
ginal PERF I cohort. Those subjects who did not respond
to the written invitation were contacted by phone. As a re-
sult of this active recruitment, a total of 2103 (75%)
Figure 1. Source studies defining the source population for the Prospective Epidemiological Risk Factor (PERF) study illustrated on a timeline
including number of participants, study duration and type of intervention. Bubble size is proportional and equivalent to the number of partici-
pants. All bubbles are sized relative to the largest study (N¼ 2,789). Color represents type of intervention; white bubbles are nonintervention
studies, light grey bubbles are placebo controlled bisphosphonate studies, medium grey bubbles are placebo controlled hormone replace-
ment therapy studies and dark grey bubbles represent other types of intervention studies. Black lines correspond to the study duration (in
years).
Figure 2. Flowchart of participants and >non-participants in the baseline
and the follow-up study. The repeating occurrence of deceased and
non-responders/declined illustrate the number of deceased and nonres-
ponders/declined between two consecutive time points on the time
scale.
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women attended the follow-up study (PERF II), which
took place either in their own home or at the CCBR clinic
in Ballerup. Figure 2 shows the number of participants and
non-participants from baseline to follow-up. All the sub-
jects were given ample time to consider participation and
gave their written consent before any study-related proced-
ure was carried out. The study was conducted in accord-
ance with Good Clinical Practice and the Helsinki
Declaration II.
Cohort characteristics, a comparison between
baseline participants, follow-up participants and
non-participants
The baseline characteristics of the entire cohort (PERF I)
and the follow-up participants (PERF II) are shown in
Table 1. The mean age in the baseline cohort (PERF I) was
70.8 years (49.7-88.8). Nearly 75% of the cohort had pri-
mary school as their highest level of education and less
than 10% had a university degree. The follow-up
Table 1. Selected baseline characteristics of the Prospective Epidemiological Risk Factor (PERF) study. The full study population
(n ¼ 5855) are shown along with specific subgroups of; subjects who died before follow-up (n ¼ 1649), subjects who attended
the follow-up visit (PERFII) (n¼ 2103) and subjects who did not attend the follow-up visit (n ¼ 2103). Numbers are shown as ab-
solute numbers with percentile in brackets for categorical variables. For numerical variables, the mean 6 standard deviation
(SD) are shown
Parameter N Baseline
Participants
(PERF I)
N ¼ 5855
Dead before
follow-up
N ¼ 1649
Follow-up
participants
(PERF II)
N ¼ 2103
Follow-up
non-participants
N ¼ 2103
P-value*
Follow-up
participants vs
non- participants
Age (mean6 SD, years) 5855 70.8 (6.5) 74.9 (5.9) 68.0 (6.0) 70.3 (5.9) <0.001
Menopause age (mean6 SD, years) 5783 49.0 (4.9) 48.7 (5.0) 49.1 (4.8) 49.1 (4.8) 0.9
Highest level of education 5841 <0.0001
Primary school, n (%) 4178 (72) 1215 (74) 1428 (68) 1535 (73)
High School, n (%) 1250 (21) 320 (20) 482 (23) 448 (21)
University, n (%) 413 (7) 110 (7) 192 (9) 111 (5)
Height (mean6 SD, cm) 5637 161 (5.9) 160 (6.0) 162 (5.8) 161 (5.8) <0.001
Weight (mean6 SD, kg) 5637 67.7 (11.7) 65.5 (11.9) 68.8 (11.4) 68.4 (11.6) 0.2
BMI (mean6 SD, kg/m2) 5637 26.1 (4.3) 25.7 (4.4) 26.2 (4.2) 26.5 (4.2) 0.07
BMI groups 5637 0.1
Underweight (<18.5), n (%) 90 (2) 46 (3) 21 (1) 23 (1)
Normal ( 18.5-25.0), n (%) 2343 (42) 699 (45) 871 (42) 773 (38)
Overweight (> 25.0-30.0), n (%) 2248 (40) 567 (37) 823 (40) 858 (43)
Obese (> 30.0), n (%) 956 (17) 238 (15) 356 (17) 362 (18)
Smoking 5844 0.6
Never, n (%) 2767 (47) 634 (39) 1077 (51) 1056 (50)
Past, n (%) 1762 (30) 525 (32) 610 (29) 627 (30)
Current, n (%) 1315 (23) 487 (30) 416 (20) 412 (20)
Alcohol 5807 <0.0001
Never, n (%) 2531 (44) 757 (46) 843 (40) 931 (45)
<10.5 alcohol units/week, n (%) 1380 (24) 348 (21) 451 (22) 581 (28)
10.5-21 alcohol units/week, n (%) 1497 (26) 423 (26) 615 (29) 459 (22)
>21 alcohol units/week, n (%) 399 (7) 107 (7) 180 (9) 112 (5)
Physical activity 5843 0.05
Never, n (%) 1840 (31) 720 (44) 525 (25) 595 (28)
1 time/week, n (%) 1233 (21) 340 (21) 451 (21) 442 (21)
2 times/week, n (%) 748 (13) 179(11) 308 (15) 261 (13)
3þ times/week, n (%) 2022 (35) 408 (25) 819 (39) 795 (38)
Blood pressure
Systolic (mean6 SD, mmHg) 5677 150 (24.4) 155 (25.4) 147 (23.3) 150 (24.2) <0.001
Diastolic (mean6 SD, mmHg) 5679 81.9 (11.5) 81.7 (12.3) 82.0 (10.7) 81.8 (11.6) 0.6
Hypertension, n (%) 5838 1807 (31) 606 (37) 523 (25) 678 (32) <0.0001
Hyperlipidaemia, n (%) 5845 530 (9) 142 (9) 224 (11) 164 (8) 0.002
Diabetes, n (%) 5842 181 (3) 75 (5) 47 (2) 59 (3) 0.06
*t test for numerical variables and chi-square test for categorical variables.
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participants were characterized as being younger and
slightly higher-educated. With an average BMI of 26.2 kg/
m2, this part of the cohort comprised 57% overweight or
obese women. There were no differences between the
follow-up participants and non-participants with regards
to BMI. In relation to lifestyle variables (smoking, alcohol
and physical activity), follow-up participants and non-
participants for PERF II were found to be similar, although
the follow-up participants comprised a higher proportion
of subjects consuming > 10.5 alcohol units per week. The
systolic blood pressure and the proportion of subjects with
self-reported hypertension were higher in the group of
non-participants than in the participating group, whereas
the proportion of subjects with self-reported hyperlipidae-
mia was lower.
Cohort and target population characteristics
Comparison of study participants with the target popula-
tion was done using data on Danish women aged 45þ,
from the Danish Health Interview Surveys (SUSY) in
200025 and 200526 and the StatBank from Statistics
Denmark27 (Table 2).
The average lifespan in the cohort is very similar to the
average life span for Danish women. When compared with
Danish women aged 45þ generally, the PERF cohort is
characterized as slightly less physically active and more
overweight/obese. The proportion of current smokers is
less in the cohort and subjects not drinking alcohol is larger
in our cohort compared with Danish women aged 45þ. In
relation to health, the two main causes of death are cardio-
vascular disease and cancer in both the cohort and the
background population, and the proportions of deaths at-
tributable to these diseases are comparable. For other
comorbidities, the proportions of subjects with diabetes
and depression in the cohort are similar to the target popu-
lation, but the prevalences of hypertension and osteopor-
osis are approximately 2-fold higher in the cohort.
How often have they been followed up?
Concomitant with the PERF II follow-up study, all subjects
have been followed with registry linkage using population-
based national registries. With approval from the author-
ities, we have collected registry data on all baseline
participants (n ¼ 5855). By use of a personal subject identi-
fication number (CPR-number), the Danish national regis-
tries contain individual-level data on the entire Danish
population. Linkage has been done with the following
registries: the National Danish Patient Registry, the
National Danish Causes of Death Registry, the Danish
National Diabetes Register, the Danish Cancer Registry
and the Danish National Pathology Registry. For more in-
formation on the registries, please refer to Table 3.
The most recent linkage was done in January 2015, and
this linkage is expected to continue until the remaining sub-
jects from the cohort are deceased. The registry information
is available for research within the scope of the study.
Table 2. Comparison of the PERF cohort and the target popu-
lation comprising Danish women aged 45 and older. Data on
the target population are derived from either Statistics
Denmark or the Danish Health Interview Surveys. Values are
shown as percentages if not otherwise indicated
Variable Baseline
cohort
(PERF I)
Danish
Women 45þ
(target
population)
P-valuee
Demography and lifestyle
Age (% of total group)
60-64 18.3 25.3a <0.01
65-69 23.2 22.0a 0.02
70-74 28.7 20.4a <0.01
75-79 20.6 18.9a <0.01
80-84 9.2 13.4a <0.01
Average lifespan (years)b 83.0 82.7a
Smoking (% of total group)
Current 22.5 31.9‡ <0.01
Never 47.3 39.8‡ <0.01
Alcohol (% of total group)
Never 43.6 28.2c <0.01
<10.5 alcohol units/week 23.8 44.1c <0.01
10.5-21 alcohol units/week 25.8 18.2c <0.01
> 21 alcohol units/week 6.9 9.5c <0.01
Physical activity (% of total group)
No 31.5 21.9c <0.01
Yes 68.5 78.1‡ <0.01
BMI (% of total group)
Underweight (<18.5) 1.6 4.1c <0.01
Normal weight ( 18.5 <25) 41.6 54.4c <0.01
Overweight ( 25) 39.8 30.8c <0.01
Obese ( 30) 17.0 10.7c <0.01
Health
Causes of death (% of total group)
Cardiovascular 27.3 25.7a
Cancer 32.2 33.8a
Comorbidities (% of total group)
Hypertension 31.0 16.4c <0.01
Diabetes 3.1 3.9c 0.02
Osteoporosis 10.9 6.1d <0.01
Depression/anxiety 6.6 5.5d 0.02
aRetrieved from Statistics Denmark.
bThe average lifespan was calculated for all deceased subjects by the end of
2014.
cData from the Danish Health Interview Surveys 2000.
dData from the Danish Health Interview Surveys 2005.
eThe z-score test for two population proportions.
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What has been measured?
Baseline and follow-up examination
At the baseline visit (PERF I), participants completed a
health examination involving a physical examination includ-
ing blood pressure measurement, electrocardiogram (ECG),
medical history and a health-related questionnaire (for more
information on the questionnaire see separate section below).
Participants provided blood and urine samples for standard
biochemical analysis and for future analysis by storage in a
biobank. Moreover, dual energy X-ray absorptiometry
(DEXA) scans of the whole-body, spine, hip and arm, X-ray
of the spine and mammography were obtained.
At the follow-up examination (PERF II), medical history
and recording of all current medications were obtained.
Measurements of height, weight, waist and hip circumfer-
ences, blood pressure, heart rate and respiratory frequency
was completed. Muscle strength was determined using a
hydraulic hand-grip dynamometer. An EQ-5D-3L evaluation
was completed by the participant to assess their self-reported
quality of life, and a Category Fluency Test together with a
Short Blessed Test was done to test cognitive performance.
Please refer to Table 4 for information on the data collected
at the baseline and the follow-up examination.
Questionnaire
The baseline and follow-up questionnaire was completed as a
structured interview with an investigator or study nurse and
the participant. Standard demographic information such as
age, menopause age and level of education, along with infor-
mation on physical activity, current and past smoking habits
and current and past drinking behaviour was included in the
questionnaire. Information on diet obtained at baseline was
limited to information on consumption of coffee/tea, dairy
products and vegetarian status. Medical history, including
treatment (medication/surgical) and familial medical history,
was obtained as part of the interview for several disorders
including, but not limited to, neurological or psychological
disorders, cardio-/cerebrovascular disease, lung disorders,
cancers, muscles and joint diseases and metabolic disorders.
Collection, analysis and storage of biological
material
For each participant, urine and fasting blood samples were
collected for routine analysis and biobank storage at base-
line (n ¼ 5668). The biobank also contains DNA samples
for those subjects who gave written consent for this specific
analysis (n ¼ 5553). At the follow-up visit, fasting blood
samples were collected. Samples are stored at -20 C (urine,
DNA samples) and -80 C (serum). Routine blood and urine
analysis was carried out at a College of American Pathology
(CAP) certified central laboratory (Nordic Bioscience
Laboratory) at both baseline and follow-up.
Genomics
In collaboration with deCODE genetics, Iceland, and Sct.
Hans Hospital, Denmark, DNA samples from the PERF
study have been genotyped and associations between single
nucleotide polymorphisms (SNPs) and selected outcomes,
including bone mineral density/osteoporotic fractures,34
Table 3. Overview of registry linkage in the Prospective Epidemiological Risk Factor (PERF) study
Registry Type of information received Time period covered Latest linking
National Danish Patient Registry Hospitalization and discharge time 1977 on 31 Dec 2014
Hospital and department 1977 on
Diagnoses (ICD classification) 1977 on
Treatments and operations 1996 on
National Danish Causes of Death Registry Time of death 1970 on 31 Jan 2015
Underlying cause of death 1970 on
Complementary cause of death 1970 on
Danish National Diabetes Register Date of inclusion 1990 on 31 Dec 2014
Inclusion criteria 1990 on
Inclusion cause 1990 on
Danish Cancer Registry Diagnosis and time of diagnosis 1943 on 31 Dec 014
Tumour distribution 1943-2003
Treatment 1943-2003
TNM classification 2004 on
Ann Arbor staging 2004 on
Treatment 1943-2003
Danish National Pathology Registry Data from pathological tests (by SNOMED code) 1997 on (1970 on) 31 Dec 2014
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type 2 diabetes,35 schizophrenia,36 depression37 and cogni-
tive impairment38 have been assessed.
What has it found? Key findings and
publications
The PERF study has generated several important findings cov-
ering the health of elderly women. Selected key findings are
summarized in Table 5. In a cross-sectional nested analysis
from PERF (n¼ 1356), it was shown that peripheral adiposity
exhibits an independent anti-atherogenic effect in elderly
women.39,40 In the entire cohort and in a nested study (n ¼
343), it was shown that endogenous estrogen and hormone re-
placement therapy administered in the early phase of the
menopause may have a protective association with cognitive
impairment later in life.41,42 More recently, it was shown that
matrix metalloproteinase (MMP)-mediated collagen type I
degradation, termed C1M, is an independent risk factor for
all-cause mortality, as subjects with high levels of type I colla-
gen degradation had a 2-fold increased mortality risk com-
pared with subjects with low levels.43 Last, a genome-wide
association study of bone mineral density (BMD) among more
than 30 000 subjects, including samples from PERF I, revealed
a new BMD locus that harbours the PTCH1 gene. The gene is
associated with reduced spine BMD.44
What are the main strengths and
weaknesses?
In this 37-year ambidirectional population-based study,
the participation rate has been higher than 70% through-
out the study. To investigate whether the study population
Table 4. Parameters measured at the baseline (PERF I) and the follow-up visit (PERF II)
Parameter Description PERF I PERF II
General information
Demographics Age  NA
Body weight  
Height  
Education level  NA
Health
Medical history Self-reported questionnaire/interview  
Physical examination Full-body examination  —
Blood pressure  
ECG  —
Cognition Short Blessed Test  
Category Fluency Test (Animals)  
Body composition Arm, hip and spine DEXA  —
Whole-body DEXA  —
X-ray Spine  —
Mammography  —
Muscle strength Hand-grip strength test — 
Lifestyle
Physical activity Walking, leisure activity  
Smoking Current and past smoking behaviour  
Alcohol Current and past drinking behaviour  
Diet Consumption of coffee/tea, dairy products  —
Vegetarians  —
Psychosocial parameters
Quality of life, well-being EQ-5D-3La — 
Blood
Haematology Haemoglobin, leukocytes and differentiation, etc.  
Lipids Total cholesterol, LDL, HDL, triglycerides  
Electrolytes Sodium, potassium, calcium  
Renal function Creatinine  
Liver ALAT, ASAT, albumin, GGT, alkaline phosphatase  
Inflammation High sensitive CRP — 
Specialty biomarkers Osteocalcin, CTX-1, VICM, C1M, C4M, TAU-C  *
NA, not applicable.
aEQ-5D-3L measures health in five dimensions (mobility, self-care, usual activities, pain/discomfort and anxiety/depression) and three levels (no problems,
some problems, extreme problems).
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resembled the target population, we compared the baseline
participants with the general female population in
Denmark aged 45 or older. It is well known that study par-
ticipation is often linked to health superior to that of an
otherwise similar, non-participant background population
(healthy participant bias). However, we did not observe a
healthier profile among the baseline study participants.
The cohort is therefore considered representative of
women aged 45þ in the Danish population. In the study
population, we found a higher prevalence of osteoporosis
at baseline. This could either be caused by selection bias,
as a number of the participants had previously participated
in randomized clinical trials focused on osteoporosis.
However it could also reflect underdiagnosis of osteopor-
osis in the general Danish population, since the source
population not only included women randomized for clin-
ical studies but also those who did not meet the inclusion
criteria (e.g. had high bone mineral density) at the time of
recruitment.
Although the follow-up cohort (PERF II) was se-
lected based on geographical limitations due to data
collection in the participants’ own homes, the similarities be-
tween follow-up participants and follow-up non-partici-
pants strengthen the internal validity of the data.
Besides the length of the follow-up period, the linkage
to a range of nationwide registries is a major strength. The
registry data are comprehensive and the registries were es-
tablished relatively early, e.g. cancer and cause-specific
death information since the 1940s and hospitalizations
since the 1970s.51 Registration has been mandatory since
1977. The registry data therefore strongly support the
identification of outcomes and, because of the limited loss
to follow-up, it adds analytical power to the study.
Moreover, this cohort is to our knowledge one of the larg-
est cohorts of postmenopausal women with full-body
DEXA scans, which enables extensive studies of body
composition.
Regarding weaknesses, the cohort only comprised
women and therefore generalization cannot be made to
men of similar ages. Moreover, the duration of time
passed from PERF I (year 1999) to PERF II (year 2014) is
long in a cohort of such advanced age. In order to prevent
selection bias towards the healthier segment of this ageing
cohort, great effort was made in following up on invited
participants not instantly replying to our invitation. Also,
visiting the subjects in their own homes increased the
number of subjects with illnesses still wanting to
participate.
Table 5. Summary of major findings from the Prospective Epidemiological Risk Factor (PERF) study
Endpoint/Exposure Major findings
Cardiovascular disease Localization of fat mass is more important for atherogenesis than obesity per se39,40
Enlarged waist circumference and elevated triglycerides are simple diagnostic tools that could facilitate the
identification of postmenopausal women at increased risk for accelerated atherogenesis and related adverse
outcomes45
Hormone replacement therapy for 2-3 years has relative cardiovascular benefits and reduces the risk of all-
cause mortality46
Bone/osteoporosis Limited hormone replacement therapy given in the early postmenopausal years can provide long-lasting
benefits in terms of preventing bone loss and related fractures47
Bone mass measurement offers effective fracture prediction independent of the site of measurement and age
of the patient48
Association of conditions Aortic calcification seems to independently contribute to the development of osteoporosis in the proximal
femur49
Independent association of peripheral vascular disease with osteoporosis in the proximal femur50
Cognitive function Protective association of body fat mass with cognitive impairment in elderly women, through a more promin-
ent exposure to endogenous estrogens41
Short-term hormone replacement therapy administered in the early phase of the menopause may provide a
long-term protection against cognitive impairment42
Genomics Variant of transcription factor 7-like 2 (TCF7L2) gene confers risk of type 2 diabetes35
Association of dopamine beta-hydroxylase gene variants with cognitive performance and depression in eld-
erly women37,38
Bone mineral density locus identified that harbours the PTCH1 gene. The gene is associated with reduced
spine BMD44
All-cause mortality Increased MMP-mediated tissue degradation, measured by C1M, is an independent risk factor for all-cause
mortality43
International Journal of Epidemiology, 2016, Vol. 00, No. 00 7
40 The Prospective Epidemiological Risk Factor (PERF) Study 
Can I get hold of the data? Where can I find
out more?
All data are stored electronically in anonymous form.
Aliquoted biological material is stored in a biobank at
the Nordic Bioscience Laboratory. Currently, the data
are available only to employees of Nordic Bioscience A/
S, Denmark; however, the PERF study group will
welcome any enquiries regarding collaboration or data
sharing for further investigations. Potential collaborators
are invited to contact the PERF study group at
[perf@nordicbio.com].
Profile in a nutshell
• The Prospective Epidemiological Risk Factor (PERF)
Study is an ambidirectional population-based study
of postmenopausal women set up with the purpose
of obtaining a better understanding of the aetiology
and pathogenesis of age-related diseases.
• Participants were recruited from a source population
of 8875 women residing in Denmark. The baseline
examination (PERF I) comprised 5855 women with
mean age of 70.8 years (49.7-88.8) and took place
between 1999 and 2001.
• All subjects have been followed up with registry link-
age using population-based national registries. Further,
a subcohort was re-invited to attend a follow-up visit
between 2013 and 2014 (PERF II). Registry data are
available for all baseline participants. From the base-
line population, 2103 were enrolled in PERF II.
• The data repository contains a wide range of health-
related and lifestyle measures, biological samples
from the baseline and follow-up studies, genetic in-
formation and linkage to nationwide registries.
• The PERF study group will welcome any enquiries
regarding collaboration or data sharing for further
investigations.
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3.2 Cognitive Screening in PERF 
The neuropsychological assessment in PERFI and PERFII included two short cognitive screening 
tools; the Short Blessed Test [171] and a category fluency test with animal naming [172]. The 
characteristics of each test, including operationalization and diagnostic performance in relation to 
dementia is outlined below.  
 
3.2.1 The Short Blessed Test 
The Short Blessed Test (SBT) is a six-item test assessing orientation, concentration, and memory. 
Scores range from 0 to 28, with lower scores indicating better performance. The SBT includes 
three questions related to orientation (Q1: What year is it now? Q2: What month is it now? Q3: 
What time is it now?), followed by two questions related to concentration (Q4: counting backwards 
from 20 to 1 and Q5: listing the 12 months backwards within 1 minute). Finally, in relation to 
memory, subjects are asked to repeat and remember a memory phrase (a name and an address) 
following the two first questions (Q1 and Q2). The memory phrase should be recalled after Q5. 
The administration time is approximately 5 minutes. Findings from the Memory and Aging Project 
suggest that a score between 0-4 is considered normal while 5-9 is consistent with questionable 
impairment (sometimes also referred to as MCI). A threshold of ≥10 was identified as cognitive 
impairment consistent with dementia [173]. The diagnostic accuracy is very comparable, 
occasionally superior, to more comprehensive tests like the Mine Mental State Examination when 
it comes to dementia screening [174–176].  
 
3.2.2 Category Fluency Test 
The category fluency test (CFT) measures verbal fluency, in this test subjects are asked to name 
as many animals as possible in 60 seconds. Higher scores indicate better performance [172]. The 
administration time is 1-2 minutes. Different fluency tests are widely used in neuropsychological 
testing for dementia, with the category of “animals” as the most frequently employed [177]. In 
relation to the separation of AD subjects from cognitive normal individuals, receiver operating 
characteristic curve analysis has found the diagnostic accuracy to be excellent (AUC > 0.9) 
[178,179]. An imaging study has shown that the temporal lobe is activated while performing the 
test [180]. Few studies have examined the prognostic performance of the test although category 
fluency has been shown to be able to discriminate between very mild AD and controls [181].  
 
3.3 Dementia in PERF 
3.3.1 The Danish health registries 
Dementia diagnosis was obtained from two Danish national health registries: The Danish National 
Patient Register (NPR) and the Danish Register of Causes of Death (RCD). The registries contain 
individual level data on the entire Danish population. Cause of death registration dates back to 
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1875 and since 1970 it has been fully computerised. In its current form, a cause of death is 
registered by the medical doctor who issues a death certificate indicating the underlying and 
contributory causes of death. The causes have been classified according to ICD-10 since 1994 
[182]. The NPR was established in 1977 and is considered the most comprehensive of its kind. 
All diagnoses have been classified in accordance with ICD-10 since 1994. Before 1994 diagnostic 
information was coded according to ICD-8 [183]. The following codes were considered a dementia 
diagnosis: F00-F03, G30-G32 and R54. 
3.3.2 Diagnostic groups in PERF 
In total 636 incident dementia cases were identified from the NPR and RCD during the follow-up 
period. As outlined in table 5 all dementia cases were divided into three differential groups. The 
majority of subjects holding a dementia diagnosis was identified from the NPR (n = 581) while the 
remaining 55 dementia cases were identified solely on their cause of death in RCD, since they 
were not diagnosed with dementia according to the NPR. 
Table 5: Overview of dementia diagnosis in PERF grouped by ICD-10 and study specific diagnostic groups. 
Study specific group ICD-10 code Description N 
AD 
F00 Dementia in Alzheimer disease 
264 
G30 Alzheimer disease 
VaD F01 Vascular dementia 47 
OD 
F02 Dementia in other diseases classified elsewhere 
325 
F03 Unspecified dementia 
G31 
Other degenerative diseases of nervous system, not 
elsewhere classified 
G32 
Other degenerative disorders of nervous system in 
diseases classified elsewhere 
R54 Senility 
All-cause dementia All All above 636 
3.3.3 Incidence of dementia 
The overall dementia incidence in the cohort was 8.3 per 1000 person years from baseline until 
the end of the follow-up period. The follow-up started on the day of study enrolment and ended 
at occurrence of event (dementia diagnosis), death, or on December 31, 2014 (retrieval of registry 
data), whichever came first. The age specific incidence rates increased with increasing age 
ranging from 1.1 per 1000 person years in the youngest age group (<60 years) to 26.8 per 1000 
person years in the oldest age group (≥80 years). The incidence approximately doubles every 5 
year from age 60 to 80 (Figure 9).  
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Figure 9: Age stratified incidence rates in the PERF cohort compared to other cohorts of relevance [35,184–
186]. Dotted lines represent the 95% confidence limits. *Only incidence for women is illustrated. EURODEM: 
Pooled analysis of four population-based prospective cohort studies. CSHA: The Canadian Study of Health 
and Aging. ACT: Adult Changes in Thought study. Rotterdam: The Rotterdam Study. 
 
This section concludes the introductory and methodological part of the thesis. The following 
section contain each of the four remaining original research papers followed by a general 
discussion and finally a few concluding remarks.
4 
Late-Life Risk Factors for All-Cause 
Dementia and Differential Dementia 
Diagnoses in Women 
4. Late-Life Risk Factors for All-Cause Dementia and
Differential Dementia Diagnoses
Late-Life Risk Factors for All-Cause Dementia and Differential
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Jesper Skov Neergaard, MSc, Katrine Dragsbæk, MSc, Henrik Bo Hansen, MSc,
Kim Henriksen, PhD, Claus Christiansen, MD, PhD, and Morten Asser Karsdal, PhD
Abstract: Since the first evidence of a decline in dementia incidence
was reported in 2011, the focus on modifiable risk factors has increased.
The possibility of risk factor intervention as a prevention strategy has
been widely discussed; however, further evidence in relation to risk
factors is still needed.
The Prospective Epidemiologic Risk Factor (PERF I) study was an
observational prospective study of postmenopausal Danish women who
were initially examined between 1999 and 2001 (n¼ 5855). Follow-up
data on diagnosis and survival as of December 31, 2014 was retrieved
from the National Danish Patient Registry and the National Danish
Causes of Death Registry. Cox proportional hazards regression model
was applied to calculate adjusted hazard ratios (HR) for selected risk
factors for dementia.
Of 5512 eligible subjects, 592 developed dementia within the
follow-up period of maximum 15 years. The independent factors
associated with increased risk of all-cause dementia were depression
(HR¼ 1.75 [95% CI 1.32–2.34]) and impaired fasting glucose levels. A
dose–response relationship was observed between fasting glucose level
and risk of dementia with HRs of 1.25 [1.05–1.49] and 1.45 [1.03–2.06]
for impaired (5.6–6.9mmol/L) and hyperglycemic (7.0mmol/L)
glucose levels, respectively. The factors associated with a decreased
risk of dementia were overweight in late-life (HR¼ 0.75 [0. 62–0.89])
and physical activity at least once weekly (HR¼ 0.77 [0.61–0.96]).
The identified risk factors for dementia in women in late-life are all
considered modifiable. This supports the notion that prevention strat-
egies may improve the poor future prospects for dementias in the ageing
population.
(Medicine 95(11):e3112)
Abbreviations: AD = Alzheimer disease, APOE = apolipoprotein
E, BMI = body mass index, CI = confidence interval, HR = hazard
ratio, OD = other/unspecified dementia, PERF = the Prospective
Epidemiologic Risk Factor study, VaD = vascular dementia.
INTRODUCTION
T he world’s population is ageing. As a result, the prevalenceand incidence of dementia has escalated. From the most
recent projections, the prevalence and thereby total number of
people with dementia is projected to nearly triple by 2050
reaching a total of 131.8 million people worldwide, driven
almost entirely by prolonged longevity.1 Since the first signs
of a potential decline in dementia incidence in the United States
were published in 2011,2 followed by several other studies from
Europe,3–5 the possibility of primary prevention by addressing
risk factors has been widely discussed.
Risk factors for dementia are divided into the nonmodifi-
able and modifiable. The nonmodifiable or genetic risk factors
include the Apolipoprotein E (APOE) e4 allele, age, and female
sex.6–8 Many modifiable risk factors have been suggested, but
despite extensive research efforts the evidence is inconclusive.
In 2010, the National Institutes of Health in the United States
stated that results from previous studies were not of sufficient
strength to warrant specific recommendations for disease pre-
vention.9 In 2014, the Alzheimer’s Association reached a
similar conclusion stating that there is still significant uncer-
tainty with respect to the relationship between individual risk
factors and dementia,10 justifying the need for further studies.
It is estimated that around one-third of Alzheimer disease
cases worldwide are caused by 7 modifiable risk factors; low
educational attainment, physical inactivity, smoking, midlife
hypertension,midlife obesity, diabetes, and depression.11 Further
evidence from the FINGER study, a randomized clinical trial in
Finland, suggests that a multidomain interventional approach
focusing on several modifiable risk factors can improve or
maintain cognitive function in the elderly population.12
Our objective was to investigate late-life risk factors for
dementia among elderly women. The women comprised the
PERF cohort in Denmark, one of the largest individual pro-
spective cohorts of elderly women. The outcome, dementia, was
assessed a maximum of 15 years after baseline.
METHODS
Study Population
The Prospective Epidemiologic Risk Factor (PERF I)
study was an observational, prospective follow-up study of
Danish postmenopausal women. The study participants were
identified from a database of subjects who had previously been
screened for participation in 1 of 21 clinical randomized
controlled trials initiated between 1977 and 1996, including
both intervention and nonintervention studies. A total of 8875
women constituted the source population, of which 5855
women gave their written informed consent to participate in
the PERF I cohort study. There were no in/exclusion criteria at
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the time of enrolment in the observational study. The baseline
examination took place between 1999 and 2001 and comprised
an interview with completion of a predefined questionnaire, a
physical examination, and blood sampling at the study site. The
questionnaire was completed by 5847 subjects. Subject’s
medical history including, but not limited to, history of depres-
sion, history of cerebral embolism/hemorrhage, history of
hypertension and current treatment, history of diabetes and
current treatment and hyperlipidemia and current treatment,
were self-reported as part of the questionnaire. The physical
examination was completed by 5677 subjects. Vital signs
including height, weight measured without shoes but with
indoor clothes and blood pressure were measured on calibrated
equipment. Blood samples were taken from 5668 subjects and
analyzed at a central laboratory. The analytical sample was
defined as subjects with nomissing data on all relevant variables
as illustrated in the flow diagram (Figure 1). The study was
carried out in accordance with ICH-GCP with study protocol
approval from local ethics committees.
Dementia Endpoint
Follow-up information on dementia status and survival as
of December 31, 2014 was retrieved from the National Danish
Patient Registry and the National Danish Causes of Death
Registry using a unique personal identification number for each
subject. The follow-up started on the day of study enrollment
and ended at occurrence of event (dementia diagnosis), death, or
on December 31, 2014 (retrieval of registry data), whichever
came first. Of the entire study population, a total of 651
dementia cases were identified from the registries. Fifteen
subjects were excluded from the analysis due to a dementia
diagnosis prior to study enrollment. Fifty-five cases were
identified based solely on their cause of death in the National
Danish Causes of Death Registry, since they were not diag-
nosed with dementia according to the National Danish Patient
Registry. The remaining subjects (n¼ 581) had a diagnosis of
dementia in the National Danish Patient Registry leading to a
total of 636 incident dementia cases prior to identification of
the analytical sample. Dementia diagnoses were classified
according to the International Classification of Diseases,
10th revision (ICD10). The following codes were considered
a dementia diagnosis: ‘‘OD’’ (dementia in other diseases
classified elsewhere; unspecified dementia and senility)
[F02-F03 and R54, n¼ 325], ‘‘AD’’ (dementia in Alzheimer
disease, other degenerative diseases of the nervous system)
[F00 and G30–G32, n¼ 264], and ‘‘VaD’’ (vascular dementia)
[F01, n¼ 47].
Statistical Analysis
Statistical analyses were conducted using MedCalc Stat-
istical Software version 14.8.1 (MedCalc Software bvba,
Ostend, Belgium) and SAS version 9.4 (SAS Institute Inc,
Cary, NC).
Baseline characteristics of controls and subjects found to
have dementia at follow-up were compared using a one-way
analysis of variance (ANOVA) for quantitative variables and x2
test for comparison of categorical variables (Table 1).
A Cox proportional hazards regression model was used to
assess the selected risk factors in an age-adjusted and a multi-
variate adjusted regression analysis, the follow-up time since
baseline was used as time scale. Age was included as continues
variable and risk estimates reported pr. 5 years of aging. In the
multivariate model, the categorical variables education level
(primary school, high school, or university), body mass index
(BMI, kg/m2) where underweight was <18.5, normal weight
18.5<25, overweight 25<30, and obese 30, smoking
(never, past, or current), alcohol consumption (never, <10.5
alcohol units/week, 10.5–21 alcohol units/week, or >21 alco-
hol units/week), physical activity (other than walking) (never,
once weekly, twice weekly, or 3 or more times per week),
history of depression (yes/no), history of cerebral embolism/
hemorrhage (yes/no), systolic blood pressure >160 mm Hg,
fasting glucose levels (normal <5.6mmol/L, impaired 5.6–
6.9mmol/L, or hyperglycemic 7.0mmol/L) and total choles-
terol levels >6.5mmol/L and age as a continuous variable were
included. Subjects who reported treatment for hypertension,
diabetes, or hyperlipidemia at baseline were included in the
hypertensive (systolic blood pressure >160 mm Hg), hypergly-
cemic (fasting glucose 7.0mmol/L), or hyperlipidemic (total
cholesterol levels >6.5mmol/L) groups, respectively.
Regression analysis was performed for all-cause dementia
and separate analyses for differential diagnoses (OD, AD,
and VaD). Due to a large proportion of missing data from
781 subjects, the family history of dementia (yes/no) was not
included in the multivariate analysis.
RESULTS
Baseline Characteristics
Of the analytical sample (n¼ 5512), a total of 592 demen-
tia cases were identified from the registries during the follow-up
period (Table 1). The maximum follow-up period was 15 years
(mean follow-up: 11.9 3.9 years) starting on the day of study
enrollment and ending at occurrence of event (dementia
FIGURE 1. Analytical sample for the assessment of risk factors for
all-cause dementia and differential dementias: Alzheimer demen-
tia, vascular dementia, and other/unspecified dementias.
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diagnosis), death, or on December 31, 2014 (retrieval of registry
data), whichever came first.
The dementia groups (AD, VaD, and OD) were charac-
terized as being markedly older than dementia-free controls
(74.4–75.8 versus 70.1 years, P<0.001). The proportion of
deceased subjects in each dementia group was markedly higher
than in the dementia-free control group. No differences were
observed in education levels (P¼ 0.2), BMI (P¼ 0.06), smok-
ing habits (P¼ 0.09), and alcohol consumption (P¼ 0.2) when
comparing all-cause dementia with dementia-free controls. The
dementia groups are characterized by a larger proportion of
subjects with elevated blood pressure (P<0.001) and a larger
proportion of physically inactive subjects (P<0.001). When
comparing the differential groups with the dementia-free con-
trols, smoking habits, physical activity, elevated blood pressure,
history of cerebral embolism/hemorrhage, history of depres-
sion, and other neural disorders were significantly different. No
significant differences were observed in the proportion of
subjects with hyperlipidemia between the differential dementia
groups and the dementia-free controls (P¼ 0.2).
Risk Factors for All-Cause Dementia
The overall incidence of dementia in the analytical sample
was 8.9 (8.3–9.7) per 1000 person years. The age-specific
incidence rates increased with increasing age ranging from
0.9 (0.3–2.7) per 1000 person years in the youngest age group
(<60) to 28.0 (23.4–33.6) per 1000 person years in the oldest
age group (80). The incidence approximately doubled every 5
year (data not shown).
A Cox proportional hazards regression model was used to
assess HRs for selected risk factors as listed in Table 2.
Age was a strong risk factor for all-cause dementia and for
differential diagnoses. From an age-adjusted model, physical
activity (other than walking) at least once a week and over-
weight were associated with decreased risk of all-cause demen-
tia, while depression and higher levels of fasting glucose
(5.6mmol/L) were associated with an increased risk of
dementia (see Table 1, Supplemental Content, which contains
the results from the age-adjusted model, http://links.lww.com/
MD/A780).
In the multivariate analysis the independent factors associ-
ated with increased risk of dementia were depression, impaired
fasting glucose levels (5.6–6.9mmol/L), and hyperglycemia
(>6.9mmol/L or treated diabetes). The factors associated with a
decreased risk were overweight and physical activity (other than
walking) at least once a week. Obesity as defined by a BMI30
was not associated with the development of dementia (Table 2).
No major differences were observed between the age-
adjusted and the multivariate-adjusted models.
Risk Factors for Differential Dementia Diagnosis
The risk factor profiles for differential diagnoses of
dementia were generally similar but certain risk factors were
notably different between the AD, VaD, and OD groups
(Table 2). The age-adjusted models revealed that family history
of dementia was associated with an increased risk of AD but no
association was observed for VaD and OD. Impaired fasting
glucose levels were solely associated with AD in the multi-
variate adjusted model, increasing the risk by 33% compared
with normal glucose levels. Being overweight had a negative
association with both AD and OD, lowering the risk by 28% and
25% respectively in the multivariate analysis. Physical activity
at least 3 times per week was associated with a decreased risk of
VaD (58%) and OD (29%) compared with those being physi-
cally inactive (apart from walking). Smoking increased the risk
of VaD, in which the risk was 156% higher than in subjects who
had never smoked. Depression increased the risk for OD with a
similar magnitude as smoking did for VaD. No association was
observed between depression and AD or VaD in either of the
regression models (Table 2).
DISCUSSION
Using public health registries we were able to follow
subjects for up to 15 years from baseline, providing an excellent
opportunity to study potential risk factors in a large sample of
elderly women. To our knowledge, this is one of the largest
individual prospective cohort studies to investigate risk of all-
cause dementia and differential dementia diagnoses in late-life.
Equal to our findings, other large cohort studies (including
the EURODEM collaboration) have found incidence rates of
dementia for women comparable to what we found in the PERF
cohort.7,13,14
The factors associated with an increased risk of all-cause
dementia were increasing age, physical inactivity, depression,
and impaired glucose levels. Being overweight in late-life was
protective against development of all-cause dementia when
compared with women with a normal BMI. The differential
diagnoses of dementia shared several risk factors. Smoking and
depression were solely associated with a higher risk of devel-
oping VaD and OD, respectively.
Our results suggest that overweight in women (mean age
70.7, SD 6.5) has a protective relation to development of all-
cause dementia, AD, and OD. Overweight and obesity have
previously been linked to dementia in both midlife and late-life.
A BMI in midlife indicating overweight or obesity has often
been proposed to increase risk of developing dementia in later
life.15,16 Evidence suggests that the association between over-
weight/obesity and dementia vanish later in life.15 A study in
late-life from the Kungsholmen cohort in Sweden (mean age
80.8, SD 4.5) showed, separately for both men and women, a
similar negative relationship between high BMI and develop-
ment of dementia as we found in our study.17 The CAIDE study
in Finland also showed a negative association between high
BMI in late-life and development of dementia.18 Contradicto-
rily, a retrospective cohort study involving nearly 2 million men
and women in the UK recently disproved the hypothesis that
obesity in midlife could increase the risk of dementia in later life
and actually strengthened the evidence that overweight and
obesity may protect against dementia in later life.19
The CAIDE study also showed that a decrease in BMI from
mid- to late-life and a low late-life BMI of <25 kg/m2 (mean
age, 71.2, SD 4.0) are associated with higher risk of all-cause
dementia and AD.18 We have also previously shown an associ-
ation between changes in body fat mass and cognitive impair-
ment in elderly women.20 The relationship is however unlikely
to be causal since weight loss is known to occur with comor-
bidities in late-life, and is therefore often linked to poor health
and mortality.21 In addition, BMI is known to have several
limitations as a health measure,22 wherefore a simple measure
like waist circumference would have been of interest in the
evaluation of bodyweight and body composition in relation
to dementia.
Among the lifestyle factors studied, only physical inactiv-
ity had an association with increased risk of all-cause dementia.
Physical activity at least once weekly reduced the risk of all-
cause dementia by 20% to 23% compared with physical
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inactivity. For the differential diagnoses of dementia, physical
inactivity was associated with risk of VaD and OD. The causal
relation between physical activity and dementia is uncertain and
some suspect the length of the follow up period may have biased
some of the previous findings.23 A study of physical activity in
late-life from the Rotterdam cohort put follow-up time into
perspective.24 The investigators suggest that physical activity
has an inverse relationship with dementia onset during up to 4
years of follow-up, after which the protective effect diminishes.
They speculate this may either be related to reverse causation or
a short-term effect of physical activity.24 An increase in
physical activity after midlife recently was shown to protect
against both all-cause dementia and AD,25 supporting the
association observed in the current study.
Smoking was not related to all-cause dementia in our
cohort. However, in the analysis of differential diagnoses,
current smoking was associated with an increased risk of
VaD. Pathologically, this makes sense since smoking is a strong
risk factor for both cerebrovascular and cardiovascular diseases.
Smoking is involved in atherosclerosis, causing narrowing of
blood vessels in the brain. In addition, smoking has been shown
to have both a direct, affecting the folding of amyloid b, and an
indirect detrimental effect in relation to dementia.26,27
Depression increased the risk of all-cause dementia and
OD. Evidence from the literature is consistent with our findings
where late-life depression has been associated with the devel-
opment of dementia.28,29 The most recent meta-analyses, one in
the 2014 World Alzheimer’s Report3 and another from Diniz
et al,30 reported increased risks of 97% and 85% respectively. In
the present study, the risk of developing all-cause dementia
increased by 75% in elderly women with a history of depres-
sion, compared with subjects who had never suffered from the
illness. The causal relationship between depression and demen-
tia is however unclear. In the current study, we have no
information about the onset of depressive symptoms. In the
case of late-life onset, the observed association could poten-
tially be a result of reverse causation.
There is somewhat more limited evidence when it comes to
depression and risk of differential dementia diagnoses. In the
current study, we found an association with OD (HR 2.58 (95%
CI 1.82–3.68), while no association was observed with AD and
VaD. Barnes et al28 studied all-cause dementia, AD, and VaD
and found associations between both AD and VaD for subjects
with either late-life depressive symptoms or subjects with both
midlife and late-life symptoms. The review from Diniz et al30
suggests similar associations in their pooled estimates with the
strongest association between depression and VaD. The missing
association with AD in the current study may be caused by
misclassification of subjects in the OD group—a heterogeneous
group that is likely to contain several subjects with AD and
mixed pathologies.
Our findings suggest a potential dose–response relation-
ship between fasting glucose levels and risk of all-cause
dementia when measured in late-life. The risk of all-cause
dementia was increased by 25% and 45% in the impaired
and hyperglycemic groups, respectively. The association
between self-reported diabetes and risk of dementia did not
confirm this relation, a potential result of under diagnosis which
has been estimated to be up to 46% worldwide.31 In relation to
diabetes increased risks of 50% and 58% have previously been
reported in the Kungsholmen Study and the French Three-City
Study.32,33 Contrarily, the Three-City Study found no associ-
ation between impaired fasting glucose and dementia only
with diabetes.
STRENGTHS AND LIMITATIONS
The follow-up information derived from registry data is
uniquely available in Denmark where all contacts with
primary care have been registered since 1977. This results
in very limited loss to follow-up and all subjects can be
followed up until time of death. We studied a large group
of elderly women in Denmark, a homogenous population
where generalization to other population is not obvious.
The cohort only comprised women and therefore generaliz-
ation cannot be made to men of similar ages. It is well known
that women are at higher risk for developing dementia and
although some risk factors are likely to be determined by the
population in study, the HRs from Cox proportional-hazard
analysis were comparable to associations found in similar
cohorts making the generalization more likely.
Among the limitations of the study is the missing Apoli-
poprotein E (APOE) assessment. The APOE e4 allele is a major
genetic risk factor for AD.6 Further, we did not include any
measures of cognitive performance or activities of daily living
at baseline in this analysis, and since we did not have screening
for dementia using a standard diagnostic criteria at baseline it is
possible that some of the dementia cases had prodromal disease
already at baseline eventually affecting the cause and effect
relationship. Risk factors assessed in the analysis were selected
based on the available data and evidence from the literature. No
measures of nutrition or information on diet were obtained at
baseline. These factors have previously been suggested as risk
factors for dementia and could potentially introduce residual
confounding in our analysis.34,35
Epidemiological study designs such as that of the PERF I
study may introduce selection bias by possible over-representa-
tion of relatively healthy subjects in the cohort. Participants in
the PERF I study were recruited by active recruitment from the
CCBR Clinical Research subject database, a recruitment
method that could lead to above-mentioned selection bias. It
should however be noted that their where no in- or exclusion
criteria’s at the time of enrolment, which could potentially
reduce the risk of selection bias.
In relation to differential diagnosis the method with reg-
istry-linkage may have reduced the accuracy of the actual
diagnosis. Differential dementia diagnoses are difficult since
many patients have a mixed pathology making a diagnosis of 1
specific type of dementia difficult.36 Another ongoing problem
is under-diagnosis of dementia in primary care which has been
reported to be more than 50% in the United Kingdom.37 The
under-diagnosis could have biased our analysis, but would
eventually drive the results toward the null hypothesis.
In conclusion, we assessed some of the most widely
studied risk factors for dementia in late-life. We found the
factors associated with an increased risk of all-cause dementia
were physical inactivity, depression, and impaired fasting glu-
cose. A protective relationship was found for overweight (BMI
25–29.9), as compared with normal weight women. These risk
factors are all considered modifiable and therefore provide
further evidence that prevention strategies could be a way to
counteract the otherwise poor future prospects for dementia in
the ageing population.
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Abstract 
Dementia and type 2 diabetes are both characterized by long prodromal phases challenging the 
study of potential risk factors and their temporal relation. The progressive relation between 
metabolic syndrome, insulin resistance, and dementia has recently been questioned, wherefore 
the aim of this study was to assess the potential association between these precursors of type 2 
diabetes and cognitive dysfunction. Using data from the Prospective Epidemiological Risk Factor 
study (n=2,103), a prospective study of elderly women in Demark, we found that impaired fasting 
plasma glucose was associated with 44% (9%-91%) larger probability of developing cognitive 
dysfunction. In addition subjects above the HOMA-IR threshold (HOMA-IR > 2.6) had 47% (9%-
99%) larger odds of cognitive dysfunction. The associations could indicate that a significant 
proportion of dementia cases in women is likely to be preventable by effective prevention and 
control of the insulin homeostasis. 
 
 
The sedentary western life-style has led to an epidemic-like increase in prevalence of obesity that 
is closely linked to occurrence of type 2 diabetes (1,2). Also the prevalence of cognitive 
dysfunction and dementia is increasing and epidemiological studies suggest an association 
between type 2 diabetes and increased risk of dementia and cognitive dysfunction (3). With 
metabolic syndrome (MetS) considered a precursor of type 2 diabetes (4) and central obesity and 
insulin resistance (IR) being recognized as important causative factors in the pathogenesis of 
MetS (5), a precursor state for dementia may be developed over several years.  
The long prodromal phases characterizing dementia and type 2 diabetes challenges the study of 
potential risk factors and their temporal relation (6,7) and in studies with short follow-up, putative 
relationships may be unreliable. Thus, reported associations between type 2 diabetes, MetS, and 
cognitive dysfunction are somewhat contrary. Until recently the brain was considered an insulin 
insensitive organ, it has however now been accepted that insulin, partly of peripheral origin, acts 
through its own receptors in the brain controlling cognition and memory(8). Thus it may be that 
IR is a condition affecting both peripheral and central insulin receptors with cerebral IR being part 
of a preclinical state of Alzheimer’s disease(9). Importantly, the temporal relation between MetS, 
IR, and cognitive dysfunction/dementia has recently been questioned (10,11). This prompted us 
to conduct the current study in which data obtained as part of The Prospective Epidemiological 
Risk Factor (PERF) study, a prospective study of Danish postmenopausal women (12), 
underwent an evaluation with the aim to study the hypothesis that there is a temporal relation 
between MetS and IR and cognitive dysfunction. Data from PERF were used to evaluate whether 
there is an association between the MetS or IR and cognitive impairment at a follow-up 15 years 
later including only subjects without signs of cognitive dysfunction at the baseline examination (n 
= 1759).  
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Research Design and Methods 
The Prospective Epidemiological Risk Factor Study 
The Prospective Epidemiological Risk Factor (PERF) Study, an observational, prospective cohort 
study of Danish postmenopausal women, was designed with the purpose to obtain knowledge of 
age-related diseases in postmenopausal women. The baseline examination (PERF I) took place 
between 1999 and 2001 (n=5,855) and over fourteen months (from September 2013) 2,103 
participants were included in a follow-up (PERF II) as described previously (12). The studies were 
carried out in accordance with ICH-GCP with study protocol approval from The Research Ethics 
Committee of Copenhagen County. Written informed consent was obtained from all subjects prior 
to any study related procedures. 
Study population 
This study was based on all subjects that completed the follow-up examination, PERF II (n = 
2,103) and from this population we identified the analytical sample as outlined in figure 1. 
(figure 1 here) 
The study population included all subjects with valid cognitive tests at baseline and follow-up. 
Exclusion criteria were cognitive dysfunction at baseline and missing data on any of the 
confounders included in the analysis. This qualified 1,759 subjects for the analysis.  
Cognitive dysfunction 
Two short cognitive screening tests were applied to assess cognitive function at baseline and 
follow-up. The Short Blessed Test (SBT) is a six-item test assessing orientation, concentration, 
and memory. The score ranges from 0 to 28, with lower scores indicating better performance. A 
threshold of ≥10 was previously identified as cognitive impairment consistent with dementia (13). 
The category fluency test with animal naming (CFT) is a measure of verbal fluency where the 
subjects should name as many animals as possible in 60 seconds. Higher scores indicate better 
performance and the recommended threshold for dementia is ≤14 (14). 
Metabolic Syndrome at baseline 
MetS was defined using a modified version of the definition recommended by the International 
Diabetes Federation(15). Beside the entrance criteria of central obesity subjects should present 
two or more of the following risk factors: Increased triglycerides (>1.7 mmol/L), lowered level of 
HDL cholesterol (<1.29mmol/L), an increase in fasting plasma glucose (>5.6 mmol/L) or 
previously diagnosed type 2 diabetes, hypertension (systolic pressure above 130 mmHg or 
diastolic pressure higher than 85 mmHg or existing treatment of hypertension) to qualify for MetS. 
A direct measure of waist circumference was not obtained at baseline and therefore, the entrance 
criteria of central obesity was only defined by a BMI above 30 kg/m2 and as specific 
hyperlipidemia treatment was not part of the baseline questionnaire, we are unable to determine 
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whether participants were on specific lipid-lowering medication. Subjects without MetS were 
divided into three groups: i) subjects having a BMI >30kg/m2, and only one additional risk factor; 
ii) subjects presenting BMI <30kg/m2 but with 1-4 risk factors for MetS; and iii) subjects without
any risk factors for MetS. This group was used as the reference group in the regression analysis. 
Insulin resistance and Glycosylated hemoglobin 
HOMA-IR index was used to assess the degree of IR (16). The HOMA-IR index was calculated 
by fasting levels of plasma glucose multiplied by the concentration of insulin divided by the 
constant 22.5. Fasting plasma glucose was measured directly after collection in both PERF I and 
II, using a Vitros 250 slide cartridge with no reagent system from Ortho Clinical, in PERF I, and 
an enzymatic measurement method using the Avida 1800, from Siemens, in PERF II. Insulin 
levels at PERF I and PERF II was measured in thawed samples from the PERF biobank (stored 
at -80°C) on a Cobas e411 analyser from Roche. The level of Glycosylated hemoglobin (HbA1c) 
was measured using the Avida 1800 from Siemens and used to determine the outcome at follow-
up. Blood samples were collected fasting in the morning.  
Statistical analysis 
Statistical analysis was conducted using R version 3.3.1 (R Foundation for Statistical Computing, 
Vienna, Austria). Spearman's Rank-Order Correlation was used to measure the association 
between scores of the two cognitive tests. By use of the glm function, logistic regression assessed 
the association between risk factors for the MetS, metabolic profiles and cognitive dysfunction. 
Three separate multivariable analyses were completed. In all analyses, baseline age and baseline 
cognitive performance were included as continuous variable and education level (primary 
school/high school/university), smoking history (never/former/current), alcohol consumption 
(none/<10.5 alcohol units per week/10.5-21 alcohol units per week/>21 alcohol units per week) 
and physical activity (Inactive/1 time per Week/2 times per Week/3+ times per week) and current 
use of hormone replacement therapy (yes/no) as categorical covariates.  
We first tested each of the single risk factors comprising the MetS. The variables were 
dichotomized as described under “Metabolic Syndrome at baseline” above. Using the 
dichotomized variables we then studied how metabolic profiles at baseline were associated with 
cognitive dysfunction. First, we used the modified definition of MetS followed by the cumulative 
sum of MetS risk factors, ranging from zero to five, then we assessed the association between IR 
and risk of cognitive dysfunction. The baseline HOMA-IR index was used as continuous variable 
and further dichotomized at 2.6, where subjects above the threshold was considered insulin 
resistant. The outcome variables used were i) cognitive dysfunction on the SBT (SBT≥10), ii) 
cognitive dysfunction on the CFT (CFT≤14), and iii) cognitive dysfunction on both SBT and CFT 
(SBT≥10 and CFT≤14). 
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The Hosmer-Lemeshow test was used to test the goodness of fit for the logistic regression 
models.  
Results 
Of the 1,759 subjects included in the analysis, 136 had cognitive dysfunction according to the 
SBT, while 326 were classified with cognitive dysfunction when it was determined by CFT. A total 
of 80 subjects showed signs of cognitive dysfunction on both tests.  
Characteristics of the study population 
The baseline characteristics of the study population is shown in table 1. All subjects were on 
average 68 years old at baseline, with the non-impaired group as the youngest and the group of 
subjects with impaired cognition on both tests as the oldest.  
(table 1 here) 
There was a negative correlation between scores in the SBT and the CFT (rho = -0.294 [-0,336 
to -0,250], p <0.0001).   
The association between Metabolic Syndrome, Insulin resistance and cognitive dysfunction 
Table 2 shows the association between metabolic risk factors, MetS, IR and cognitive dysfunction 
at follow-up. Fasting plasma glucose was associated with impairment in CFT suggesting that 
hyperglycemia increases the risk for development of cognitive dysfunction with 44% (OR 1.44, 
95% CI 1.09-1.91). Having from one to four metabolic risk factors did not significantly alter the 
risk of cognitive dysfunction at follow-up when compared to subjects with no risk factors. In 
subjects with the worst metabolic profile, holding all five risk factors for MetS, the risk for cognitive 
dysfunction on verbal fluency was three times higher (OR 3.09, 95% CI 1.09-8.69) as compared 
to subjects who did not present any of the MetS risk factors. MetS was however not associated 
with increased risk of cognitive dysfunction at follow-up. 
(table 2 here) 
IR was associated with an increased risk of cognitive dysfunction, calculated both as CFT and a 
combination of the SBT and the CFT (Table 2). The risk of cognitive dysfunction increased 
between 8-10% for every unit increase on the HOMA-IR index scale and when dichotomized, 
subjects above the threshold of 2.6 had a 47% higher risk of cognitive dysfunction on verbal 
fluency (OR 1.47, 95% CI 1.09-1.99) as compared to subjects below the HOMA-IR threshold. 
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Discussion 
In the present study we assessed the temporal relation between biomarkers and precursors of 
type 2 diabetes and cognitive dysfunction and specifically we evaluated whether MetS and IR are 
associated with development of cognitive dysfunction. Based on data with a follow-up period of 
up to 15 years it is demonstrated that i) subjects with impaired fasting plasma glucose have larger 
odds of developing cognitive dysfunction and ii) subjects with IR as determined by the HOMA-IR 
index have higher probability of developing cognitive dysfunction. While fasting plasma glucose 
were specifically associated with dysfunction on the verbal fluency test, IR seemed to result in 
more global cognitive dysfunction as determined by a combination of two short cognitive 
screening tests. The third important finding is that subjects with a poor metabolic profile, reflected 
by the presence of several metabolic and cardiovascular risk factors, have a 3- to 4-fold larger 
odds of developing cognitive dysfunction than subjects with an ideal metabolic profile. Overall the 
data suggest that IR is a cause rather than a consequence of cognitive dysfunction. 
Fasting plasma glucose was the single metabolic risk factor that was most strongly associated 
with cognitive dysfunction. With cognitive function assessed by the CFT, subjects with impaired 
fasting plasma glucose levels had a 44% (9%-91%) larger odds of cognitive dysfunction as 
compared to normoglycemic subjects. While presence of MetS in itself does not seem to provoke 
an elevated risk of cognitive dysfunction, subjects with a poor metabolic profile have a three to 
four time’s larger odds of developing cognitive dysfunction when compared to subjects with an 
ideal metabolic profile. The Framingham cohort have recently shown that subjects with ideal 
cardiovascular health, determined from a 7-point scale proposed by the American Heart 
Association, are at lower risk of dementia, cognitive decline and brain atrophy(17). Out of the 
seven risk factors defining an ideal cardiovascular health profile, four is identical or at least very 
similar to those defining the MetS, suggesting that cardiovascular and metabolic health is closely 
linked to brain health.  
Peripheral IR has been shown to alter the transport of insulin through the blood-brain barrier. The 
insulin transport is reduced by peripheral hyperinsulinemia (18), which can directly contribute to 
cognitive impairment and promote AD pathology(19,20). It has also recently been shown that IR 
predicts worse memory performance through a reduction in regional cerebral glucose metabolism 
(21), supporting IR being a causal risk factor for development of cognitive dysfunction. While the 
study design does not allow for causal conclusions, the data presented here can be taken to 
indicate a temporal relation between IR and cognitive dysfunction. However, we cannot rule out 
the possibility that dementia or cognitive dysfunction leads to a diabetic phenotype and that a 
disturbance in insulin homeostasis, as a secondary process, may accelerate certain dementia 
pathologies (22). IR may be a shared underlying pathological mechanism, since it is part of the 
prodromal phase of both type 2 diabetes and dementia. Interestingly amyloid formation is a 
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pathological hallmark of both type 2 diabetes and AD: islet amyloid polypeptide is found in the 
pancreas of subjects with type 2 diabetes and β-amyloid is in the brain of subjects with AD (23). 
A recent study even suggest that pancreatic derived amyloid may enter the brain and exacerbate 
the deposition of β-amyloid through cross-seeding (24). 
There are previous studies indicating an association between sleep disturbances and dementia 
(25). Mechanisms underlying the association are many, and IR is speculated to play an important 
role, however the causal link has not been elucidated. The menopausal transition is associated 
with sleep disturbances, which are also found to increase the risk of type 2 diabetes (26,27). As 
we observed a link between IR and cognitive dysfunction, it could indicate that IR is an 
intermediate mechanism for the causal association between sleep disturbances and cognitive 
dysfunction. We can however not address this in the current study as we did not collect 
information on sleep disturbances and sleep patterns at baseline. 
The small, albeit significant, correlation between the two tests was expected and indicate that the 
two tests are not equivalent. This was reflected in the observed domain-specific effect of fasting 
plasma glucose and IR on cognition specifically related to verbal fluency. A similar domain-
specific effect on verbal fluency has previously been found in two cross-sectional studies (28,29). 
One of the studies found that the effect of IR on cognition was modulated by gender, indicating 
that IR was associated with poor performance on verbal fluency only in women. Verbal fluency 
performance is functionally linked to the frontal and temporal lobe areas. These brain areas rich 
in insulin receptors, are found to be associated with memory function(28,30). There are several 
neuropathological conditions that affect memory-related areas in the brain, with AD being one of 
them. A structural alteration of semantic networks located in the frontal and temporal lobe areas 
has been found to be characteristic for AD even in the early stages of AD (31,32). 
The concept of precision medicine is emerging in relation to prevention and treatment of AD (33) 
and the abundant evidence of various AD phenotypes, the metabolic phenotype being one, 
suggests that it is extremely relevant in this field. A recent meta-analysis indicate that insulin 
sensitizer drugs, like metformin and thiazolinediones, might be useful in the prevention of 
dementia in diabetic patients (34). Whether there is a direct mechanistic link is still controversial, 
but evidence from rat studies has shown that the glucagon-like peptide 1 analog liraglutide, 
another insulin sensitizer, interacts directly with processes leading to amyloid plaques and 
neurofibrillary tangles, the two pathological hallmarks of AD (35,36). Moreover, clinical trials have 
shown promising effects of intranasal insulin in subjects with AD and its prodrome, mild cognitive 
impairment (37,38) and also on spatial memory in young men (39).  
Metabolic Syndrome, Insulin Resistance and Cognitive Dysfunction 63 
The analysis was restricted to subjects attending the follow-up examination, therefore selection 
bias may affect the internal validity and question the generalizability of our results as it is well-
known that cognitive dysfunction and dementia affect attrition. We have previously assessed the 
similarities between follow-up participants and follow-up non-participants on a cohort level, and 
found that the two populations are very similar (12). This should strengthen the internal validity. 
Further, we based our determination of cognitive dysfunction on two short cognitive screening 
tools at the follow-up visit, therefore we cannot not rule out the possibility that cognitive 
dysfunction in the current study may be caused by reversible conditions and thereby potentially 
result in misclassification. The diagnostic accuracy of the two tests in relation to dementia is 
excellent (40–43). They have even been shown to outperform more comprehensive tests like the 
Mini Mental State Examination in the identification of milder levels of impairment (44,45). In the 
absence of a comprehensive diagnostic workup with a complete neuropsychological test battery, 
this evidence support the use of these simple tests. 
Another limitation is the lack of repeated measurement of glucose, insulin and cognition 
throughout the follow-up period as it would allow for a better assessment of the mutual trajectories 
and also resulted in a more accurate determination of the onset of cognitive dysfunction. Given 
the previously reported interconnection between genetic and metabolic risk factors, the lack of 
genetic risk factors in our studies is a limitation that could result in unmeasured confounding. For 
example it has been suggested that the insulin metabolism may differ between Apolipoprotein E 
epsilon 4 allele carriers and non-carriers (46).  
Conclusion 
The precursors of type 2 diabetes; impaired fasting plasma glucose and IR, are associated with 
increased risk of developing cognitive dysfunction in elder women. Moreover, subjects with a poor 
metabolic profile are more likely to develop cognitive dysfunction than subjects with an ideal 
metabolic profile. If the observed association between metabolic risk factors and cognitive 
dysfunction is truly causal it could suggest that a significant proportion of dementia cases in 
women may be preventable by effective control of insulin homeostasis.  
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Tables 
Table 1: Baseline characteristics of the study population.  Numbers are shown as absolute numbers 
with percentile in brackets for categorical variables. For numerical variables the mean  standard deviation 
(SD) are shown. 
Variable 
Non 
impaired 
n = 1377 
SBT ≥ 10 
n = 136 
CFT ≤ 14 
n = 326 
SBT ≥ 10 
CFT ≤ 14 
n = 80 
Demographics             
Age (years) 66.9 ± 5.6 70.6 ± 6.5 70.5 ± 5.8 72.4 ± 5.7 
Education:  Primary school, n (%) 903 (65.6) 96 (70.6) 225 (69.0) 56 (70.0) 
     High School, n (%) 332 (24.1) 26 (19.1) 77 (23.6) 17 (21.2) 
     University, n (%) 142 (10.3) 14 (8.1) 24 (7.4) 7 (8.8) 
Lifestyle             
BMI (kg/m2) 26.0 ± 4.0 26.3 ± 4.8 26.5 ± 4.4 26.3 ± 4.3 
     <18,5, n (%) 19 (1.2) 1 (0.7) 2 (0.6) 0 
     18,5-24,9, n (%) 686 (42.3) 63 (46.3) 133 (40.8) 36 (45.0) 
     25,0-29,9, n (%) 653 (40.2) 46 (33.8) 127 (39.0) 28 (35.0) 
     ≥30,0, n (%) 265 (16.3) 26 (19.1) 64 (19.6) 16 (20.0) 
Smoking History: Never, n (%) 723 (52.5) 68 (50.0) 167 (51.2) 45 (56.2) 
     Former, n (%) 403 (29.3) 41 (30.1) 89 (27.3) 23 (28.7) 
     Current, n (%) 251 (18.2) 27 (19.9) 70 (21.5) 12 (15.0) 
Alcohol: None, n (%) 512 (37.2) 66 (48.5) 148 (45.4) 36 (45.0) 
     <10.5 alcohol units/week, n (%) 312 (22.7) 22 (16.2) 61 (18.7) 15 (18.8) 
     10.5–21 alcohol units/week, n (%) 423 (30.7) 38 (27.9) 89 (27.3) 22 (27.5) 
     >21 alcohol units/week, n (%) 130 (9.4) 10 (7.4) 28 (8.6) 7 (8.8) 
Physical activity: Inactive, n (%) 306 (22.2) 40 (29.4) 103 (31.6) 22 (27.5) 
     1 time /week, n (%) 310 (22.5) 29 (21.3) 54 (16.6) 17 (21.2) 
     2 times/week, n (%) 204 (14.8) 18 (13.2) 48 (14.7) 11 (13.8) 
     3+ times/week, n (%) 557 (40.5) 49 (36.0) 697 (37.1) 30 (37.5) 
Metabolic and Vascular factors             
Systolic Blood Pressure (mmHg) 145.5 ± 23.1 148.9 ± 23.7 148.8 ± 23.2 150.2 ± 23.9 
Diastolic Blood Pressure (mmHg) 81.9 ± 10.5 82.0 ± 10.5 82.0 ± 11.0 81.5 ± 10.8 
Fasting Plasma Glucose (mmol/L) 5.4 ± 1.0 5.6 ± 1.5 5.6 ± 1.1 5.8 ± 1.8 
Insulin (mmol/L) 54.9 ± 34.6 58.7 ± 44.5 60.9 ± 38.8 61.5 ± 42.1 
HOMA-IR 2.0 ± 1.5 2.4 ± 3.6 2.3 ± 2.6 2.6 ± 4.3 
High density lipoprotein (mmol/L) 1.7 ± 0.4 1.7 ± 0.4 1.8 ± 0.5 1.8 ± 0.4 
Triglycerides (mmol/L) 1.3 ± 0.6 1.4 ± 0.7 1.4 ± 0.7 1.4 ± 0.7 
Cognitive performance             
Short Blessed Test 1.3 ± 1.9 2.4 ± 2.4 1.7 ± 2.1 2.4 ± 2.3 
Category Fluency Test 24.3 ± 5.2 21.5 ± 4.5 20.6 ± 4.2 20.8 ± 4.4 
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Table 2: Association between Metabolic Syndrome, Insulin resistance and cognitive dysfunction 
  
Predictor variables 
  Cognitive status at follow up 
 SBT ≥10  CFT ≤14  
SBT ≥10 & 
CFT≤14 
  OR* 95% CI   OR* 95% CI  OR* 95% CI 
Individual Component of the MetS                               
  Body Mass Index  (>30kg/m2) 
 
1.22 0.76 - 1.94 
 
1.24 0.88 - 1.74 
 
1.26 0.70 - 2.30 
  Elevated Blood Pressure  
 
0.88 0.56 - 1.38 
 
1.07 0.76 - 1.50 
 
0.68 0.38 - 1.23 
  Impaired Fasting Plasma Glucose  
 
1.12 0.76 - 1.64 
 
1.44 1.09 - 1.91 
 
1.56 0.96 - 2.52 
  Low High Density Lipoprotein 
 
1.01 0.59 - 1.74 
 
1.19 0.81 - 1.74 
 
0.99 0.47 - 2.09 
  Elevated Triglycerides 
 
1.25 0.81 - 1.91 
 
0.98 0.71 - 1.36 
 
1.09 0.61 - 1.95 
Cumulative sum of risk factors for MetS                              
  0 risk factors 
 
reference 
  1 " 
 
0.72 0.40 - 1.27 
 
1.02 0.65 - 1.59 
 
0.72 0.34 - 1.56 
  2 " 
 
0.64 0.35 - 1.19 
 
1.06 0.66 - 1.69 
 
0.60 0.27 - 1.38 
  3 " 
 
1.18 0.61 - 2.27 
 
1.19 0.70 - 2.03 
 
1.02 0.41 - 2.52 
  4 " 
 
0.59 0.22 - 1.60 
 
1.39 0.71 - 2.71 
 
0.66 0.19 - 2.33 
  5 " 
 
2.56 0.75 - 8.79 
 
3.07 1.09 - 8.69 
 
4.35 1.02 - 18.6 
Metabolic Syndrome                              
  No MetS 
 
reference 
  Risk factors for MetS with BMI < 30 kg/m2 
 
0.98 0.65 - 1.49 
 
1.08 0.80 - 1.46 
 
0.94 0.55 - 1.61 
  BMI  >30kg/m2 and < 2 risk factors 
 
1.11 0.53 - 2.33 
 
1.30 0.77 - 2.19 
 
1.61 0.69 - 3.77 
  Metabolic Syndrome   1.28 0.71 - 2.29   1.30 0.82 - 1.94   1.18 0.55 - 2.55 
Insulin Resistance (HOMA-IR)                              
  Dichotomized (HOMA-IR > 2.6)  0.98 0.64 - 1.52 
 
1.47 1.09 - 1.99  1.33 0.77 - 2.27 
  Continuous (per unit increase)   1.05 0.98 - 1.13   1.08 1.01 - 1.16   1.10 1.01 - 1.19 
 *Odds ratios were adjusted for Age at Baseline, Smoking history, Alcohol Consumption, Physical Activity, 
Education and Hormone replacement therapy 
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Figure 1: Flowchart for the identification of the analytical sample. Each outcome was determined 
independent of the other outcomes. SBT: Short Blessed Test, CFT: Category Fluency test. 
6 
Objective Cognitive Impairment and 
Progression to Dementia in Women 
6. Objective Cognitive Impairment and Progression to
Dementia in Women
Received December 23, 2016
Accepted for publication January 4, 2017 1
Original Research
The Journal of Prevention of Alzheimer’s Disease - JPAD©
Objective Cognitive Impairment and Progression to Dementia in 
Women: The Prospective Epidemiological Risk Factor Study
J. Skov Neergaard1,2, K. Dragsbæk1,2, C. Christiansen1, M. Asser Karsdal1, S. Brix2, K. Henriksen1
1. Nordic Bioscience A/S, Herlev, Denmark; 2. DTU Bioengineering, Technical University of Denmark, Kgs. Lyngby, Denmark
Corresponding Author: Jesper Skov Neergaard, Nordic Bioscience A/S, DK-2730 Herlev, Denmark, jsn@nordicbio.com, Phone: +45 4452 5252; Fax: +45 4454 7765
J Prev Alz Dis 2016 inpress
Published online inpress
Abstract
BACKGROUND: Identification of subjects with a progressive 
disease phenotype is an urgent need in the pharmaceutical 
industry where most of the recent clinical trials in Alzheimer’s 
disease have failed.
OBJECTIVES: The objective of this study was to identify 
subgroups of individuals with objective cognitive impairment 
(OCI), who were most likely to progress to dementia and to 
identify the risk factors associated with progression.
DESIGN: Prospective cohort study.
SETTING: Population-based.
PARTICIPANTS: 5,380 elderly women from Denmark.
MEASUREMENTS: The Short Blessed Test and a category 
fluency test with animal naming, was used to assess cognitive 
function, and to classify them into different groups of OCI.
RESULTS: OCI was identified in 852 subjects at baseline. The 
risk of dementia was elevated for OCI subjects as compared 
to subjects with normal cognition (HR 1.46[1.19-1.79]). The 
courses of OCI were studied in a sub-cohort who completed the 
cognitive assessment at both the baseline and the follow-up visit 
(n = 1,933). Of these subjects 203 had OCI at baseline. The multi-
domain subtypes of OCI were associated with progressive OCI. 
Subjects most likely to progress were older, physically inactive, 
had a higher level of total cholesterol (>6.5 mmol/L) and had 
a history of depression as compared to subjects with a non-
progressive course of OCI.
CONCLUSIONS: In this cohort we identified a risk profile 
associated with progression from OCI in older women. The 
degree of impairment at baseline was an important predictor 
of conversion to dementia, additionally several modifiable risk 
factors were associated with progression.
Key words: Dementia, Cohort studies, Mild Cognitive Impairment, 
Cognitive Impairments. 
Introduction
Mild Cognitive Impairment (MCI) has become the most widely used term to describe the subtle cognitive changes in the prodromal 
phases of dementia. The causes of MCI are not yet 
completely understood, it is however well-known that 
MCI increases the risk of later developing dementia, 
although some people with MCI never progress or 
even return to a normal cognitive state (1, 2). MCI is a 
heterogeneous condition (3, 4) and previous research 
suggests that the domains involved in MCI are not 
uniform across different subtypes (5).          
Identification of subpopulations with pre-symptomatic 
disease is an urgent need in the pharmaceutical industry 
where most of the recent clinical trials in AD have 
failed, most likely due to patient selection difficulties 
(6). Identification of high-risk subjects with a progressive 
disease phenotype would likely increase the rate 
of success for disease-modifying interventions. In the 
absence of reliable biomarkers, risk profiles remain one 
of the best alternatives in identifying subjects with the 
highest likelihood of progression, underlining the need 
for identification of risks factors for progression. 
In the current study, we used two short cognitive 
screening tests, namely the Short Blessed Test (SBT) 
and a category fluency test with animal naming (CFT), 
to assess cognitive function in 5,380 older women from 
the PERF study (7, 8). Based on their objective cognitive 
performance subjects were grouped in four subgroups. 
A total of 852 women were classified with objective 
cognitive impairment (OCI) at baseline. The study aimed 
to investigate the risk of progression to dementia from 
the four subtypes of OCI. Further, we assessed the risk 
profile for progression by studying the cognitive courses 
in a subgroup of subjects who attended a follow-up visit 
15 years after baseline. 
Materials and Methods
Study population
The PERF study was an observational, prospective 
study originally designed to study age-related diseases 
in women. The baseline examination took place in 
1999-2001 (n=5,855) with a follow-up visit in 2013-2014 
(n=2,103). Except for being women and postmenopausal, 
there were no other in/exclusion criteria at the time of 
enrolment. The baseline and follow-up visits comprised 
a physical examination, blood sampling and a self-
reported questionnaire compiling information on medical 
history, medication, smoking status, alcohol intake, and 
physical activity. The cohort has been described in details 
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previously (9).
Of the baseline population (n=5,855), a total of 257 
subjects were excluded since they did not undergo 
neuropsychological testing at the baseline examination. 
A further 206 subjects were excluded based on their 
cognitive performance at baseline, indicating cognitive 
impairment consistent with dementia (SBT ≥10). Lastly 
12 subjects were excluded from the analysis due to a 
dementia diagnosis derived from the registry prior to 
study enrolment (Figure 1A).
A: Flow diagram of OCI subtypes and progression to dementia. B: Overview of 
courses for progression from baseline to follow-up.
In the study of cognitive courses we identified all 
subjects with valid cognitive tests at both study visits 
who were dementia free at baseline (n= 1,933) (Figure 1B).
The studies were carried out in accordance with ICH-
GCP with study protocol approval from The Research 
Ethics Committee of the Copenhagen County. Written 
informed consent was obtained from all subjects prior to 
study enrolment. 
Cognitive Screening Tests
The SBT is a six-item test assessing orientation, 
concentration, and memory. Scores range from 0 to 28, 
with lower scores indicating better performance (7). A 
threshold of ≥10 was previously identified as cognitive 
impairment consistent with dementia (10). The CFT 
measures semantic fluency and executive functions; in 
this test subjects are asked to name as many animals 
as possible in 60 seconds. Higher scores indicate better 
performance (8). Both tests were oral, and administered 
by the investigator. 
Determination of dementia outcome
Follow-up information on dementia status was 
retrieved from the National Danish Patient Registry and 
the Danish Register of Causes of Death using a unique 
personal identification number for each subject. The 
follow-up started on the day of study enrolment and 
ended at occurrence of event (dementia diagnosis), death, 
assessment of cognitive function at follow-up, or on 
Dec 31th 2014 (retrieval of registry data), whichever 
came first. A total of 542 incident dementia cases were 
identified from the registries. Dementia diagnoses were 
classified according to The International Classification of 
Diseases, 10th revision (ICD10). The following codes were 
considered a dementia diagnosis: Other/Unspecified 
dementia (OD) [F02-F03 and R54, n=272], Alzheimer’s 
disease (AD) [F00 and G30-G32, n=233] and Vascular 
dementia (VaD) [F01, n=37].
Definition of OCI subgroups
The International Working Group on Mild Cognitive 
Impairment outlined a consensus criteria for the 
categorization of MCI subtypes in 2004 (2). Differently 
from the consensus criteria, subjective memory 
complaints and activities of daily living were not used in 
the current study since this information was not collected 
at the baseline examination. Based solely on their 
objective cognitive performance, we therefore grouped 
subjects into four subtypes of OCI. We defined OCI as at 
least 1.5 SDs below age and education stratified norms 
derived from our cohort (Supplementary Table 1).
Subjects qualifying for OCI with impairment in only 
the memory domain of the SBT were classified as having 
single domain memory+ OCI (m+OCIsd), while subjects 
with impairment in memory and at least one additional 
domain was classified as having multi domain memory+ 
OCI (m+OCImd) . Impairment in a single domain other 
than memory was classified as memory- single domain 
OCI (m-OCIsd) and signs of impairment in more than 
one domain other than memory classified subjects with 
memory- multi domain OCI (m-OCImd). A total of 852 
subjects was classified with OCI.  
Courses of OCI
The courses of OCI were defined in a sub-cohort of 
subjects who completed the cognitive assessment at 
both the baseline and the follow-up examination (n = 
1,933). The courses were based on the objective cognitive 
performance at the baseline and the follow-up visits. A 
total of 203 subjects with OCI at baseline attended the 
follow-up examination. The remaining 1,730 subjects had 
normal objective cognitive performance at baseline. The 
progressive courses from either normal cognition or OCI 
were defined by progression to dementia (reported at 
the follow-up) or cognitive impairment consistent with 
dementia at follow-up (SBT ≥10) (n=148 and n=48). A 
stable OCI group: OCI at both baseline and follow-up (n= 
53) and likewise a stable group with normal cognitive
performance at both baseline and follow-up (n=1,297). A 
Figure 1. Overview from baseline to follow-up
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reverse trajectory group comprised subjects with OCI at 
baseline who returned to normal cognitive performance 
at follow-up as determined from the norms in our cohort 
(n=103). The remaining 285 progressed from normal 
cognitive performance to OCI at the follow-up (Figure 
1B).
Statistical Analysis
Statistical analysis was conducted using MedCalc 
Statistical Software version 16.8.4 (MedCalc Software 
bvba, Ostend, Belgium) and R version 3.3.1 (R 
Foundation for Statistical Computing, Vienna, Austria). 
The baseline characteristics in subjects with normal 
cognition and subjects with OCI were compared using a 
one-way analysis of variance (ANOVA) for quantitative 
variables and Chi-squared test for categorical variables 
(Table 1). 
The prevalence was calculated as the fraction of 
subjects with OCI at baseline. The incidence of dementia 
was calculated by dividing the number of cases by the 
number of person-years at risk. The differences in all-
cause and differential dementia incidence were assessed 
using pair-wise comparison of rates. Differences in time 
to dementia diagnosis was assessed using one-way 
ANOVA. 
Age and educational adjusted cause-specific Cox 
proportional hazards regression were used to assess the 
association between subtypes of OCI and risk of all-cause 
dementia and its subtypes. Dementia-free mortality was 
included as a competing risk as outlined by Benichou 
and Gail (11). Follow-up time was used as time scale. 
Age was included as continuous variable, education 
level (primary school, high school or university) and 
subtypes of OCI as categorical variables. Risk of dementia 
was assessed jointly for all OCI cases, followed by a 
distinction between memory+ and memory- subtypes 
Table 1. Baseline characteristics of defined OCI subtypes and non-impaired group. Numbers are shown as absolute numbers with 
percentile in brackets for categorical variables. For numerical variables the mean and standard deviation (SD) are shown      
Subtypes of Mild Cognitive Impairment
Memory + OCI Memory - OCI
Non-impaired
N = 4528
single domain 
N = 402
multi domain  
N = 104
single domain  
N = 305
multi domain 
N = 41
 P-value
Age (years) 70.4 ± 6.5 71.5 ± 6.1 71.6 ± 6.4 71.1 ± 6.2  73.7 ± 7.4 <0.001
Education, n (%) 
  Primary school 3136 (69.3) 327 (81.5) 82 (78.8) 213 (69.8) 33 (80.5)  < 0.0001
  High School 1047 (23.2) 53 (13.2) 18 (17.3) 62 (20.3) 6 (14.6)
  University 339 (7.5) 21 (5.2) 4 (3.8) 30 (9.8) 2 (4.9)
BMI (kg/m2) 26.1 ± 4.2 26.3 ± 4.3 26.6 ± 4.4 26.1 ± 4.3 27.7 ± 4.2 0.09
  <18.5, n (%) 69 (1.5) 5 (1.3) 1 (1.0) 5 (1.7) 0  0.2
  18.5-24.9, n (%) 1898 (42.0) 157 (39.4) 43 (41.3) 127 (42.1) 11 (26.8)
  25.0-29.9, n (%) 1797 (39.8) 166 (41.7) 36 (34.6) 126 (41.7) 16 (39.0)
  ≥30.0, n (%) 754 (16.7) 70 (17.6) 24 (23.1) 44 (14.6) 14 (34.1)
Smoking, n (%)
  Never 2149 (47.5) 196 (48.8) 50 (48.1) 140 (45.9) 19 (46.3)  0.6
  Past 1391 (30.7) 111 (27.6) 32 (30.8) 89 (29.2) 9 (22.0)
  Current 984 (21.8) 95 (23.6) 22 (21.2) 76 (24.9) 13 (31.7)
Alcohol consumption, n (%)
  Never 1870 (41.6) 210 (52.8) 60 (57.7) 147 (48.5) 16 (39.0)  0.0001
  <10.5 alcohol units/week 1076 (23.9) 85 (21.4) 23 (22.1) 72 ( 19.5) 8 (19.5)
  10.5-21 alcohol units/week 1217 (27.1) 86 (21.6) 17 (16.3) 69 (22.8) 13 (31.7)
  >21 alcohol units/week 335 (7.4) 17 (4.5) 4 (3.8) 15 (5.0)  4 (9.8)
Physical activity, n (%)
  None 1353 (29.9) 113 (28.2) 32 (30.8) 107 (35.1) 16 (39.0)  0.4
  1 time/week 945 (20.9) 88 (21.9) 24 (23.1) 74 (24.3) 9 (22.0)
  2 times/week 596 (13.2) 57 (14.2) 13 (12.5) 39 (12.8) 5 (12.2)
  3+ times/week 1629 (36.0) 143 (35.7) 35 (33.7) 85 (36.0) 11 (26.8)
Systolic Blood Pressure >160 mmHg or treated 
hypertension
1712 (37.9) 151 (37.7) 35 (34.3) 133 (43.6) 18 (43.6) 0.3
History of cerebral embolism/hemorrhage 132 (2.9) 12 (3.0) 4 (3.8) 9 (3.0) 2 (4.9) 0.9
Fasting Glucose
  Normal (<5.6 mmol/L) 2888 (64.2) 257 (64.6) 64 ( 62.1) 202 (66.9) 18 (43.9) 0.3
  Impaired (5.6-6.9 mmol/L) 1378 (30.6) 120 (30.2) 34 (33.0) 88 (29.1) 20 (48.8)
  Hyperglycemic (≥7.0 mmol/L) or treated 
  diabetes 
230 (5.1) 21 (5.3) 5 (4.9) 12 (4.0) 3 (7.3)
Total Cholesterol (>6.5 mmol/L) or treated 
hyperlipidemia 
1963 (43.7) 176 (44.2) 48 (46.6) 129 (42.7) 22 (53.7) 0.7
History of depression 264 (5.8) 36 (9.0) 4 (3.8) 35 (11.5) 9 (22.0) < 0.0001
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and finally split into the four subtypes. The group of 
subjects who did not meet the study specific definition of 
OCI was used as the reference group.
Logistic regression was used to assess the risk and 
corresponding risk factors for progression. Two separate 
analyses were conducted, one including the entire follow-
up population and secondly an analysis including only 
those with OCI at baseline. The progressive course was 
compared with the non-progressive courses (stable and 
reverse trajectory). Age was included as continuous 
variable and the categorical covariates education level 
(primary school, high school and university), BMI 
(normal weight [≤25 kg/m2], overweight [>25<30 kg/
m2] or obese [30+ kg/m2]),  smoking (never, past or 
current), alcohol consumption (never, <10.5 alcohol 
units/week, 10.5-21 alcohol units/week or >21 alcohol 
units/week), physical activity (other than walking) 
(never, once weekly, twice weekly or three or more 
times per week), systolic blood pressure (>160 mmHg 
or treated hypertension), fasting glucose levels (≥7.0 
mmol/L or treated diabetes) and total cholesterol levels 
(>6.5 mmol/L or treated hyperlipidaemia), history of 
depression (yes/no) and history of cerebral embolism/
haemorrhage (yes/no) were included in the analyses. 
In relation to model diagnostics we used the Hosmer 
& Lemeshow test and the Nagelkerke pseudo R2 as 
goodness of fit measures.
Results
Baseline characteristics of the study population
Of the non-demented study population comprising 
5,380 older women, 852 were categorized with OCI, 
while the remaining 4,528 had neuropsychological 
tests indicating normal cognition. All subtypes of 
OCI, excluding m-OCIsd, were significantly older as 
compared to the non-impaired group. The non-impaired 
group had generally higher levels of education (table 
1). With regards to alcohol consumption the subtypes 
with memory involvement, in particular, had larger 
proportions of subjects that were abstinent and lower 
proportions of subjects that consumed larger amounts 
of alcohol. A history of depression was more frequent in 
those with m-OCI (table 1).
Prevalence of OCI and risk of progression to 
dementia
The overall prevalence of OCI was 16% (14.9-16.8). 
Among the subtypes of OCI the incidence of dementia 
was largest in the group with m-OCImd followed by 
m+OCImd, m+OCIsd and m-OCIsd (Supplementary 
Table 2). The incidence rates however had overlapping 
confidence intervals. For differential diagnoses, the 
incidence of AD was largest in the m+OCImd subgroup, 
while the incidences for OD and VaD were largest in 
subjects with m-OCImd, although still with overlapping 
confidence intervals (Supplementary Table 2). The fastest 
conversion rate (time to diagnosis) was found in subjects 
with m-OCImd. The average time to diagnosis of 5.1 
years was significantly lower than the subtypes with 
single domain OCI only (p = 0.05).  
Over the entire follow-up period of maximum 15 years 
(median 13.7 years), the risk of all-cause dementia was 
elevated for all OCI cases as compared to subjects with 
normal cognition (HR 1.46[1.19-1.79]). The association 
with differential diagnoses suggested that OCI was 
more strongly associated with AD (HR 1.65[1.22-
2.23]) than with VaD or OD. For subtypes of OCI the 
maximum lengths of the follow-up period were 15 years 
(median 13.7 years), 15 years (median 13.7 years), 15 
years (median 13.6 years), 14 years (median 12.0 years) 
for m+OCIsd, m+OCImd, m-OCIsd and m-OCImd, 
respectively. The association with all-cause dementia 
and AD was strongest for subjects with multi domain 
involvement, although the confidence intervals overlap. 
There was no association between OCI and its subtypes 
and VaD and neither with OD (table 2).
Courses of OCI and risk factors for progression
Subjects with OCI at baseline had distinct prognostic 
courses with 24% (48/203) having a progressive course, 
Table 2. Association between Objective Cognitive Impairment (OCI) and Risk of Dementia
All-cause Dementia  Alzheimer’s Disease Vascular Dementia Other/Unspecified 
Dementia
Groups of OCI HR* (95% CI) HR* (95% CI) HR* (95% CI) HR* (95% CI)
Cognitively normal 1 (reference) 1 (reference) 1 (reference) 1 (reference)
All OCI cases 1.46 (1.19-1.79) 1.65 (1.22-2.23) 1.23 (0.54-2.80) 1.33 (0.99-1.80)
Memory+ OCI 1.39 (1.08-1.80) 1.50 (1.03-2.21) 1.40 (0.54-3.63) 1.30 (0.90-1.89)
  Single domain 1.31 (0.98-1.76) 1.27 (0.81-2.01) 1.77 (0.69-4.58) 1.29 (0.85-1.95)
  Multiple domains 1.71 (1.05-2.78) 2.43 (1.28-4.59) no cases 1.38 (0.65-2.93)
Memory- OCI 1.55 (1.15-2.09) 1.87 (1.22-2.87) 0.94 (0.22-3.93) 1.38 (0.89-2.14)
  Single domain 1.47 (1.06-2.04) 1.85 (1.18-2.91) 0.54 (0.07-3.95) 1.29 (0.85-1.95)
  Multiple domains 2.14 (1.06-4.31) 2.00 (0.64-6.26) 3.67 (0.50-27.0) 2.02 (0.75-5.45)
*Hazard ratios are adjusted for age and education
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26% (53/203) remaining stable and 50% (102/203) having 
a reverse trajectory from baseline to follow-up. The 
multi-domain subtypes of OCI, especially m+OCImd, 
were associated with progressive OCI. Several other 
risk factors were associated with progression. Age, 
hyperlipidaemia and history of depression were 
positively associated with progression, while physical 
activity (≥1 time/week) lowered the risk of progression 
from OCI (table 3).
The risk factors for progression in the entire follow-
up population were age, abstinence from alcohol 
consumption, hyperlipidemia and history of depression.  
Discussion
In this large prospective study we identified a high-
risk progressive profile among subjects classified with 
OCI at baseline. We assessed which subtypes of OCI that 
were associated with progression to dementia and severe 
cognitive impairment. Subjects that were most likely to 
progress had m+OCImd, were older, physically inactive, 
higher level of total cholesterol and had a history of 
depression compared to subjects with a non-progressive 
course of OCI over the entire follow-up period. 
Although the study design prevented us from using 
the core clinical criteria for MCI, the prevalence of OCI 
of 16% observed in the current study corresponds well 
with previous MCI studies, mostly within the range of 
14-18% (12, 13). The incidence of dementia was largest in 
subjects with multi-domain involvement, while the time 
to diagnosis was shortest as compared to single domain 
OCI subtypes. These findings support the literature 
suggesting that the degree of impairment (single vs. 
multi-domain) at baseline is an important predictor of 
conversion to dementia (14-16). In the current study 
we found that OCI, and especially m+OCImd, were 
associated with higher risk of AD. Coherently, previous 
evidence suggests that subjects with amnestic MCI have 
increased risk for AD, while subjects with non-amnestic 
MCI may have a larger risk for other dementia types (17, 
18). 
Our finding that subjects with multi-domain OCI, 
the subtype with memory involvement in particular, 
were more likely to progress than those with single-
domain OCI, corresponds well with previous findings, 
although these findings are primarily based in the MCI 
criteria by Petersen (16, 19, 20). In the current study, 
the risk profile associated with progression for women 
was characterized by advanced age, physical inactivity, 
higher total cholesterol levels and a history of depression. 
Likewise, researchers from the 3C study also found that 
age and depression predicted progression in women (21). 
For alcohol consumption, results from the ILSA 
study show that subjects consuming up to 15 grams of 
alcohol per day (equivalent to 1.9 alcohol units in our 
study) had a lower rate of progression when compared 
to abstainers. Although the study uses different cut-
off values for alcohol consumption the direction of the 
association is the same suggesting that light to moderate 
alcohol consumption is associated with lower risk of 
progression (22). The Nurses’ Health Study found a 
similar association where moderate drinkers lowered 
their relative risk of impairment approximately 20%, as 
compared with abstainers (23).
Table 3. Risk Factors for Progression from Objective 
Cognitive Impairment (OCI) 
OCI only  
(n = 203) 
Progressive vs. 
Non-progressive
Entire population  
(n = 1933)
Progressive vs. 
Non-progressive
Variable OR* (95% CI) OR* (95% CI)
  Memory+ OCI single domain 2.21 (0.88-5.55)
  Memory+ OCI multi-domain 8.30 (1.79-38.5)
  Memory- OCI single domain 1 (reference)
  Memory- OCI multi-domain 5.18 (0.80-33.6)
Age (per 5 years of ageing) 1.72 (1.15-2.57) 1.78 (1.56-2.04)
Education
  Primary school 1 (reference) 1 (reference)
  High School 1.23 (0.41-3.72) 0.73 (0.49-1.09)
  University 0.25 (0.05-1.32) 0.62 (0.35-1.10)
BMI  
  Normal (<25) 1 (reference) 1 (reference)
  Overweight (25.0-29.9) 0.60 (0.22-1.59) 0.81 (0.57-1.14)
  Obese (≥30.0) 0.92 (0.30-2.85) 1.09 (0.71-1.69)
Smoking history 
  Never 1 (reference) 1 (reference)
  Past 1.63 (0.60-4.45) 1.10 (0.78-1.45)
  Current 2.83 (0.90-8.94) 1.32 (0.87-1.99)
Alcohol Consumption 
  None 2.07 (0.66-6.51) 1.60 (1.06-2.42)
  Little (<10.5 units/week) 1 (reference) 1 (reference)
  Moderate (10.5-21 units/week) 0.53 (0.13-2.23) 0.96 (0.60-1.52)
  Heavy (>21 units/week) 0.18 (0.01-2.55) 0.84 (0.42-1.71)
Physical activity 
  None 1 (reference) 1 (reference)
  1 time/week 0.29 (0.09-0.94) 0.82 (0.53-1.25)
  2 times/week 0.44 (0.13-1.55) 0.70 (0.43-1.15)
  3+ times/week 0.28 (0.09-0.84) 0.77 (0.53-1.14)
Fasting Glucose 
  <5.6 mmol/L 1 (reference) 1 (reference)
  5.6-6.9 mmol/L 0.59 (0.23-1.53) 0.95  (0.68-1.32)
  ≥7.0 mmol/L or treated diabetes 1.60 (0.22-11.6) 1.12  (0.54-2.32)
Systolic Blood Pressure >160 mmHg 
or treated hypertension
0.91 (0.38-2.19) 1.27  (0.92-1.75)
Total Cholesterol (>6.5 mmol/L) or 
treated hyperlipidemia
4.82 (2.01-11. 5) 1.51  (1.11-2.04)
History of cerebral embolism/
hemorrhage (yes/no)
4.12 (0.24-70.8) 1.23  (0.54-2.78)
History of depression (yes/no) 4.72 (1.02-21.8) 1.85  (1.03-3.32)
*All odds ratios are mutually adjusted
We found a positive association between history of 
depression and progression. Similarly, a previous study 
found that subjects with MCI and depression had a 
two-fold increased risk of developing AD than those 
with MCI without depression (24). The Kungsholmen 
study however found no association between depressive 
symptoms and risk of dementia in a group of subjects 
with MCI at baseline (25). Our study is the first 
to report a positive association between higher total 
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cholesterol levels and a risk of progression from OCI to 
dementia. The 3C cohort found no association between 
hypercholesterolemia and progression from OCI to 
dementia. This conflicting evidence could potentially be 
explained by differences in baseline age and length of 
follow up, where women from the 3C study on average 
were nearly four years older and only followed for four 
years (21). 
Limitations
First, the cohort only comprised women and therefore 
generalization cannot be made to men of similar ages. 
Further, our neuropsychological assessment could have 
been more comprehensive. Although the SBT is said to 
assess both orientation, concentration and memory and 
the CFT to assess verbal fluency, they are limited to a 
few cognitive domains and the study lacks assessment 
of perceptual or visual-spatial abilities and a more 
comprehensive assessment of memory. Nonetheless, 
the two tests have diagnostic accuracies in relation 
to dementia equivalent to the Mini Mental State 
Examination (26, 27) and the SBT has been proven to 
have very good predictive capacity since it is superior 
in the identification of milder levels of impairment 
(27). Further poor performance on delayed recall as 
assessed with memory question in the SBT indicates a 
high risk of progression to dementia and has also been 
used as diagnostic criteria for amnestic mild cognitive 
impairment in several large randomized clinical trials 
(12). All evidence that, in the absence of a complete 
neuropsychological test battery, supports the use of these 
simple tests.
Another limitation is the deviation from the core 
clinical MCI criteria. This was caused by the missing 
assessment of subjective memory complaints and 
activities of daily living. Unfortunately this makes 
the direct comparison with previous studies difficult 
since this could give raise concerns in relation to 
misclassification. In favour of valid comparisons is the 
previous evidence suggesting that the application of 
subjective memory complaints and activities of daily 
living may be questionable in population-based studies 
(28). Further, a previous study found that self-reported 
memory complaints did not predict a cognitive decline 
(29, 30). Subjective memory complaints have however 
also been reported to be associated with increased risk of 
cognitive impairment and dementia (31, 32). It is likely 
that the predictive value of subjective memory complains 
vary across different clinical settings. Finally, subjective 
memory complaints for subjects enrolled in population-
based studies are normally elicited by standardized 
questions rather than being spontaneously reported, 
and their response may therefore vary in prognostic 
significance (33). It must however still be noted that 
the distinction between normal cognition and MCI are 
difficult and eventually rely on a clinical judgment which 
was not the case in the current study.
In the first part of our study we used registry-linkage 
to obtain information on incident dementia diagnoses. 
Registry-linkage is associated with very limited loss to 
follow up, however the validity of the diagnosis may be 
questioned. Similar registries are found in Sweden and 
Finland and studies from these countries indicate high 
validity and very good accuracy of the diagnoses, but 
underestimation is present (34, 35). In the analysis of 
risk factors for progression our analysis was restricted 
to subjects who attended the follow-up visit. This 
may question the generalizability of our findings as 
survivorship bias cannot be ruled out in studies of elderly 
women like the current study. 
Conclusion
In this cohort we identified a risk profile associated 
with progression of OCI in women. The degree of 
impairment at baseline was an important predictor of 
conversion to dementia and several modifiable risk 
factors, including physical activity, alcohol consumption, 
total cholesterol levels and history of depression were 
associated with progression. The subgroups of OCI that 
were most likely to progress to all-cause dementia and 
dementia subtypes was multi-domain OCI. 
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Supplement: Objective Cognitive Impairment and Progression to Dementia in Women: The 
Prospective Epidemiological Risk Factor Study
Supplementary Table 1. Population-based means (SD) and cut-off values of tests used for classification of Objective 
Cognitive Impairment
Category Fluency Short Blessed Test Total 
score
Short Blessed Test 
Memory question
Age groups Level of  education Mean SD Cut-off Mean SD Cut-off Mean SD Cut-off
50-60 (N = 264) Primary School 22.6 5.2 ≤14 1.8 2.1 >4 1.6 2.1 >4
High School 24.9 5.6 ≤16 0.7 1.3 >2 0.6 1.3 >2
University 24.2 3.9 ≤18 0.7 1.4 >2 0.6 1.1 >2
60-70 (N = 2185) Primary School 22.2 5.5 ≤13 1.9 2.3 >5 1.6 2.1 >4
High School 23.4 5.6 ≤14 1.4 2.0 >4 1.2 1.8 >3
University 24.9 6.1 ≤15 1.3 2.0 >4 1.1 1.8 >3
70-80 (N = 2498) Primary School 20.3 5.4 ≤12 2.3 2.5 >5 2.0 2.3 >5
High School 21.8 5.7 ≤13 1.6 2.0 >4 1.4 1.8 >4
University 23.4 6.0 ≤14 1.6 2.1 >4 1.4 2.0 >4
80+ (N = 433) Primary School 18.9 5.2 ≤11 2.7 2.6 >6 2.3 2.3 >5
High School 19.9 5.0 ≤12 1.9 2.3 >5 1.6 2.1 >4
University 23.0 6.5 ≤13 1.2 2.0 >4 1.2 1.9 >4
Supplementary Table 2. Progression to dementia in subtypes of Objective Cognitive Impairment. Differences in 
Incidence rates and average time to diagnosis were tested using one-way analysis of variance
Subtypes of Objective Cognitive Impairment
m+OCI 
single domain 
N = 402
m+OCI
multi domain
N = 104
m-OCI
single domain
N = 305
m-OCI
multi domain
N = 41
P-value
Number of new cases 52 17 40 8
Person years at risk 4731.7 1177.3 3482.7 409.8
Dementia Incidence  (per 1000 person years), (95 % CI) 11.0 (8.4-14.4)  14.4 (9.0-23.2) 11.5  (8.4-15.7) 19.5 (9.8-39.0) ns
Differential incidence (per 1000 person years), (95 % CI)
  Alzheimer’s Disease 4.4 (2.9-6.8) 8.5 (4.6-15.8) 6.0 (3.9-9.2) 7.3 (2.4-22.7) ns
  Vascular Dementia 1.1 (0.4-2.5) no cases 0.3 (0.0-2.0) 2.4 (0.3-17.3) ns
  Other/Unspecified dementias 5.5 (3.7-8.1) 5.9 (2.8-12.5) 5.2 (3.3-8.2) 9.8 (3.7-26.0) ns
Time to diagnosis (years), (95 % CI) 8.5 (7.4-9.5) 6.5 (4.3-8.7) 8.2 (7.1-9.4) 5.1 (2.4-7.9) 0.05
m+OCI: objective cognitive impairment with memory involvement, m-OCI: objective cognitive impairment without memory involvement
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Abstract  
Background: There is a need for non-invasive and reliable biomarkers to aid in early prognosis 
and diagnosis for neurodegenerative disorders. Truncated tau appears to be specifically related 
to disease pathology and recent studies have shown the presence and elevation of several 
truncated tau species in Cerebrospinal fluid (CSF) of subjects with Alzheimer’s disease (AD). The 
aim of the current study was to assess the longitudinal associations between baseline levels of 
two novel serum biomarkers measuring truncated tau, Tau-A and Tau-C, and the risk of incident 
dementia and Alzheimer’s disease in a large prospective cohort of nearly 6,000 elderly women. 
Methods: Using solid phase competitive ELISA, two tau fragments were detected in serum of 
5,309 elderly women from the Prospective Epidemiological Risk Factor (PERF) study. The PERF 
study was an observational, prospective study of Danish postmenopausal women. Subjects were 
followed with registry-linkage for a maximum of 15 years (median follow-up time 13.7 
years).Cause-specific Cox regression was used to assess the utility of the biomarkers in relation 
to incident dementia and AD. 
Results: High levels of Tau-A and Tau-C (above the median) were associated with lower risk of 
dementia and AD (Tau-A: Dementia HR [95% CI] = 0.85[0.70-1.04]; AD 0.71[0.52-0.98] and Tau-
C: Dementia 0.84[0.70-1.00]; AD 0.78[0.60-1.03]). Tau-C gave a very modest increase in the AUC 
in a 5-year prediction horizon as compared to a reference model with age and education. 
Conclusions: Measurement of tau in serum is feasible. The serological tau turnover profile may 
be related to the diagnosis and development of dementia and AD. The exact processing and 
profile in serum in relation to cognitive disorders remains to be further assessed to provide simple 
non-invasive serological tests to identify subjects with progressive cognitive disorders.  
 
Keywords: Dementia, Alzheimer’s disease, Serum Biomarkers, Prognosis 
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Background 
The global burden of dementia is rising, with a new case registered every 3.2 seconds. Dementia 
is ranked as the 9th most burdensome disease for people aged 60 years and older, however the 
costs associated with dementia are enormous and place dementia as the most expensive disease 
in the United States. The reason for this increase in dementia prevalence and the following 
increased costs are mainly caused by the shifting epidemiological trend of increasing numbers of 
elder people, caused by low fertility rates and increasing longevity [1,2].  
 
To counteract this dreary trend there is a need for better treatments. The success in 
pharmaceutical drug development has been greatly challenged due to the difficulties in detecting 
the disease at a stage allowing for intervention and thereby detecting efficacy. Consequently, 
there is a clear need for non-invasive and reliable biomarkers to aid in early diagnosis, prognosis 
and early efficacy assessment. Cerebrospinal fluid (CSF) biomarkers exist, and while they aid in 
diagnosis, their clinical utility is limited due to the invasive nature of the lumbar puncture.  
 
Evidence suggests that tau is possibly the protein triggering and driving the process of cognitive 
decline and neuronal loss in Alzheimer’s disease (AD)[3,4]. Besides AD, tau is known to be 
involved in the pathogenesis of several other neurodegenerative diseases referred to as 
tauopathies. The common denominator for these diseases is an alteration of the tau protein 
leading to the generation of neurotoxic tau aggregates known as neurofibrillary tangles (NFT). 
During this process the tau protein is known to undergo several different posttranslational 
modifications, where phosphorylation is among the most well studied. Several studies indicate 
that proteolytic processing of tau plays an important role in neurodegeneration and it has been 
suggested that caspase cleavage of tau may precede the hyper-phosphorylation, where 
especially caspase cleavage at Asp421 has been shown to initiate the cascade leading to tau 
aggregation[5–7].  
 
Recently our research group developed two solid phase competitive ELISA assays detecting the 
caspase-generated fragment cleaved at Asp421 (Tau-C) and another detecting an ADAM10-
generated fragment cleaved at Ala152 (Tau-A) of tau. These novel biomarkers have shown 
promising results in the initial biological validation: In ice hockey players suffering from mild 
traumatic brain injury, serum levels of Tau-C were significantly higher in post-concussion samples 
compared with preseason samples[8], confirming that tau processing and release into the 
circulation is associated with brain damage. Further, levels of Tau-A correlated with the duration 
of post-concussive symptoms, clearly indicating relevance to the neuronal damage[8]. In a 
smaller dementia cohort the tau fragments have been shown to be able to discriminate between 
AD and Mild Cognitive Impairment (MCI) which shows that the tau fragments can provide 
guidance on the differential diagnosis of dementia[9]. 
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The aim of the current study was to assess the longitudinal associations between baseline levels 
of Tau-A and Tau-C and the risk of incident dementia and Alzheimer’s disease in a large 
prospective cohort of 5,309 elderly women. 
 
Methods 
Study population 
The Prospective Epidemiological Risk Factor (PERF) study was an observational, prospective 
study of Danish postmenopausal women. The cohort has been described in details 
elsewhere[10]. A total of 5,855 women aged 55–85 were enrolled in the study. Being woman and 
postmenopausal were the only inclusion criteria’s at the time of enrolment. The baseline 
examination took place between 1999 and 2001 and comprised a questionnaire, physical 
examination and blood sampling at the study site. The study was carried out in accordance with 
ICH-GCP with study protocol approval from The Research Ethics Committee of Copenhagen 
County. Written informed consent was obtained from all subjects prior to any study related 
procedures. 
 
Of the entire baseline population (n=5,855), a total of 206 subjects were excluded based on their 
cognitive performance at baseline, indicating cognitive impairment consistent with dementia (a 
Short Blessed Test score ≥10). Two hundred fifty-three subjects did not complete the cognitive 
testing at baseline and were also excluded in the current study. In addition, 12 subjects were 
excluded from the analysis due to a preexisting dementia diagnosis derived from the National 
Danish Patient Registry prior to study enrolment. Further 75 subjects were excluded since no 
serum samples was available for biomarker measurement. The analytical sample in the current 
study therefore constituted 5,309 subjects. 
 
ELISA methodology 
The neo-epitope fragments of tau were detected using solid phase competitive ELISA. Fragments 
were detected by mouse monoclonal antibodies raised against human tau. The antibodies detect 
an ADAM10-generated cleavage site at Ala152 (Tau-A) and the caspase-3-generated cleavage 
site at Asp421 (Tau-C). The monoclonal antibodies recognize a decamer sequence containing 
the cleavage site. Both assays have previously been described in details elsewhere[11,12]. The 
lower limit of quantification (LLOQ) for Tau-A was 29.4 ng/ml. For Tau-A 68% (n = 3,595) of 
samples were below the LLOQ. If their reported value were above the lower limit of detection 
(LLOD, n = 3,443) and their respective Intra-Assay Coefficients of Variability (CV) allowed for it 
(<15%) these samples were assigned their absolute value (n = 2,293). In total 1,150 samples in 
the range between LLOQ and LLOD were excluded from the main analysis due to an Intra-Assay 
CV ≥ 15%. A sensitivity analysis including these samples was performed as outlined in the 
statistical analysis section. The LLOD was 9.3 ng/ml. Samples measured below the LLOD were 
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assigned the LLOD value (n = 152). The LLOQ for Tau-C was determined as 8.6 ng/ml. For Tau-
C, samples measured below the LLOQ were assigned the LLOQ value (n = 139). The LLOD for 
Tau-C was 0.8 ng/ml. The biomarker analysis were conducted at a College of American Pathology 
(CAP) certified central laboratory (Nordic Bioscience Laboratory). The staff at the central 
laboratory had no knowledge of the study participants.  
 
Dementia diagnosis 
Follow-up information on dementia status was retrieved from the National Danish Patient Registry 
and the National Danish Causes of Death Registry using a unique personal identification number 
for each subject. The follow-up started on the day of study enrollment and ended at the 
occurrence of an event (dementia diagnosis), death, or on the day of the retrieval of registry data 
(December 31th 2014), whichever came first. A total of 538 incident dementia cases were 
identified from the registries. Dementia diagnoses were classified according to The International 
Classification of Diseases, 10 th revision (ICD10). The following codes were considered a 
dementia diagnosis: F00-F04, G30-G32 and R54, while F00 and G30 was used to identify AD (n 
= 232). 
 
Statistical analysis 
Statistical analysis was conducted using R version 3.3.1 (R Foundation for Statistical Computing, 
Vienna, Austria). Serum levels of Tau-A and Tau-C were log-transformed to account for the 
skewness and then z-score standardized using the population mean and standard deviation (SD). 
In cause-specific Cox proportional hazards regression models, all-cause dementia and 
Alzheimer’s disease were used as the dependent variables. Age was used as timescale and 
event-free mortality was included as a competing risk as outlined by Benichou and Gail[13]. 
Levels of the tau fragments were included as either a continuous variable to reflect the risk 
associated with a change of one SD on the log scale, or as a categorical variable either 
dichotomized at the median (the group below the median was used as reference) or divided into 
quartiles (the lowest quartile (Q1) was used as reference). Initially we modeled the crude risk in 
the separate univariate analysis (model 1). Secondly, in addition to age, we adjusted for education 
level (primary school, high school and university) (model 2). Lastly we made a multivariate model 
adjusted for the continuous variables; age (as timescale), body mass index (kg/m2), platelet count 
(109/L), white blood cell count (109/L), albumin (mmol/L), alkaline phosphatase (unit/L), gamma 
glutamyltransferase (unit/L), high-density lipoprotein (mmol/L) and the categorical variables; 
education level, smoking (never, past or current), alcohol consumption (never, <10.5 alcohol 
units/week, 10.5-21 alcohol units/week or >21 alcohol units/week), physical activity (other than 
walking) (never, once weekly, twice weekly or three or more times per week) (model 3). Selection 
of covariates was based on significant association with levels of Tau-A and Tau-C using a multiple 
linear regression analysis (data not shown) and relevant risk factors as reported in the literature. 
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A sensitivity analysis was performed for Tau-A by including all samples between LLOQ and LLOD 
with an intra-assay CVs above the initial requirement of <15%.  
 
The cumulative incidence of a dementia event in a competing risk framework taking the risk of 
death without dementia into account was illustrated in quartiles of Tau-A and Tau-C. The 
cumulative incidence was estimated using the Aalen–Johansen method[14]. The difference 
between cumulative incidence curves was tested using the modified χ2 statistic outlined by 
Gray[15]. 
 
Finally we investigated the predictive value of the two biomarkers when added i) to a reference 
model containing age and educational level and ii) to a reference model containing all the 
independent variables from the multivariate model. The predictive value was assessed by 
computing the area under the Receiver-Operating Characteristics curve (AUC) for a 5-year and 
10-year prediction horizon using time from baseline as timescale.  
 
Results 
Selected baseline characteristics of the study population are summarized in Table 1. During the 
follow-up period of maximum 15 years (median follow-up time 13.7 years) a total of 538 incident 
dementia cases were identified from the registries, of which 232 had AD. 
 
(table 1 here) 
 
Cause-specific Cox proportional hazards regression models were used to assess the association 
between the biomarker levels and the risk of incident dementia or AD as listed in Table 2. Higher 
levels of Tau-C, both as a continuous measure and categorized, were associated with a 
decreased risk of all-cause dementia and AD in the age-adjusted model. Subjects in the highest 
quartile had a 29% (HR [95% CI] 0.71 [0.55-0.91]) decreased risk of dementia and a 34% (HR 
[95% CI] 0.66 [0.46-0.96]) decreased risk of AD as compared to subjects within the lowest 
quartile. A dose-response tendency was observed for Tau-C in all three models, indicating 
decreasing risk of dementia with increasing levels of the biomarker. 
 
(table 2 here) 
 
The association between Tau-C and incident dementia and AD remained significant after 
adjustment for age and education and in the multi adjusted model. Tau-C levels in the highest 
quartile were associated with a 29% lower risk of dementia and 34% lower risk of AD, when 
adjusted for age and education. In the multi adjusted model, subjects in the highest quartile had 
a 24% (HR [95% CI] 0.76 [0.58-0.98]) lower risk of dementia as compared to subjects in the lowest 
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quartile. Further, the risk of dementia and AD decreased 10% (HR [95% CI] 0.90 [0.82-0.99]) and 
13% (HR [95% CI] 0.87 [0.75-1.00]) with every log SD increase of the biomarker, respectively. 
A dose-response relation was also observed with across the quartiles of Tau-A, and as continuous 
measure the risk decreased 13% (HR [95% CI] 0.87 [0.79-0.96]) in relation to all-cause dementia 
and 17% (HR [95% CI] 0.83 [0.72-0.96]) in relation to AD with every log SD increase of the 
biomarker in the age and educationally adjusted model, respectively. When dichotomized at the 
median subjects above the median had a 19% lower risk of dementia (HR [95% CI] 0.81 [0.67-
0.98]) and a 32% lower risk of AD (HR [95% CI] 0.68 [0.50-0.91]). After multi factor adjustment 
the association between Tau-A and incident dementia and AD vanished, however the association 
remained significant between Tau-A and all-cause dementia as a continuous measure and in the 
dichotomized analysis, where subjects above the median had 29% decreased risk of AD (HR 
[95% CI] 0.71 [0.52-0.98]). The sensitivity analysis for Tau-A did not alter the overall results. Thus, 
there was a minor tendency for both outcomes where the HRs was shifted modestly towards the 
null (data not shown).  
 
The two tau biomarkers were also stratified into quartiles and illustrated as cumulative incidence 
curves (Figure 1). The analysis showed that the separation between Q1 and Q4 for Tau-A in 
relation to all-cause dementia is poor, and with significant overlap between confidence intervals 
for Q1 and Q4 (Figure 1A, p = 0.2). For AD on the other hand, the separation between Q1 and 
Q4 is larger (Figure 1D, p = 0.03). For Tau-C, the separation between the quartiles is larger and 
with only minor overlap between the confidence limits of Q1 and Q4 (figure 1B, E, p = 0.0009 for 
dementia and p = 0.01 for AD). Moreover, a dose-response relation across the four quartiles is 
observed for Tau-C in relation to both dementia and AD. The overlay plots (figure 1C and 1F) 
illustrate Q1 and Q4 for both biomarkers. It appears that the distance and thereby the separation 
between Q1 and Q4 increases from Tau-A to Tau-C.   
 
As outlined in table 3, Tau-A did not improve the risk prediction of dementia or AD within a 5-year 
and 10-year prediction horizon. Using a 5-year prediction horizon, Tau-C improved the prediction 
for both dementia and AD minimally, with an AUC change of 0.01 and 0.02, respectively (p = 0.05 
for both), although only with model 2 as the reference model. In the 10-year prediction horizon 
Tau-C did not improve the prediction as compared to any of the reference models. 
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Discussion 
In this study we assessed the prognostic utility of two novel serum biomarkers of 
neurodegeneration in a large prospective study. Both biomarkers, Tau-C in particular, were 
associated with incident dementia, where high levels of the biomarkers were associated with 
lower risk of incident dementia and AD.  
 
The inverse association between levels of tau and risk of dementia seems counterintuitive since 
higher levels of tau are found in the CSF of subjects with AD and to a lesser degree in other types 
of dementia[16–18]. Sparks and colleagues, however, also found lower levels of tau in plasma of 
AD patients and explain their association with a reduced transport of excess central tau to the 
periphery, caused by pathological alterations of tau[19]. Likewise, a similar situation has been 
observed with the Glial Cell-Line Derived Neurotrophic Factor protein in AD subjects. Here, the 
protein level is decreased in serum and increased in CSF in AD versus control subjects. The 
authors speculate that it could be related to an altered function of the blood-brain barrier thus 
disturbing clearance or facilitating crossing of potentially harmful fragments in the healthy 
brain[20]. Another plausible explanation is linked to neuroinflammation where microglia exhibit 
significant phenotypic changes during the course of the disease. In early AD microglial activation 
is believed to be neuroprotective by enhancing phagocytosis and degradation of β-amyloid and 
tau[21,22], a process that may result in less release of tau to the periphery. In later stages, where 
microglia become over-activated, they lose their phagocytic abilities resulting in uncontrolled 
inflammation[23]. This would result in higher levels of both central and peripheral tau.   
 
There are previous reports of measurements of tau protein in circulating blood, but most studies 
are small in size, low in numbers, and show inconsistent results[19,24–30]. A recent meta-
analysis has therefore concluded that plasma tau is not a useful marker for AD[31]. The meta-
analysis included six studies, whereof some reported an increase[25,27,28], others a 
decrease[19,24] and one study reported no change in AD patients as compared to healthy age-
matched controls[26]. The heterogeneity across the studies illustrates one of the challenges of 
biomarker assessment in blood. An important difference between the previous studies and ours 
is that previous studies measured total tau and not truncated tau. Truncated tau appears to be 
specifically related to disease pathology and recent studies have shown the presence and 
elevation of several truncated tau species in CSF of AD patients[32]. Besides being more specific 
for pathological changes than the intact proteins, the truncated fragments might more easily pass 
through the blood-brain barrier, due to their smaller size, as larger fragments do not cross the 
barrier.  
 
Another important difference is the setting in which the markers are assessed. With one 
exception[30], the previous studies of plasma tau are cross-sectional, while ours is longitudinal, 
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and thereby the first large cohort study to assess the prognostic utility of truncated tau in serum. 
Importantly the longitudinal design limit the concern of reverse causation. Mattson and colleagues 
recently touched upon the prognostic potential of plasma tau where they found that higher plasma 
tau was associated with progression, measured as the change in cognitive performance over 
time, however this was assessed in subjects with MCI and established dementia and not 
cognitively normal individuals [30]. The biomarker dynamics of Tau-A and Tau-C as a function of 
disease severity are still to be elucidated, but based on the current observations we speculate 
that the levels of the biomarkers are time-dependent and may change direction during the course 
of the disease. In minor cross-sectional studies of dementia and mild traumatic brain injury 
subjects, we found that the levels of Tau-A and Tau-C were elevated in diseased versus control 
subjects[8,9]. Associations with opposite direction as to what we found in this prognostic analysis. 
While the influence on the disease path after processing of tau by ADAM10 is unknown, evidence 
suggests that the caspase cleavage leading to the generation of Tau-C may play an important 
role in the cascade leading to tau aggregation[33]. The Tau-C fragment has been found to be one 
of the truncated tau forms in NFTs[7]. This evidence suggests that Tau-C may accumulate within 
the neurons during the process of NFT formation, and eventually be released to the circulation, 
at a more advanced disease stage, where the NFT load is sufficient to cause neuronal cell death. 
This process could explain the associations we have observed in our cross-sectional and 
longitudinal studies, respectively. There are previous indications of a non-linear relation between 
tau and disease severity over time. Using data from the ADNI database, Mouiha and colleagues 
investigated the time course of the CSF biomarkers, Aβ, t-tau and p-tau, and for all three markers 
the most likely model describing the relation between the biomarkers and disease severity was 
non-linear[34]. The most likely time course for t-tau and p-tau was found to be a penalized B-
spline model, where multiple inflexion points could indicate multiple phases of accumulation as 
opposed to a continuous, uninterrupted process. Recent longitudinal data from the DIAN study 
also suggest that the biomarker trajectories may differ as a function of disease severity[35]. 
 
While the associations of Tau-C and Tau-A with incident dementia and AD revealed a potential 
value of these novel biomarkers, their predictive value as individual markers was limited. Tau-C 
gave a very modest increase in the AUC in a 5-year prediction horizon as compared to a reference 
model based on age and education, however the increase in AUC vanished in the fully adjusted 
model. It must be noted that this assessment was done in a population-based cohort without any 
specific enrichment e.g. a requirement for Aβ positivity. The heterogeneous population may leach 
out the predictive performance. Despite the limited predictive value as stand-alone biomarkers, it 
is likely that the markers could be useful in combination with other serum biomarkers e.g. other 
tau-species and β-amyloid. From our study it is clear that the interpretation of a peripheral signal 
and its relation to alterations within the brain is difficult, albeit studies, including the current study, 
begin to highlight that serological assessment of pathophysiological tau processing is possible. 
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Understanding the link between the biomarker signal and the pathophysiological processes is 
however of paramount importance and studies that can reveal the time-dependency and 
biomarker dynamics in relation to disease severity e.g. with repeated measures should therefore 
be a priority for the future.   
 
A peripheral biomarker of biologically processed tau has several advantages as compared to β-
amyloid. First, while the Amyloid Precursor protein is also expressed in peripheral tissues like the 
pancreas, kidney, heart and liver[36], animal studies suggest that circulating tau protein arises 
from central neurons[37]. This implies that the peripheral pool of tau would arise directly from the 
brain, while β-amyloid in plasma or serum probably reflects a mixture of peripheral and brain-
derived protein. This might make the interpretation of a peripheral tau signal easier, although the 
processing, release and transport of tau from the brain to the periphery is yet not fully understood. 
Similar to a previous study of total tau measured in plasma, our markers did not show any 
correlation with t-tau or p-tau levels in CSF suggesting that the steady-state concentrations of tau 
are differentially regulated in these two body fluids[9,25]. Secondly, it has become quite clear that, 
although CSF Aβ aids in the early diagnosis of AD, the marker is not related to disease severity 
and duration[38,39]. CSF Tau, on the other hand, correlates with disease severity during the 
whole time course of AD[39–41]. An association that is also likely with truncated tau in the 
periphery. Finally, tau outperformed Aβ in a head-to-head comparison from a recent meta-
analysis, where tau proved to have a larger effect size (measured by the disease to control ratio) 
in both CSF and plasma/serum[42]. 
 
Limitations 
Generally the dementia field is hampered by misdiagnosis and underdiagnoses which complicate 
the evaluation of new diagnostic and prognostic biomarkers. In the current study we used registry-
linkage to collect information on dementia diagnoses. This method has the advantage of a very 
limited loss to follow up, however one could question the validity of the diagnoses due to its origin. 
Similar registries are found in other countries in Scandinavia, and studies from Sweden and 
Finland have shown that the diagnoses in the registries have very good accuracy, but 
underestimation is present. This underestimation may result in an underestimation of the 
biomarker potential. [43,44] 
 
Like most other studies we based our biomarker assessment on a binary distinction between 
cases and controls. Since dementia evolves over decades with a long preclinical phase the binary 
distinction is probably not the most appropriate method as the control group may contain several 
subjects with preclinical disease at the time of biomarker assessment. Although this is difficult to 
work around, a long follow-up time as in the current study, is one of the best possibilities to avoid 
misclassifications. 
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In literature, variability in assays and detection challenges are reported as two major hurdles with 
peripheral biomarkers that should be overcome before the full potential of these biomarkers is 
expressed[45,46]. At least for our Tau-A assay we also faced a challenge with sensitivity, which 
we hope to overcome with assay optimization. In a sensitivity analysis, we did not observed any 
significant impact on the overall findings of the samples measured below the LLOQ with intra-
assay CVs above 15%. The current study was limited to women and therefore generalization 
cannot be made to men of same age. The biomarkers should be tested in other cohorts to ensure 
reproducibility and generalizability. 
 
Conclusions 
The current study demonstrates that serological assessment of pathophysiological tau processing 
is possible. Tau-A and Tau-C measured in serum could be useful prognostic biomarkers to aid in 
early diagnosis of preclinical dementia and AD. Additional validation in relation to prognosis and 
time-dependency of these novel biomarkers should be a subject for future investigations. 
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Figure title and legend 
Figure 1: Cumulative incidence curves. Cumulative incidence in quartiles of Tau-A and Tau-C as a 
function of follow-up time. Left panel (A-C) illustrates the cumulative incidence for all-cause dementia. Right 
panel (D-F) illustrates the cumulative incidence for AD. The bottom graphs (C and F) are overlay plots of 
Tau-A and Tau-C showing only Q1 and Q4 for both markers. Confidence intervals (95%) are shown for the 
lowest (Q1) and highest quartiles (Q4) in A, B, D and E. 
8 
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8. Summary of Results
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8. Summary of Results 
The presented studies found that age, lifestyle factors such as BMI, level of physical activity, 
fasting plasma glucose levels and total cholesterol levels as well as history of depression and 
cognitive test performance are important predictors of dementia in elderly women from the PERF 
cohort. The results are summarized in table 6. 
 
Table 6: Overview of significant findings from paper II-V. The papers reporting the findings are listed. OCI: 
Objective Cognitive Impairment, BMI: Body Mass Index, HR: Hazard ratio, HOMA-IR: Homeostasis Model 
Assessment Index, OR: Odds ratio, CI: Confidence Interval 
Predictor  Description of association Reported in 
Age 
Age was a strong risk factor for all-cause dementia and for 
differential diagnoses (HR 2.05 [1.89-2.21])  
Paper II 
Cognitive 
Performance 
Subjects with Objective Memory Impairment (OCI) had elevated risk 
of dementia (HR 1.46 [1.19-1.79]).  
Paper IV 
Body Mass Index 
Overweight (BMI 25-30 kg/m2) was associated with lower risk of 
dementia (0.75 [0.62-0.89]), AD and OD. 
Paper II 
Smoking Habits Smoking increased the risk of VaD (HR 2.56 [1.18-5.55]) Paper II 
Physical Activity 
Physical activity reduced the risk of dementia (HR 0.77 [0.61-0.96]) 
and was associated with lower risk of progression from OCI to 
dementia/severe impairment (OR 0.29 [0.09-0.94]) 
Paper II 
Paper IV 
Alcohol 
Consumption 
Lower risk of progression for light alcohol consumers as compared to 
abstainers (Abstainers OR 1.60 [1.06-2.42]) 
Paper IV 
Fasting Plasma 
Glucose 
Dose–response relationship between FPG and risk dementia. 
Impaired FPG had larger odds of cognitive dysfunction (OR 1.42 
[1.09-1.84]) 
Paper II 
Paper III 
Insulin 
Resistance 
Subjects with insulin resistance have higher probability of developing 
cognitive dysfunction (OR 1.55 [1.16-2.07])  
Paper III 
Number of MetS 
risk factors 
Presence of several metabolic risk factors elevated odds of cognitive 
dysfunction (OR 2.98 [1.10-8.07]) 
Paper III 
Total Cholesterol 
Higher total cholesterol associated with risk of progression to 
dementia/severe impairment (OR 4.82 [2.01-11.5]) 
Paper IV 
History of  
Depression 
Depression associated with dementia (HR 1.75 [1.32-2.34]) and risk 
of progression to dementia/severe impairment (OR 4.72 [1.02-21.8]) 
Paper II 
Paper IV 
Tau-A and Tau-C 
High levels of Tau-A and Tau-C associated with lower risk of 
dementia (Tau-A: HR 0.85 [0.70-1.04]; Tau-C: 0.84 [0.70-1.00]).  
Paper V 
 
Paper II assessed risk factors for all-cause dementia and differential dementia diagnoses in a 
study population free from dementia at baseline, while Paper III specifically studied metabolic risk 
factors and their relation to cognitive dysfunction in a sub-cohort free from dementia and cognitive 
dysfunction at baseline who also attended the follow-up visit. These studies found that BMI in the 
overweight range and physical activity were associated with lower risk of dementia (Paper II), 
while age, history of depression, insulin resistance and elevated fasting plasma glucose increased 
the risk of incident dementia (Paper II or Paper III). Paper IV included subjects at different stages 
on the cognitive continuum. The degree of OCI was found to be associated with risk of dementia 
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in a study population free from dementia and severe cognitive impairment at baseline. In subjects 
with OCI at baseline, Paper IV also revealed that physical inactivity, elevated total cholesterol 
levels and a history of depression were all associated with progression to dementia or severe 
cognitive impairment, while abstinence from alcohol consumption was associated with 
progression in a larger study population including also those with normal cognitive test 
performance at baseline. Paper V introduced two novel biomarkers measuring truncated tau 
protein in the circulation. The study showed that Tau-A and Tau-C were associated with risk of 
dementia and thereby potentially important predictors of dementia. As individual markers, the 
predictive performance was very modest although Tau-C did result in a small improvement in the 
risk prediction compared to a reference model with age and level of education. The markers may 
have potential for identification of high-risk subjects if used in combination with other peripheral 
biomarkers and risk factors. Overall, the presented papers contribute to extend knowledge on 
dementia and cognitive impairment specifically in elderly Danish women. 
 
The nomogram in figure 10 illustrates a simple tool useful for individually tailored risk prediction 
as it is based on the risk profile of an individual subject. In the context of this thesis it is thought 
as an example of how assessment of risk factors can be translated into a simple and useful tool 
for population screening or in the everyday clinic. The nomogram is used to manually obtain 
prediction by making vertical readings from each of the variables to the point scale on the upper 
part of the nomogram. Finally, all readings from individual variables are summarized and the 
predicted risk is read vertically from the total points scale to the predicted risk scale.    
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The nomogram was generated from a multivariate Cox proportional hazards regression model 
including all of the independent predictors depicted in the nomogram. The variables were selected 
based on findings from paper II-V. Insulin Resistance was excluded from the analysis as blood 
levels of insulin was only available for the sub-cohort attending the follow-up study and as the 
purpose of the screening tool was to identify all-cause dementia, information on smoking was not 
included. At present, no effort was made to simplify the underlying prediction model and it has not 
been validated in any independent cohorts. The accuracy was assessed by computing the area 
under the Receiver-Operating Characteristics curve (AUC) for a 5-year, 10-year and 15-year 
prediction horizon. The AUCs were: 0.79 (5-year), 0.76 (10-year) and 0.66 (15-year). What is 
clear from the nomogram is that age is the single most important predictor of dementia followed 
by cognitive test performance and level of the tau biomarkers. The other risk factors individually 
add little to the overall predicted risk. As an example, the nomogram was used to predict risk for 
a 75-year old women with either a low-, intermediate- or high-risk profile for development of 
dementia in late-life (table 7). The number of points was read manually by making vertical lines 
on the nomogram for each individual predictor.  
 
Table 7: Predicted risk for a 75-year old women with a low-, intermediate- or high-risk profile. 
Risk Factor 
Low Risk Intermediate Risk High Risk 
Profile Points Profile Points Profile Points 
Age (years) 75 42 75 42 75 42 
Body Mass Index (kg/m2) 28 0 24 8 18 10 
Level of Education 2 2 2 2 2 2 
Alcohol Consumption (units/week) 8 0 13 2 25 3 
Physical Activity (times/week) 3 0 2 2 0 7 
Fasting Plasma Glucose (mmol/L) 5.0 0 6.1 8 7.5 10 
Total Cholesterol (mmol/L) 5.0 5 7.0 7 10.0 11 
Short Blessed Test (Score) 4 8 8 18 18 39 
Category Fluency Test (Score) 40 12 25 31 12 48 
History of Depression (yes/no) No 0 No 0 Yes 13 
Level of Tau-C (ng/mL) 80 16 40 24 20 27 
Level of Tau-A (ng/mL) 100 15 100 15 20 27 
Total Score  98  159  239 
Prediction Horizon    
5-year ≈ 0 ≈ 0 ≈ 40 
10-year ≈ 0 ≈ 10 ≈ 85 
15-year ≈ 0 ≈ 20 > 90 
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9. General Discussion 
The manuscripts included in this thesis have investigated a range of risk factors and possible 
predictors of dementia in late-life, including two novel serum biomarkers. With specific focus on 
elderly women, the findings have added to the previous evidence base and additionally presented 
potential new tools for the identification of at-risk individuals. The thesis supports the idea that 
dementia disorders, AD in particular, are complex multifactorial conditions and that the etiology 
should be viewed in a life-course perspective. The specific findings from each manuscript are 
discussed within the individual manuscripts. In this general discussion, the findings are put in 
context to prevention of dementia. Also, some project related and general methodological 
challenges that hamper the transition from observation to action are discussed.  
 
To set the scene we will start by outlining the estimated impact of successful prevention. A report 
from Alzheimer’s Research UK estimates the impact of a 5-year delay in dementia onset. In 
absolute numbers this would mean 666,000 fewer people with dementia by 2050 in the United 
Kingdom alone, a reduction by 33% [187]. In cost savings, this would translate to £21.2 billion. 
Further it has been estimated that around one-third of AD cases worldwide can be attributed to 
seven modifiable risk factors; low educational attainment, physical inactivity, smoking, midlife 
hypertension, midlife obesity, diabetes, and depression [188]. An intervention on each of these 
risk factors resulting in a prevalence reduction by 10% would potentially reduce the worldwide AD 
prevalence by 8% (8.8 million cases) in 2050. This illustrates that even a slight delay will have 
great social and economic impact. 
 
9.1 Risk and protective factors in relation to prevention 
Age is the main risk factor for dementia [27], and the huge impact of this non-modifiable risk factor 
previously made some researchers speculate that an intervention on one or several of the 
modifiable risk factors will not be effective as a prevention strategy [189]. The relative importance 
between the risk factors in this thesis, as illustrated in the nomogram, supports age as the most 
important risk factor for dementia. Many of the modifiable risk factors have minimal individual 
contribution to the overall risk prediction, however as these modifiable risk factors often are co-
expressed and tend to accumulate over time, they are still important in relation to prevention. 
Likewise, previous evidence suggests that clustering of certain risk factors implies synergistic 
effects [190]. The extensive research on modifiable risk and protective factors suggest that there 
might be a critical time period where the risk factor exerts its greatest impact on the future risk of 
dementia. The possibility that risk factors may change over time challenges the ability to draw 
firm conclusions for many of the risk factors reported in the literature, and is likely one of the 
reasons why the current evidence has not yet been translated into proper prevention strategies 
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[191]. Another important aspect is that risk factors may interact, which further challenges the 
possibility of establishing true cause effect relationships and therefore also the ability to identify 
the most important risk factors and appropriate time point for prevention. Albeit these challenges 
the nonpharmacological prevention strategies may very well represent the type of intervention 
with the largest potential effect in relation to dementia. 
 
With the introduction of the life-course approach to the etiology of late-onset dementias [192], it 
has become even more obvious that risk factors build up across the lifespan and accumulate from 
midlife, where also the underlying pathological alterations are starting to accumulate in the brain 
[154]. Therefore, many speculate that this is the “window of opportunity” for prevention [193]. The 
primary risk factors in midlife are the lifestyle-related cardiovascular factors like hypertension, 
obesity, type 2 diabetes, physical inactivity and smoking, which are also the risk factors with the 
highest and most consistent level of evidence [62]. These factors are therefore speculated to be 
the factors with the largest potential effect on dementia prevention. Historically the attempts to 
translate and confirm the findings from the observational studies in RCTs have been 
disappointing. With few exceptions, single intervention RCTs have consistently failed to identify 
efficacious pharmacological (e.g. lipid-lowering, antihypertensive, hormone replacement therapy, 
non-steroid anti-inflammatory drugs) or nonpharmacological interventions [194,195]. Physical 
activity is indeed a single intervention where researchers have been able to translate the findings 
from observational studies to RCTs with success. This has been shown across the cognitive 
continuum, e.g. in subjects with MCI [196], and recently in the ADEX trial where supervised 
moderate-to-high intensity exercise was found to reduce neuropsychiatric symptoms and 
potentially preserve cognition in patients with mild AD [197]. The positive effect could be related 
to the multidomain effects of physical activity on both neurogenesis, vascular risk factors, 
inflammation and depressive symptoms [198]. There are other examples of successful single 
intervention RCTs involving cognitive training and nutrition, however, because of the 
heterogeneity between studies, including different outcome measures, type of intervention, timing 
of intervention, duration of intervention and length of follow-up, cross-study comparisons are 
difficult. These methodological challenges are also speculated to be one of the reasons for the 
lacking preventive recommendations [199].  
The disappointing results from single intervention studies, the evolving recognition of dementia 
as a multifactorial syndrome and the life-course approach therefore initiated a transition from 
single intervention into a new era with multidomain intervention in the search for successful 
prevention strategies [193]. Three recent studies have tested non-pharmacological multidomain 
interventions that simultaneously target several modifiable risk factors. Two studies, the FINGER 
and the MAPT studies, reported positive outcomes showing modest improvements in cognition in 
the intervention groups [75,76]. In the FINGER study the multidomain invention was: diet, 
exercise, cognitive training, vascular risk monitoring while the intervention in MAPT consisted of 
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nutritional counselling, physical exercise and cognitive stimulation, in combination with omega-3 
fatty acid supplementation. The reported findings are very promising, however whether these 
interventions will delay cognitive decline and dementia in the long term is still unknown. The 
preliminary results from the third study, the PreDIVA study, testing a nurse-led 6-year intervention 
with multidomain cardiovascular tailored lifestyle advice, discouragingly showed no overall effect 
on the incidence of all-cause dementia [200]. We therefore still remain to see an effect on 
dementia incidence, an effect that would provide robust proof of concept for these multidomain 
interventions as preventive strategies. Interestingly, both the FINGER and the MAPT studies have 
on-going follow-up studies with the primary aim to assess the long-term efficacy on dementia and 
AD incidence. Each of these trials differed in a methodological sense as they used different 
outcome measures, different recruitment strategies, different duration of intervention and varying 
length of follow-up. Therefore, these studies should be seen as the very start of this new era 
where improvement and standardization of trial methods are of paramount importance for 
successful prevention. 
 
Primary prevention appears to be feasible as a stabilization or even a potential decline in 
dementia prevalence has been observed in both Western Europe and the United States 
[201,202]. Although the causes behind the reductions have not been confirmed, researchers 
speculate that the decline has been driven by an increase in educational attainment and a positive 
repercussion from the large efforts on cardiovascular disease prevention in the western world 
[203]. Opposed to the positive trends in dementia and cardiovascular disease prevalence the 
prevalence of obesity and diabetes is still increasing, and as diabetes is considered a major risk 
factor for dementia, prevention of diabetes could potentially reduce dementia prevalence even 
more [204]. Despite the declining trend in high-income countries, the worldwide burden of 
dementia will still pose a major threat to society especially in low-to-middle income countries 
where unhealthy lifestyles and less focus on non-communicable disease prevention has led to an 
increase in dementia prevalence [6,205]. 
 
The RCTs represent the highest level of evidence and are therefore often considered a necessity 
on the path towards dementia prevention. This is primarily supported by the fact that RCTs 
generally are the best way to determine causality [206]. In the context of dementia prevention the 
RCTs have limitations given the substantial duration of an intervention and the long timescales 
needed to attain a meaningful clinical endpoint [207]. Due to the lack of sufficiently qualified 
biomarkers that may act as surrogate endpoints the RCTs may therefore not always be the 
optimal choice [199]. Also ethical issues may limit the applicability of RCTs as known risk factors 
cannot be left untreated in the control group. The alternative, the observational studies, also have 
limitations in relation to potential bias, confounding and causation. Although, the longitudinal 
design generally limits the concern of reverse causation, it cannot be ruled out because of the 
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long latent phase of dementia in particular if the studies are not properly designed. The 
MELODEM guidelines highlight a range of common methodological challenges that arise 
specifically in studies of cognitive decline and dementia [208], challenges that may compromise 
the translation of research findings into preventive strategies. The guideline outlines methods for 
reporting and evaluating potential sources of bias and is therefore a promising framework towards 
high quality standardized studies.   
 
9.2 Identifying at-risk individuals: Moving to the individual level 
Statistical associations and trends are important in medicine and public health, but do not 
necessarily translate into good individual level associations. In other words there is no guarantee 
that associations found at the group level will be applicable for every individual. Moving to the 
individual level is therefore important for proper risk prediction in the general population. Risk 
prediction at the individual level is applicable for two main reasons: i) targeting of preventive 
measures to high-risk individuals [209] and ii) recruitment and enrichment of high-risk subjects in 
clinical trials [210]. A recent paper by Hampel et al. [93] stated that this can be achieved through 
the assessment of modifiable and non-modifiable risk factors, cognitive profile, biomarker proof 
of disease and changes of these factors over time. During the past decade, a range of risk scores 
for the prediction of dementia has been developed. The development was spearheaded by 
researchers from the Finnish Cardiovascular Risk Factors, Aging, and Dementia (CAIDE) study 
who published the CAIDE Dementia Risk Score in 2006 [209]. The score was specifically 
developed to predict dementia among middle aged people using a 20-year prediction horizon and 
has the strength of being externally validated [211]. Other risk scores target older populations 
using shorter prediction horizons [210,212]. The methodological approach is very similar across 
the different studies where a prediction model is built by evaluating a range of candidate predictors 
using primarily Cox proportional hazard regression models. The relative size of the parameter 
estimates is then used to convert the estimates into an easily interpretable scoring system. The 
absolute differences in accuracy between the various prediction tools are relatively small, 
although prediction tools developed for use in late-life tend to have slightly higher accuracy 
underlining the understanding that an event, in this case dementia, is easier to predict closer to 
time of occurrence [213].  
 
Our nomogram has a number of similarities with the previous prediction tools. Age is consistently 
included in all prediction tools as the most important predictor [209,210,212,214]. We found that 
cognitive test performance was the second most important predictor, which is consistent with the 
Late-Life Dementia Risk Index and the Brief Dementia Risk Index [210,214]. As compared to the 
other late-life prediction tools our study is characterized by a longer follow-up period minimizing 
the risk of misclassification bias. Rounding to the nearest integer was used to obtain risk scores 
for each of the predictors in the previous prediction tools, while we used the exact parameter 
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estimates in the generation of the nomogram ensuring the most accurate reflection of the risk. 
Several of the previous prediction tools may also suffer from survival bias as the outcome 
assessment was based on attendance to one or several re-examinations during the follow-up 
period [209,212]. Survival bias is less likely in our study as we used registry-linkage to obtain 
information on the dementia diagnosis. This method of follow-up is less sensitive to attrition and 
is independent of the outcome and the risk factor profile at baseline. 
 
Interestingly, we included two serum biomarkers of tau that in our analysis proved to be 
associated with dementia, a novel approach not previously seen with dementia prediction tools. 
Thereby our nomogram combines knowledge on modifiable risk factors, cognitive performance 
and neurodegenerative biomarker assessment, a combination that is believed the first critical step 
towards implementing precision medicine in the dementia field [93]. A question that remains is 
whether a single prediction tool can be applied across the lifespan, the cognitive continuum and 
in different settings. This is likely not possible as it is well-known that the modifiable risk factors 
may have important interactions with time and genes that are difficult to incorporate under the 
assumptions underlining the available prediction models. Also, as we observed in our studies it 
may not necessarily be the same prognostic markers in subjects with MCI as compared to a 
preclinical or healthy population. Finally varying accuracies have been observed across different 
settings e.g. in memory clinics where the prevalence is high, some tools perform well while the 
performance in the general population can be less accurate [215]. 
 
The current trend in pharmacological prevention trials is that study populations are enriched by 
means of biomarker positivity. The A4 study (NCT02008357) is enrolling asymptomatic or very 
mildly symptomatic individuals who have biomarker evidence of Aβ deposition while the 
TOMMORROW trial (NCT01931566) is including asymptomatic high risk subjects carrying the 
APOE and TOMM40 risk genes [73]. The individual risk of each subject is assessed using an 
algorithm based on their age, cognitive performance at enrollment and the above mentioned 
genotypes. This may be considered precision medicine, however it can also threat the external 
validity of these trials since an excessive enrichment e.g. on less prevalent genotypes, potentially 
can limit the generalizability to the overall population. Importantly, the use of Aβ deposition for 
enrichment may also result in a significant number of misdiagnoses, as about one third of very 
old people without dementia or cognitive impairment show signs of Aβ pathology [216]. 
 
Another unexplored potential use of multivariate prediction tools is risk-stratified analyses in 
RCTs. The risk-stratified analysis is, in contrast to the conventional subgroup analysis, taking 
several patient attributes into account simultaneously, which does not only increase the power of 
detecting a treatment effect but also facilitates precision medicine [217]. This strategy is currently 
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being tested in the above mentioned TOMMORROW trial where the risk genes are used to assign 
trial subjects into low- and high-risk groups [74]. 
 
9.3 Assessment of tau and the utility of blood-based biomarkers 
The ultimate aim with precision medicine is to develop tailor made interventions for individual 
patients. Blood-based biomarkers are potential cost-effective tools that may aid in precision 
medicine by: i) identification of patients who are in greatest need and who may benefit the most 
from a given treatment, ii) identification of patients who respond optimally to a specific treatment 
(safe and efficacious treatment), iii) identification of the optimal treatment for selected 
subpopulation of patients, and iv) efficient use of health care resources [218]. The most obvious 
use of blood-based biomarkers is for screening in medical practice, a setting where the large-
scale use of CSF and imaging biomarkers is limited. 
 
The development of blood-based biomarkers for dementia is still lagging behind the CSF 
biomarkers. The perceived main reason is the natural barrier, limiting for the transfer of 
substances from the brain to the blood. In contrast, the CSF can communicate freely with the 
brain interstitial fluid where neurons are known to secrete proteins such as tau [219]. Importantly, 
there is a certain degree of protein exchange between the brain and the periphery. First, there is 
the active and passive transport over the BBB, which also functions as a clearance system that 
removes waste materials from the brain [220]. Both AD and vascular pathology have been 
associated with increased BBB permeability, that potentially may enable the passage of small 
and lipid soluble molecules that would otherwise not be able to pass [221,222]. The ability of tau 
and truncated tau species to cross the BBB has also been shown very recently, emphasizing that 
blood levels of tau can indeed be useful as a biomarker [223]. Secondly, other studies have 
revealed a novel path for the clearance of macromolecules from the brain. The studies confirmed 
the presence meningeal lymphatic vessels that together with a glymphatic clearance pathway 
facilitates the drainage of CSF to the periphery [165,224,225]. This glymphatic system has been 
shown to be an important route of clearance for both Aβ and tau [164,224]. If these pathological 
agents are transported between the glymphatic and lymphatic systems are still unknown. These 
findings support further research in developing brain-derived proteins as biomarkers for dementia-
related diseases. 
 
In general, the previous studies of peripheral tau have been challenged by the low protein 
concentration in the circulation. Total tau is found at very low concentrations in the CSF 
approximately around 300-500 pg/ml and the plasma levels are approximately 100 times lower 
[226,227]. Due to the very low abundance, the assessment in plasma requires ultrasensitive 
technologies and highly specific antibodies to detect the protein. Albeit concerns when making 
cross study comparisons where findings are based on serum versus plasma we have shown that 
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the Tau-A and Tau-C fragments are measurable by standard enzyme-linked immunosorbent 
assay techniques [169,228]. This underscores the fact that smaller protein fragments, due to their 
molecular size, may more easily be transported from the brain to the periphery, as compared to 
their intact counterparts. A lack of correlation between the tau levels in the CSF and blood has 
been demonstrated [170,227] and also the half-life of tau is found to be much shorter in blood 
compared to the CSF [229,230]. This suggests that the protein is cleared through different 
mechanisms in the two compartments and implies that the understanding of the mechanism of 
release, the potential subsequent processing, and the clearance of brain-derived proteins from 
the periphery are of key importance. The biomarker trajectories of Tau-A and Tau-C are presently 
unknown but jointly our data and previous data suggest that the association may be time and/or 
disease stage dependent. Knowing the trajectories are important in the validation of these 
biomarkers and could be investigated e.g. in a cross-sectional cohort including subjects across 
the cognitive continuum from normal aging to severe dementia. Another possibility would be to 
assess the trajectories in a longitudinal cohort with several repeated measures. As the biomarker 
levels are measured following a complex process including processing in the brain, release, 
subsequent peripheral processing and clearance, one could also speculate the use of a single-
threshold rule does not reveal the full potential of these markers. Rather, the longitudinal changes 
as a function of progression or intervention should be tested. This has been found with the 
biomarker CA125 used within cancer, where longitudinal changes in contrast to using a single-
threshold increase the accuracy in ovarian cancer screening and also lead to earlier identification 
[231,232].  
 
The tau biomarkers may be useful for differential diagnosis especially since proteolytic cleavage 
is a hallmark of all dementias. By targeting the PTMs i.e. disease specific combinations of proteins 
and proteases, it can potentially allow for a better separation between the various dementia 
diagnoses. CSF p-tau is a well-described example, as it has been found to be almost exclusively 
elevated in AD as compared to a range of other neurodegenerative diseases including other 
tauopathies [219]. Abnormal excessive phosphorylation of tau is found in many 
neurodegenerative diseases, and since as many as 85 phosphorylation sites have been identified 
in the tau molecule, it may be that the specificity for AD is related to some sort of disease-specific 
phosphorylation [233]. In line with this, it was previously shown that our Tau-A biomarker was 
able to separate AD patients from other types of dementias [170], suggesting that the combination 
of a specific protein and a specific protease provides additional information that reduces the 
crossover between the different pathologies. 
 
The paradigm shift in AD diagnosis from a clinical-pathological to a clinical-biological entity has 
mainly been possible due to advances in the biomarker field. The core CSF biomarkers: Aβ1-42, t-
tau and p-tau as well as MRI and PET-amyloid imaging are all qualified by the European 
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Medicines Agency for enrichment in regulatory trials [234]. Although the regulatory authorities are 
beginning to recognize the use of biomarkers in clinical trials of AD, none of the biomarkers are 
yet qualified as diagnostic tools, outcome measures or longitudinal measures as the current data 
is not sufficiently strong to support this [234]. To obtain such qualifications, there is an on-going 
validation and standardization process, where global standards for both pre-analytical and 
analytical aspects are being developed to ensure reproducibility and consistency within 
laboratories, across laboratories and across different kit manufacturers [235–237]. The 
measurement of CSF biomarkers is associated with high costs and requires an invasive 
procedure. These limitations justify the development of blood-based biomarkers as these are 
considered more relevant for large-scale use [71]. If properly validated, blood-based biomarkers 
could be implemented as a first step in a multi-stage screening process for clinical trials as 
outlined by Henriksen et al. [166]. Such test would apply a stringent filter in the enrolment process 
by ruling out subjects without disease and thereby decrease the number of screen-failures that 
would otherwise have undergone more invasive and costly procedures like neuroimaging or CSF 
sampling. Current evidence suggests that blood-based biomarker panels are able to identify 
progression from MCI to AD and also from cognitively normal to some level of cognitive 
impairment [238,239]. Similar to the CSF biomarkers there is also an on-going standardization 
process for blood-based biomarkers [240]. There has indeed been a lot of progress with blood-
based biomarkers recently and if the progress continues, it could mean that the blood-based 
biomarkers may very well have the potential to bypass the CSF biomarkers. 
 
9.4 Strengths and Limitations 
9.4.1 Bias and Confounding 
A significant proportion of people with dementia do not receive a clinical diagnosis at any time or 
do so only late in the disorder where it is often too late to intervene. Primary care is considered 
the gateway to early diagnosis, however the diagnostic sensitivity in primary care is estimated to 
be as low as 0.09 for subjects presenting with few or mild symptoms of dementia [241]. Under-
diagnosis has also been found to increase with age [242], which can be worrisome as dementia 
incidence increases exponentially with age. Results from the Canadian Study of Health and Aging 
previously estimated 64% of undetected dementia in community-dwelling older people [243]. This 
indicates that dementia clearly is underdiagnosed and this underestimation will cause 
misclassification bias in epidemiological studies, like the PERF study, that do not have a 
comprehensive diagnostic workup. Even delayed diagnosis may lead to misclassification bias, 
however this can be minimized with a long follow-up period as in PERF. The causes of under-
diagnosis in primary care are many and include; limited time with the patient, lack of standardized 
validated screening protocols, and unfeasible assessment tools in practice [241]. This indicates 
that short cognitive screening tools like those used in the PERF study are relevant tools in primary 
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care. Whether these tools are the most appropriate from a research perspective can of course be 
questioned, but in the transition from observation to action, they are highly relevant. 
 
In paper III and IV we used information obtained at the follow-up visit (PERF II) to determine the 
outcome. This can lead to survival bias which is not uncommon in longitudinal studies of 
dementia. In contrast we used registry-linkage in paper II and V, a method characterized by very 
limited loss to follow-up and thereby less inflicted by survival bias. In the analyses using registry-
linkage we were also able to take into account the competing risk of dementia-free mortality which 
can be a problem in longitudinal studies of such advanced age, especially when it comes to 
prediction [244]. A previous study specifically assessed the validity of dementia diagnose in the 
Danish national registries [245]. They found a validity of 86% for all-cause dementia and therefore 
concluded that registry-linkage is suitable for use in epidemiological dementia studies.  
 
The two outcomes used are not interchangeable and this should be kept in mind as we included 
findings based on both outcomes in our nomogram. The use of cognitive tests to define the 
outcome is associated with large variation and the performance can be affected by many factors, 
which are not necessarily due to the disease of interest [246]. Due to the long latent phase of 
dementia preceding the clinical diagnosis, some of the observed associations may be caused by 
reverse causation, a problem particular relevant to consider in late-life studies were the exposure 
may be assessed close to the outcome. Given the previously reported interconnection between 
genetic and modifiable risk factors, the lack of genetic risk factors in our studies is a limitation that 
could result in unmeasured confounding. For example it has been reported that carriers of the 
APOE ε4 allele are more vulnerable to certain risk factors, while some protective factors like high 
education and physical activity can counteract the genetic risk [247]. 
 
Our study on cognitive trajectories from paper IV is limited by only two time points and a relatively 
simple cognitive assessment. Repeated cognitive assessments e.g. with one or two year intervals 
during the follow up period would have been optimal as it would have given us the opportunity to 
study the rate of progression in more detail. The evaluation of the tau biomarkers would also have 
benefited from such a study design especially if repeated cognitive assessments were 
accompanied by repeated biomarker measurements.   
 
9.4.2 Reliability of the clinical diagnosis 
Several studies have investigated the concordance between clinical dementia diagnoses and 
neuropathological changes at autopsy [20,21,248]. As an autopsy confirmed diagnosis remain s 
the gold-standard in the field, these studies are particular important as both epidemiological and 
biomarker studies mostly rely on the clinical diagnosis. The sensitivity and specificity varies 
between the studies but some are as low as 50%, indicating that the clinical diagnosis does not 
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always correspond to the diagnosis at autopsy. Importantly, it gives an indication of what accuracy 
we can expect when evaluating new diagnostic and prognostic tools, especially in population-
based studies and results should therefore always be interpreted in this context. Risk of circular 
reasoning can also occur if the clinical diagnoses are used to validate the biomarkers and those 
same biomarkers are used to validate the clinical diagnoses without any consideration of the 
concordance between the clinical diagnoses and autopsy findings [249]. 
 
Finally, there may also be challenges associated with the transition towards earlier diagnosis as 
the diagnosis will rely heavily on biomarkers. As described, normal cognition is associated with 
deposition of the typical pathological hallmarks of AD [216], and even if these subjects would 
eventually have developed dementia if they had lived long enough, the underlying pathology did 
not affect their lifespan nor their quality of life. In such people, it is likely that a pharmacological 
intervention would lead to more harm (e.g. adverse events, healthcare costs etc.) than good [250]. 
In other words, early diagnosis may lead to over diagnosis if the underlying processes and 
pathways discriminating the “benign” abnormalities from the abnormalities driving the progression 
to dementia are not properly understood.
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10. Concluding Remarks 
10.1 Conclusion 
The results presented in this thesis provide evidence that modifiable risk factors are associated 
with late-life dementia and thereby add to the existing evidence from previous epidemiological 
studies on dementia and cognitive impairment.  
 
In paper II and III we found that physical inactivity, a history of depression and impaired fasting 
glucose increased the risk of developing dementia while overweight (BMI 25–29.9), as compared 
with normal weight women was associated with a lower risk of dementia. Also the precursors of 
type 2 diabetes; impaired fasting plasma glucose and insulin resistance were associated with 
increased risk of developing cognitive dysfunction in the subpopulation who attended the follow-
up study. This jointly suggests that a significant proportion of dementia cases in women is likely 
to be preventable by effective prevention and control of these modifiable risk factors. 
 
For subjects with signs of mild objective cognitive impairment at baseline we found that the degree 
of impairment at baseline along with age, physical inactivity, higher level of total cholesterol and 
a history of depression were associated with cognitive progression over the follow-up period. 
 
Finally we showed that serum levels of two truncated tau species, Tau-A and Tau-C, were 
associated with incident dementia underlining the hypothesis that these biomarkers may serve as 
non-invasive, affordable and widely available tools that can aid in early identification as well as 
guide the design of clinical trials for identification of the right patients and potentially also 
monitoring of treatment efficacy either alone or as part of a biomarker panel. 
 
The findings jointly serve as an example of a first in-line screening tool for the identification of at-
risk individuals which could serve two obvious needs: i) identifying subjects in most need of 
preventive interventions or ii) identify subjects suitable for enrollment in clinical trials of new 
disease-modifying interventions.   
 
10.2 Perspectives 
There has been an enormous and accelerating scientific effort in the study of dementia etiology 
and pathophysiology, all driven by an overarching objective to curb the epidemic. To redeem this 
ambitious goal there is still a need for a better understanding of the pathways leading to dementia. 
In LOAD for example, where a plethora of processes are speculated to be involved in the 
pathogenesis, we need to understand what triggers these processes and how they interact 
through time. This complexity will require systems-based approaches where different sources of 
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data (genetic, epigenetic, proteomic and environmental factors) are jointly integrated. There are 
data-sharing initiatives on-going that will enable more systems-based approaches in big data in 
the future [251]. Such systems-based approach would also aid in the identification of different 
phenotypes and thereby potentially promote precision medicine by the identification of patients 
who are in greatest need and who may benefit the most from a given treatment. An early example 
of a systemic approach used a biomarker-guided cluster analysis to identify five different 
subgroups of AD [252], subgroups that are speculated to respond differently to pharmacological 
treatment [253]. 
 
With the availability of an extensive amount of registry data on comorbidities, the observations 
and data from PERF I and PERF II and the potential for analyzing genetic material (available in 
the biobank) the PERF cohort is a great resource in relation to the systems-based approach. Also, 
there is great potential in further research on dementia risk factors for example all participants 
underwent whole body dual energy X-ray absorptiometry (DEXA) scanning at the baseline visit 
and this gives a unique possibility to study associations between body composition (bone, 
muscles and fat) and dementia.   
 
The tau biomarkers and potentially other future blood-based biomarkers based on this technology 
(Specifically focusing on protein fragments generated by disease-specific combinations of 
proteins and proteases) have potential to benefit subjects with pathophysiological signs of 
disease. The future work should focus on validating the biomarkers in large prospective studies 
designed specifically for dementia. Studies should clarify the biomarker trajectories and their 
relation to diagnosis, prognosis and prediction but also focus on mapping the processes from the 
initial protein cleavage to the measurement of the fragments in blood.  
 
The nomogram presented in this thesis require validation. First the efforts should be focused on 
whether a simplification of the predictive model can be done without significantly altering the 
predictive accuracy. Also the performance of the predictive model should be evaluated with e.g. 
cross-validation and subsequent validation in an independent cohort.
XI 
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